Patent application title: VEGF Analogs and Methods of Use
Inventors:
Mariusz W. Szkudlinski (Rockville, MD, US)
Bruce D. Weintraub (Rockville, MD, US)
Bruce D. Weintraub (Rockville, MD, US)
Assignees:
Trophogen, Inc.
IPC8 Class: AC07K14475FI
USPC Class:
Class name:
Publication date: 2015-10-01
Patent application number: 20150274793
Abstract:
Modified VEGF proteins that inhibit VEGF-mediated activation or
proliferation of endothelial cells are disclosed. The analogs may be used
to inhibit VEGF-mediated activation of endothelial cells in
angiogenesis-associated diseases such as cancer, inflammatory diseases,
eye diseases, and skin disorders.Claims:
1. A modified vascular endothelial growth factor (VEGF) comprising at
least one mutation causing the modified VEGF to act as a receptor
antagonist, wherein the mutation results in a dissociation of receptor
binding affinity and bio activity.
2. The VEGF receptor antagonist of claim 1, wherein the receptor binding affinity of the antagonist to a native VEGF receptor is greater than the receptor binding affinity of wild-type VEGF to the native VEGF receptor.
3. The VEGF receptor antagonist of claim 2, wherein the native VEGF receptor is Flt-1 or KDR.
4. The VEGF receptor antagonist of claim 2, wherein there is at least about a 3 to 4 fold increase in receptor binding affinity.
5. The VEGF receptor antagonist of claim 2, wherein there is at least about a 2 fold increase in receptor binding affinity.
6. The VEGF receptor antagonist of claim 1, wherein the bioactivity for the antagonist is decreased compared to the bioactivity for a wild-type VEGF.
7. The VEGF receptor antagonist of claim 1, wherein the antagonist is expressed as a homodimer or heterodimer.
8. The VEGF receptor antagonist of claim 7, wherein each subunit of the homodimer or heterodimer contains the at least one mutation.
9. The VEGF receptor antagonist of claim 8, wherein one subunit of the homodimer or heterodimer contains the at least one mutation.
10. The VEGF receptor antagonist of claim 1, wherein the antagonist is expressed as a fusion protein comprising one or more VEGF subunits.
11. The VEGF receptor antagonist of claim 10, wherein the one or more VEGF subunits each contain the at least one mutation.
12. The VEGF receptor antagonist of claim 10, wherein at least one VEGF subunit contains the at least one mutation.
13. The VEGF receptor antagonist of claim 10 further comprising a linker peptide.
14. The VEGF receptor antagonist of claim 10 further comprising a toxin.
15. The VEGF receptor antagonist of claim 1, wherein the mutation is a basic amino acid substitution at a position corresponding to position 83 of SEQ ID NO.: 4.
16. The VEGF receptor antagonist of claim 15, wherein said basic amino acid is I83K.
17. The VEGF receptor antagonist of claim 15, wherein said basic amino acid is I83R.
18. The VEGF of claim 15, wherein the antagonist contains one or more additional basic amino acid substitutions corresponding to the group consisting of positions 44, 67, 72, 73 and 87 of SEQ ID NO.: 4.
19. The VEGF receptor antagonist of claim 18, wherein the additional substitutions are selected from the group consisting of E72R and E73R.
20. The VEGF receptor antagonist of claim 18, wherein the additional substitutions are selected from the group consisting of E72K and E73K.
21. The VEGF receptor antagonist of claim 18, wherein the additional substitution is E44R or E44K.
22. The VEGF receptor antagonist of claim 18, wherein the additional substitution is Q87K or Q87L.
23. The VEGF receptor antagonist of claim 18, wherein the additional substitution is E67K.
24. The VEGF receptor antagonist of claim 1, wherein interaction of the VEGF-A receptor antagonist and a native VEGF receptor results in inhibition of angiogenesis.
25. The VEGF receptor antagonist of claim 24, wherein the native VEGF receptor is KDR.
26. The VEGF receptor antagonist of claim 18, wherein the antagonist contains the amino acids E72R+E73R+I83K.
27. The VEGF receptor antagonist of claim 18, wherein the antagonist contains the amino acids E44R+E72R+E73R+I83K.
28. The VEGF antagonist of claims 15 and 18, wherein the antagonist contains one or more additional amino acid substitutions in amino acids corresponding to positions 111-165 of SEQ ID NO.: 4 which disrupt neuropilin-1 binding.
29. The VEGF antagonist of claim 28, wherein the additional amino acid substitutions do not disrupt heparin sulfate binding.
30. The VEGF antagonist of claim 28, wherein the antagonist contains an amino acid substitution at the position corresponding to C146 or C160 of SEQ ID NO.: 4.
31. The VEGF antagonist of claim 30, wherein the amino acid substitution is C146S or C160S.
32. The VEGF antagonist of claim 28, wherein the antagonist contains amino acid substitutions at the positions corresponding to C146 and C160 of SEQ ID NO.: 4.
33. The VEGF antagonist of claim 32, wherein the amino acid substitution is C146S and C160S.
34. The VEGF antagonist of claims 15 and 18, wherein the antagonist contains one or more additional amino acid substitutions which reduce or prevent protease cleavage of the antagonist.
35. The VEGF antagonist of claim 34, wherein the protease is plasmin.
36. The VEGF antagonist of claim 34, wherein the one or more additional amino acid substitutions are selected from the group of positions corresponding to positions A111 and A148 of SEQ ID NO.: 4.
37. The VEGF antagonist of claim 36, wherein the amino acid substitution is A111P or A148P.
38. The VEGF antagonist of claim 36, wherein the amino acid substitutions are A111P and A148P.
39. The VEGF antagonist of claim 14, wherein the toxin is selected from the group consisting of a Pseudomonas exotoxin (PE), a Diphtheria toxin (DT), ricin toxin, abrin toxin, anthrax toxins, shiga toxin, botulism toxin, tetanus toxin, cholera toxin, maitotoxin, palytoxin, ciguatoxin, textilotoxin, batrachotoxin, alpha conotoxin, taipoxin, tetrodotoxin, alpha tityustoxin, saxitoxin, anatoxin, microcystin, aconitine, exfoliatin toxins A, exfoliatin B, an enterotoxin, toxic shock syndrome toxin (TSST-1), Y. pestis toxin and a gas gangrene toxin.
40. The VEGF antagonist of claims 8-12, wherein at least one of said subunits is a VEGF-A subunit.
41. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is a VEGF165 subunit.
42. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is VEGF165b.
43. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is a VEGF.sub.121. subunit.
44. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is VEGF.sub.145.
45. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is a VEGF.sub.148. subunit.
46. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is VEGF.sub.183.
47. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is a VEGF.sub.189. subunit.
48. The VEGF antagonist of claim 40, wherein the said VEGF-A subunit is VEGF.sub.206.
49. The VEGF antagonist of claims 8-12, wherein at least one of said subunits is a VEGF-B subunit.
50. The VEGF antagonist of claim 49, wherein the said VEGF-B subunit is a VEGF-B167 subunit.
51. The VEGF antagonist of claim 49, wherein the said VEGF-B subunit is VEGF-B.sub.186.
52. The VEGF antagonist of claims 8-12, wherein at least one of said subunits is a VEGF-C subunit.
53. The VEGF antagonist of claims 8-12, wherein at least one of said subunits is a VEGF-D subunit.
54. The VEGF antagonist of claims 8-12, wherein at least one of said subunits is a PlGF subunit.
55. The VEGF antagonist of claim 54, wherein the said PlGF subunit is PlGF-1.
56. The VEGF antagonist of claim 54, wherein the said PlGF subunit is PlGF-2.
57. The VEGF antagonist of claims 1-56, wherein angiogenesis is partially inhibited.
58. The VEGF antagonist of claims 1-56, wherein angiogenesis is about almost completely inhibited.
59. A pharmaceutical composition comprising the VEGF receptor antagonist of any of claims 1-58.
60. The composition of claim 59 further comprising a pharmaceutically acceptable carrier.
61. The composition of claim 60, wherein said composition is formulated for aerosol deliver.
62. The composition of claim 61, wherein said composition is formulated as a nasal spray.
63. The composition of claim 60, wherein the composition is formulated for oral administration.
64. The composition of claim 63, wherein the composition is formulated as a tablet, pill, or capsule.
65. The composition of claim 60, wherein the composition is formulated as a depot or suppository.
66. The composition of claim 60 further comprising one or more additional drugs from the group consisting of anti-VEGF drug, anti-angiogenic drug, anti-cancer drug, infertility drug, autoimmune drug, inflammation drug, ocular disease drug, and skin disease drug.
67. A method of treating a patient diagnosed with cancer with a therapeutically effective amount of the VEGF receptor antagonist of any of claims 1-58, comprising administering said antagonist to said patient such that spread of said cancer is reduced or inhibited.
68. The method of claim 67 wherein said cancer is a solid tumor cancer selected from the group consisting of bladder, breast, liver, bone, kidney, colon, ovarian, prostate, pancreatic, lung, brain, breast, and skin.
69. A method of treating a patient diagnosed with an angiogenesis-associated eye disease with a therapeutically effective amount of the VEGF receptor antagonist of any claims 1-58, comprising administering said antagonist to said patient such that said eye disease is reduced or inhibited.
70. The method of claim 69, wherein said eye disease is selected from the group consisting of retinopathy of prematurity, diabetic retinopathy, retinal vein occlusion, macular degeneration, and neovascularization associated with corneal injury or grafts.
71. A method of treating a patient diagnosed with an angiogenesis-related disease or condition with a therapeutically effective amount of the VEGF receptor antagonist of any claims 1-58, comprising administering said antagonist to said patient such that said angiogenesis-related disease is reduced or inhibited.
72. The method of claim 71, wherein said disease or condition is selected from the group consisting of hemangiomas, rheumatoid arthritis, osteoarthritis, septic arthritis, asthma, atherosclerosis, idiopathic pulmonary fibrosis, vascular restenosis, arteriovenous malformations, meningiomas, neovascular glaucoma, psoriasis, Kaposi's Syndrome, angiofibroma, hemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic granuloma, retrolental fibroplasias, scleroderma, trachoma, von Hippel-Lindau disease, vascular adhesion pathologies, synovitis, dermatitis, unexplained female infertility, endometriosis, unexplained male infertility, pterygium, wounds, sores, skin ulcers, gastric ulcers, and duodenal ulcers.
73. The VEGF receptor antagonist of claim 1, wherein one or both subunits of the VEGF comprise a modification to prolong half-life.
74. The VEGF receptor antagonist of claim 73, wherein the modification to prolong half-life is a N terminal or C terminal extension.
75. The VEGF receptor antagonist of claim 73, wherein the modification to prolong half-life is pegylation.
76. The VEGF receptor antagonist of claim 10, wherein the fusion protein contains two VEGF or VEGF-related protein subunits fused together.
77. The VEGF receptor antagonist of claim 76, wherein the two VEGF or VEGF-related protein subunits are selected from the group consisting of a VEGF-A subunit fused to a VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, PDGF or PlGF subunit; a VEGF-B subunit fused to a VEGF-A, VEGF-C, VEGF-D, VEGF-E, VEGF-F, PDGF or PlGF subunit; a VEGF-C subunit fused to a VEGF-A, VEGF-B, VEGF-D, VEGF-E, VEGF-F, PDGF or PlGF subunit; a VEGF-D subunit fused to a VEGF-A, VEGF-B, VEGF-C, VEGF-E, VEGF-F, PDGF or PlGF subunit; and a PlGF subunit fused to a VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, or PDGF subunit.
78. A VEGF165b receptor antagonist comprising one or more mutations selected from the group consisting of E44B, E67B, E72B, E73B, I83B and Q87B of SEQ ID NO.: 13, wherein B is a basic amino acid.
79. The VEGF165b receptor antagonist of claim 78, wherein the antagonist exhibits an increased receptor binding affinity compared to wild-type VEGF165 or wild-type VEGF165b.
80. A VEGF receptor antagonist comprising one or more mutations disrupting neuropilin-1 binding and comprising one or more basic amino acid substitutions from the group consisting of E44, E67, E72, E73, I83 and Q87 of SEQ ID NO.:4.
81. The VEGF receptor antagonist of claim 80, wherein said one or more mutations disrupting neuropilin-1 binding are selected from the group consisting of C146S and C160S.
Description:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/723,917, filed Oct. 6, 2005, and U.S. Provisional Application No. 60/808,106, filed May 25, 2006, which are herein incorporated by reference in their entireties.
FIELD OF INVENTION
[0002] This application relates to the design and use of vascular endothelial growth factor (VEGF) analogs as VEGF receptor antagonists to inhibit or reduce angiogenesis for the treatment of conditions and diseases associated with angiogenesis. The application also discloses VEGF analogs that exhibit increased receptor binding affinity to native receptors such as KDR.
BACKGROUND OF INVENTION
[0003] Vascular endothelial growth factors (VEGFs) regulate blood and lymphatic vessel development. They are predominantly produced by endothelial, hematopoietic and stromal cells in response to hypoxia and stimulation with growth factors such as transforming growth factors, interleukins and platelet-derived growth factor.
[0004] In mammals, VEGFs are encoded by a family of genes and include VEGF-A, VEGF-B, VEGF-C, VEGF-D and Placenta like Growth Factor (PlGF). Highly related proteins include orf virus-encoded VEGF-like proteins referred to as VEGF-E and a series of snake venoms referred to as VEGF-F. VEGFs and VEGF-related proteins are members of the Platelet Derived Growth Factor (PDGF) supergene family of cystine knot growth factors. All members of the PDGF supergene family share a high degree of structural homology with PDGF (see U.S. patent application Ser. No. 09/813,398 which is herein incorporated by reference in its entirety).
[0005] VEGF-A, VEGF-B and PlGF are predominantly required for blood vessel formation, whereas VEGF-C and VEGF-D are essential for the formation of lymphatic vessels. Angiogenesis is the process by which new blood vessels or lymphatic vessels form by developing from pre-existing vessels. The process is initiated when VEGFs bind to receptors on endothelial cells, signaling activation of endothelial cells. Activated endothelial cells produce enzymes which dissolve tiny holes in the basement membrane surrounding existing vessels. Endothelial cells then begin to proliferate and migrate out through the dissolved holes of the existing vessel to form new vascular tubes (Alberts et al., 1994, Molecular Biology of the Cell. Garland Publishing, Inc., New York, N.Y. 1294 pp.).
[0006] Three type III receptor tyrosine kinases are activated by VEGFs during angiogenesis: fins-like tyrosine kinase (Flt-1, also known as VEGFR1), kinase domain receptor or kinase insert domain-containing receptor (KDR, also known as VEGFR2 and Flk-1) and Flt-4 (also known as VEGFR3). KDR is the predominant receptor in angiogenic signaling, whereas Flt-1 is associated with the regulation of blood vessel morphogenesis and Flt-4 regulates lymphangiogenesis. These receptors are expressed almost exclusively on endothelial cells, with a few exceptions such as the expression of Flt-1 in monocytes where it mediates chemotaxis (Barleon et al., 1996, Blood. 87: 3336-3343).
[0007] VEGF receptors are closely related to Fms, Kit and PDGF receptors. They consist of seven extracellular immunoglobulin (Ig)-like domains, a transmembrane (TM) domain, a regulatory juxtamembrane domain, an intracellular tyrosine kinase domain interrupted by a short peptide, the kinase insert domain, followed by a sequence carrying several tyrosine residues involved in recruiting downstream signaling molecules. Mutation analysis of the extracellular domains of Flt-1 and KDR show that the second and third Ig-like domains constitute the high-affinity ligand-binding domain for VEGF with the first and fourth Ig domains apparently regulating ligand binding and receptor dimerization, respectively (Davis-Smyth et al., 1998, J. Biol. Chem. 273: 3216-3222; Fuh et al., 1998, J. Biol. Chem. 273: 11197-11204; and Shinkai et al., 1998, J. Biol. Chem. 273: 31283-31288). Receptor tyrosine kinases are activated upon ligand-mediated receptor dimerization (Hubbard, 1991, Prog. Biophys. Mol. Biol. 71: 343-358; Jiang and Hunter, 1999, Curr. Biol. 9: R568-R571; and Lemmon and Schlessinger, 1998, Methods Mol. Biol. 84: 49-71). Signal specificity of VEGF receptors is further modulated upon recruitment of coreceptors, such as neuropilins, heparin sulfate, integrins or cadherins.
[0008] VEGF molecules interact with one or more tyrosine kinase receptors during angiogenesis. For instance, VEGF-A acts predominantly through KDR and Flt-1. VEGF-C and VEGF-D similarly are specific ligands for KDR and VEGFR3. PlGF and VEGF-B are believed to bind only to Flt-1. Viral VEGF-E variants activate KDR. VEGF-F variants interact with either VEGFR3 or KDR.
[0009] In addition to the two classical receptors, there are several membrane or soluble receptors modulating VEGF bioactivity and angiogenesis. For instance, neuropilin-1 and neuropilin-2 interact with both KDR and Flt-1, respectively, stimulating signaling of those receptors. Isoforms of VEGF-A, VEGF-B, PlGF-2 have been shown to bind to neuropilin-1 (Soker et al., 1998, Cell. 92: 735-745; Makinen et al., 1999, J. Biol. Chem. 274: 21217-21222; and Migdal et al., 1998, J. Biol. Chem. 273: 22272-22278). VEGF isoforms capable of interacting of interacting with neuropilin, i.e., those isoforms with exon 7 or 6 and 7, are also capable of interacting with heparin sulfate.
[0010] Although VEGF-A is the best characterized of the VEGF proteins, the molecular basis of the interaction between VEGF-A and KDR and Flt-1 is not well understood. Although VEGFR1 binds VEGF-A with a 50-fold higher affinity than KDR, KDR is considered to be the major transducer of VEGF-A angiogenic effects, i.e., mitogenicity, chemotaxis and induction of tube formation (Binetruy-Tourniere et al., supra). There is, however, growing evidence that Flt-1 has a significant role in hematopoiesis and in the recruitment of monocytes and other bone-marrow derived cells that may home in on tumor vasculature and promote angiogenesis (Hattori et al., 2002, Nature Med. 8: 841-849; Gerber et al., 2002, Nature. 417: 954-958; and Luttun et al., 2002, Nature Med. 8: 831-840). Further, in some cases Flt-1 is expressed by tumor cells and may mediate a chemotactic signal, thus potentially extending the role of this receptor in cancer growth (Wey et al., 2005, Cancer. 104: 427-438).
[0011] A single VEGF-A homodimer induces dimerization of two KDR receptors and autophosphorylation of their cytoplasmatic portions. Previous studies suggested that by analogy to glycoprotein hormones, the charged amino acid residues in the peripheral loops of VEGF-A are also critical in providing high affinity electrostatic interactions with its respective receptors (Szkudlinski et al., 1996, Nat. Biotechnol. 14(10): 1257-63; Fuh et al., supra; Muller et al., 1997, Proc. Natl. Acad. Sci. U.S.A. 94(14): 7192-7; Keyt et al., 1996, J. Biol. Chem. 271(10): 5638-46). However, it should be noted that many mutations in VEGF-A have no major effect on receptor binding affinity. Mutations in the peripheral loops of VEGF primarily have resulted in loss-of-function. Further, there appear to be no previous amino acid substitutions increasing binding affinity to KDR more than 2-fold.
[0012] Angiogenesis is responsible for beneficial biological events such as wound healing, myocardial infarction repair, and ovulation. On the other hand, angiogenesis is also responsible for causing or contributing to diseases such as growth and metastasis of solid tumors (Isayeva et al., 2004, Int. J. Oncol. 25(2):335-43; Takeda et al., 2002, Arm Surg. Oncol. 9(7):610-16); atherosclerosis; abnormal neovascularization of the eye as seen in diseases such as retinopathy of prematurity, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration (Yoshida et al., 1999, Histol Histopathol. 14(4):1287-94; Aiello, 1997, Ophthalmic Res. 29(5):354-62); chronic inflammatory conditions such as rheumatoid arthritis osteoarthritis, and septic arthritis; neurodegenerative disease (Ferrara, N., 2004, Endocr. Rev. 25: 581-611); placental insufficiency, i.e., preeclampsia (Ferrara, supra); and skin diseases such as dermititis, psoriasis, warts, cutaneous malignancy, decubitus ulcers, stasis ulcers, pyogenic granulomas, hemangiomas, Kaposi's sarcoma, hypertrophic scars, and keloids (Arbiser, 1996, J. Am. Acad. Dermatol. 34(3):486-97). During rheumatoid arthritis, for example, endothelial cells become activated and express adhesion molecules and chemokines, leading to leukocyte migration from the blood into the tissue. Endothelial cell permeability increases, leading to edema formation and swelling of the joints (Middleton et al., 2004, Arthritis Res. Ther. 6(2):60-72).
[0013] VEGF, in particular VEGF-A, has been implicated in many of the diseases and conditions associated with increased, decreased, and/or dysregulated angiogenesis (Binetruy-Tourniere et al., 2000, EMBO J. 19(7): 1525-33). For instance, VEGF has been implicated in promoting solid tumor growth and metastasis by stimulating tumor-associated angiogenesis (Lu et al., 2003, J. Biol. Chem. 278(44): 43496-43507). VEGF is also a signficant mediator of intraocular neovascularization and permeability. Overexpression of VEGF in transgenic mice results in clinical intraretinal and subretinal neovascularization, and the formation of leaky intraocular blood vessels detectable by angiography, as seen in human eye disease (Miller, 1997, Am. J. Pathol. 151(1): 13-23). Additionally, VEGF has been identified in the peritoneal fluid of women with unexplained infertility and endometriosis (Miedzybrodzki et al., 2001, Ginekol. Pol. 72(5): 427-430), and the overexpression of VEGF in testis and epididymis has been found to cause infertility in transgenic mice (Korpelainen et al., 1998, J. Cell Biol. 143(6): 1705-1712). Recently, VEGF-A has been identified in the synovial fluid and serum of patients with rheumatoid arthritis (RA), and its expression is correlated with disease severity (Clavel et al., 2003, Joint Bone Spine. 70(5): 321-6). Given the involvement of pathogenic angiogenesis in such a wide variety of disorders and diseases, inhibition of angiogenesis, and particularly of VEGF signaling, is a desirable therapeutic goal.
[0014] Inhibition of angiogenesis and tumor inhibition has been achieved by using agents that either interrupt VEGF-A and KDR interaction and/or block the KDR signal transduction pathway including: peptides that block binding of VEGF to KDR (Binetruy-Tourniere et al., 2000, EMBO J. 19(7): 1525-33); antibodies to VEGF (Kim et al., 1993, Nature 362, 841-844; Lanai et al., 1998, J. Cancer 77, 933-936; Margolin et al., 2001, J. Clin. Oncol. 19, 851-856); antibodies to KDR (Lu et al., 2003, supra; Zhu et al., 1998, Cancer Res. 58, 3209-3214; Zhu et al. 2003, Leukemia 17, 604-611; Prewett et al., 1999, Cancer Res. 59, 5209-5218); soluble receptors (Holash et al., 2002, Proc. Natl. Acad. Sci. USA 99, 11393-11398; Clavel et al. supra); tyrosine kinase inhibitors (Fong et al., 1999, Cancer Res. 59, 99-106; Wood et al., 2000, Cancer Res. 60, 2178-2189; Grosios et al., 2004, Inflamm Res. 53(4):133-42); anti-VEGF immunotoxins (Olson et al., 1997, Int. J. Cancer 73, 865-870); ribozymes (Pavco et al., 2000, Clin. Cancer Res. 6, 2094-2103); antisense mediated VEGF suppression (Forster et al., 2004, Cancer Lett. 20; 212(1):95-103); RNA interference (Takei et al., 2004, Cancer Res. 64(10):3365-70; Reich et al., 2003, Mol Vis. 9:210-6); and undersulfated, low molecular weight glycol-split heparin (Pisano et al., 2005, Glycobiology. 15(2) 1-6). Some of these treatments, however, have resulted in undesirable side effects. For instance, Genentech's Avastin, a monoclonal antibody that targets VEGF, has been reported to cause an increase in serious arterial thromboembolic events in some colon cancer patients and serious, and in some cases even fatal, hemoptysis in non-small cell lung cancer patients (Ratner, 2004, Nature Biotechnol. 22(10):1198). More recently, Genentech has reported that gastrointestinal perforations were observed in 11% of ovarian cancer patients (5 women out of 44 in trial) treated with Avastin (Genentech Press Release dated Sep. 23, 2005). Similarly, the first VEGF-targeting drug, Pfizer's receptor tyrosine kinase inhibitor SU5416, exhibited severe toxicities that included thromboembolic events, prompting Pfizer to discontinue development (Ratner, supra). Given the wide variety of patients that stand to benefit from the development of effective anti-angiogenic treatments and the drawbacks of some known anti-angiogenesis treatments, there remains a need for novel anti-angiogenic therapeutics.
SUMMARY OF INVENTION
[0015] This invention encompasses VEGF analogs and nucleic acids encoding the same, which exhibit strong binding affinity for one or more native VEGF receptors compared to wild-type VEGF. The invention also encompasses VEGF analogs and nucleic acids encoding same, which exhibit a dissociation of receptor binding affinity and bioactivity. Specifically, the in vivo and in vitro bioactivities of the disclosed analogs are substantially decreased compared to wild-type VEGF, whereas the binding affinity to one or more native receptors is about the same or substantially increased compared to wild-type VEGF. The VEGF analogs may demonstrate at least about a three to four fold increase in receptor binding affinity to a native receptor such as KDR.
[0016] In one embodiment of the invention, the VEGF analogs are modified VEGF homodimers or heterodimers. These molecules contain at least one mutation which can be present in one or both subunits of the VEGF molecule. In one embodiment of the invention, the VEGF analog containing the one or more mutations is VEGF-A. The VEGF-A analog can be any VEGF-A isoform, for instance, an isoform of 121, 145, 148, 165, 183, 189, or 206 amino acids. In one embodiment, the VEGF-A analog of the invention is a VEGF165b isoform. In another embodiment, the VEGF molecule containing one or more mutations is VEGF-B, VEGF-C, VEGF-D or PlGF.
[0017] The present invention includes a VEGF fusion protein containing one or more mutations in one or more subunits. The VEGF fusion protein of the invention includes at least one VEGF subunit, i.e., subunit, fused to at least one subunit of a different protein, including, but not limited to, other cystine knot growth factors or glycoproteins. For instance, the invention includes a chimera VEGF analog in which the VEGF molecule contains a VEGF-A subunit fused to a VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, PDGF or PlGF subunit; a VEGF-B subunit fused to a VEGF-A, VEGF-C, VEGF-D, VEGF-E, VEGF-F, PDGF or PlGF subunit; a VEGF-C subunit fused to a VEGF-A, VEGF-B, VEGF-D, VEGF-E, VEGF-F, PDGF or PlGF subunit; a VEGF-D subunit fused to a VEGF-A, VEGF-B, VEGF-C, VEGF-E, VEGF-F, PDGF or PlGF subunit; or a PlGF subunit fused to a VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, or PDGF subunit. The subunits may optionally be separated by a linker peptide. The invention also includes different isoforms of the same VEGF fused together, e.g., VEGF165 subunit fused to VEGF165b.
[0018] In one embodiment, the VEGF analog is a single chain molecule. For instance, the VEGF analog of the invention includes two VEGF subunits, i.e., monomers, linked together via a linker peptide. One or both linked subunits can contain one or more basic amino acid substitutions. Further, the linked subunits can be different VEGF protein subunits and can be different isoforms of the same subunit. For instance, the present invention includes a wild-type VEGF165 subunit linked via a GS linker to a VEGF165 subunit with a I83K amino acid substitution.
[0019] In another embodiment of the invention, a VEGF-A, VEGF-B, VEGF-C, VEGF-D, or PlGF subunit or dimer comprising one or more mutations is fused to a toxin. The peptide of this embodiment can be useful for the targeting and destruction of tumor cells.
[0020] The VEGF analogs of the invention include one or more basic amino acid substitutions, such as lysine or arginine, from the group of positions 44, 67, 72, 73, 83, and 87. In one embodiment of the invention, the VEGF analog contains a basic amino acid substitution at position 83 and optionally one or more basic amino acid substitutions at positions 44, 67, 72 and 73. For instance, the invention includes a VEGF analog with a I83K mutation. The invention also includes, for instance, a VEGF analog with basic amino acids at positions 72, 73 and 83.
[0021] VEGF analogs with the basic amino acid substitutions described herein may contain additional amino acid substitutions to further increase receptor binding affinity to KDR and/or decrease receptor binding affinity to neuropilin-1. For instance, the invention includes mutations at positions 146 and 160 in the which act to disrupt the neuropilin-1 binding site.
[0022] Analogs of the invention can also contain additional amino acid substitutions which confer enhanced stability and increased serum half-life. For instance, the invention includes amino acids substitutions which eliminate proteolytic cleavage sites such substitutions at positions 111 and 148.
[0023] The VEGF receptor antagonists of the present invention can exhibit increased plasma half-life as compared to wild-type VEGF. This may be accomplished by further modifying a VEGF analog by methods known in the art to increase half-life or, alternatively, increased plasma half-life may be an inherent characteristic of a VEGF analog. The VEGF receptor antagonists of the invention can also exhibit an increase in rate of absorption and/or decreased duration of action compared to wild-type VEGF.
[0024] The modified analogs of the invention act as VEGF receptor antagonists and thus provide a long awaited solution for patients suffering from a wide spectrum of diseases and conditions associated with angiogenesis. The VEGF receptor antagonists can be administered to a patient alone or in conjunction with another VEGF receptor antagonist, an anti-cancer drug, or an anti-angiogenesis drug for the treatment of disease associated with angiogenesis, including but not limited to, solid tumor cancers, hemangiomas, rheumatoid arthritis, osteoarthritis, septic arthritis, asthma, atherosclerosis, idiopathic pulmonary fibrosis, vascular restenosis, arteriovenous malformations, meningiomas, neovascular glaucoma, psoriasis, Kaposi's Syndrome, angiofibroma, hemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic granuloma, retrolental fibroplasias, scleroderma, trachoma, von Hippel-Lindau disease, vascular adhesion pathologies, synovitis, dermatitis, neurological degenerative diseases, preeclampsia, unexplained female infertility, endometriosis, unexplained male infertility, pterygium, wounds, sores, skin ulcers, gastric ulcers, and duodenal ulcers.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] FIG. 1A is a graph comparing binding of the I83K mutant and wild-type VEGF-A to KDR. FIG. 1B is a graph showing a decrease in proliferation of HUVEC-2 endothelial cells in the presence of the I83K VEGF-A mutant compared to wild-type VEGF-A.
[0026] FIG. 2A is a graph comparing binding of the E44R analog and wild-type VEGF-A to KDR. FIG. 2B is a graph comparing HUVEC-2 cell proliferation in the presence of the E44R VEGF-A analog versus wild-type VEGF-A.
[0027] FIG. 3A is a graph comparing binding of the E72R+E73R VEGF mutant and wild-type VEGF-A to KDR. FIG. 3B is a graph comparing HUVEC-2 cell proliferation in the presence of the E72R+E73R VEGF mutant versus wild-type VEGF-A.
[0028] FIG. 4 is a graph comparing binding of E44R and EE72/73RR mutants to wild-type VEGF-A.
[0029] FIG. 5 is a graph comparing binding of Q87K mutant to wild-type VEGF-A.
[0030] FIG. 6 is a graph comparing binding of E67K mutant to wild-type VEGF-A.
DETAILED DESCRIPTION OF THE INVENTION
[0031] The present invention provides modified angiogenic growth factors of the vascular endothelial growth factor (VEGF) family which exhibit surprising activity as VEGF receptor antagonists. As VEGF receptor antagonists, the compounds of the invention have "anti-angiogenic" properties. Being "modified" means that, while the protein contains an amino acid sequence which differs from a wild-type VEGF of interest, i.e., human VEGF or animal VEGF, the sequence has not been changed such that it is identical to the known VEGF sequence of other species. The terms "mutated" and "substituted" are used interchangeably herein to refer to modified amino acid residues. The terms "modified VEGF molecules", "modified VEGF proteins", "VEGF analogs", "VEGF receptor antagonists", "VEGF chimeras", "VEGF fusion proteins" and "VEGF single chain molecules" are used interchangeably herein to refer to modified VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF analog molecules.
[0032] "Antagonists" are used interchangeably herein to refer to molecules which act to block, inhibit or reduce the natural, biological activities of VEGF, such as the induction of angiogenesis. The term "anti-angiogenic" as used herein means that the modified VEGF molecules of the invention block, inhibit or reduce the process of angiogenesis, or the process by which new blood or lymphatic vessels form from pre-existing vessels. The activities of the VEGF analogs of the invention disrupt normal VEGF/receptor signaling which usually occurs when VEGF binds to a receptor. Accordingly, the analogs of the invention are VEGF receptor antagonists. Without wishing to be bound by a theory, it is believed that the VEGF analogs of the invention disrupt the dimerization of KDR necessary for signaling.
[0033] Inhibition of angiogenesis may be complete or partial. The VEGF receptor antagonist may inhibit angiogenesis at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, and at least about 100% in vitro and in vivo. Inhibition of angiogenesis can be measured by a skilled artisan by methods known in the art. The determination of inhibition of angiogenesis can include the use of negative and/or positive controls. For instance, a skilled artisan can conclude that a VEGF analog of the invention inhibits VEGF-induced angiogenesis by comparing angiogenesis in a subject treated with a VEGF analog of the invention to a similar subject not treated with a VEGF analog.
[0034] The modified VEGF molecules of the invention display increased receptor binding affinity or similar receptor binding affinity to one or more native VEGF receptors compared to that of wild-type VEGF. As used herein, a native VEGF receptor is an unmodified receptor that specifically interacts with VEGF. For instance, an endogenous VEGF receptor is a native VEGF receptor. In one embodiment of the invention, the native receptor is KDR. KDR is a receptor of VEGF-A, VEGF-C, VEGF-D, VEGF-E and VEGF-F. In another embodiment, the native receptor is Flt-1. Flt-1 is a receptor of VEGF-A, VEGF-B and PlGF.
[0035] "Receptor binding affinity" refers to the ability of a ligand to bind to a receptor in vivo or in vitro and can be assessed by methods readily available in the art including, but not limited to, competitive binding assays and direct binding assays. As used herein, receptor binding affinity refers to the ability of VEGF molecules to bind to native VEGF receptors, including, but not limited to, Flt-1 (also known as VEGF-R1), KDR (also known as VEGF-R2) and Flt-4 (also known as VEGF-R3). For instance, the modified VEGF-A molecules of the invention display increased binding receptor affinity or similar binding affinity to KDR compared to wild-type VEGF-A. In one embodiment, the increase in receptor binding affinity of the modified VEGF molecules of the invention is at least about 1.25 fold, at least about a 1.5 fold, at least about a 1.75 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold or at least about 10 fold greater than that of wild-type VEGF.
[0036] In another embodiment, the modified VEGF exhibits a receptor binding affinity to KDR and/or other receptor that is involved in angiogenesis that is similar or comparable to that of wild-type VEGF. Similar or comparable receptor binding affinity is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97% or more of that of wild-type VEGF. For instance, the invention includes VEGF-A analogs exhibiting about 75% to 85%, about 85% to 95% and about 95% to 100% the receptor binding affinity exhibited by wild-type VEGF.
[0037] The present invention also includes VEGF analogs which display increased or similar receptor binding affinity to at least one native receptor but display decreased receptor binding affinity to another native receptor. For instance, VEGF-A analogs of the invention may display increased or similar receptor binding affinity to KDR compared to wild-type VEGF-A, but may display decreased receptor binding affinity to Flt-1, neuropilin-1 or neuropilin-2 compared to wild-type VEGF-A.
[0038] The VEGF analogs of the invention also display a decrease in bioactivity compared to wild-type VEGF. "Bioactivity" refers to the natural, biological activities of VEGF in vivo and in vitro, including, but not limited to, the ability of VEGF to induce cell proliferation in endothelial cells. A decrease in bioactivity results in a decrease in angiogenesis. In one embodiment of the invention, the VEGF analogs of the invention display a decrease in bioactivity compared to wild-type VEGF of the same isoform. For instance, a VEGF165 analog of the invention can display a decrease in bioactivity compared to wild-type VEGF165, and a VEGF165b analog can display a decrease in bioactivity compared to wild-type VEGF165b.
[0039] Bioactivity can be assessed by several methods known in the art, including, but not limited to, in vitro cell viability assays which assay the viability of endothelial cells such as human umbilical vein endothelial cells (HUVEC) upon exposure to VEGF. A decrease in endothelial cell viability of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% or more compared to resulting from exposure to wild-type VEGF is indicative of a decrease in bioactivity.
[0040] Bioactivity can be assessed in vivo as well. For instance, bioactivity can be assessed in vivo in a subject with a tumor by detecting a lack of increase in angiogenesis around a tumor. The detection of a lack of increase in angiogenesis can be accomplished by several methods known in the art including, but not limited to, an in vivo matrigel migration assay, a disc angiogenesis assay, an assay comprising a dorsal skinfold chamber in mice, a corneal transplant and a sponge implant model of angiogenesis. In one embodiment, angiogenesis is assessed by comparing angiogenesis of and around the tumor to that of a tumor of similar type, size and location in an untreated subject. Biopsy methods as known in the art can be used to extract tissue and analyze for vessel formation.
[0041] "Dissociation" of receptor binding affinity and bioactivity refers to the concept that receptor binding affinity and bioactivity are not correlated. In comparison, receptor binding affinity and bioactivity are correlated for wild-type VEGF proteins such as wild-type VEGF-A. An increase in receptor binding ability, for example, would be expected to result in an increase in bioactivity for wild-type VEGF-A. On the other hand, the modified VEGF molecules of the invention demonstrate a similar receptor binding affinity or an increase in receptor binding affinity as compared to wild-type VEGF but a decrease in bioactivity as compared to wild-type VEGF.
[0042] Mammalian VEGFs are produced in multiple isoforms due to alternative splicing of a family of related genes. The present invention describes VEGF analogs which correspond to VEGF isoforms involved in angiogenesis. The VEGF analogs of the present invention can be created using any VEGF isoform unless otherwise indicated.
[0043] VEGF-A can exist in isoforms including, but not limited to, 121, 145, 148, 165, 183, 189, and 206 amino acids, respectively. The three main mRNA species are VEGF121, VEGF165 and VEGF189. As used herein, VEGF121 (SEQ ID NO.: 6), VEGF145 (SEQ ID NO.: 8), VEGF148 (SEQ ID NO.: 10), VEGF165 (SEQ ID NO.: 4), VEGF165b (SEQ ID NO.: 13), VEGF183 (SEQ ID NO.: 15), VEGF189 (SEQ ID NO.: 17) and VEGF206 (SEQ ID NO.: 19) are isoforms of VEGF-A capable of being modified to possess anti-angiogenic properties. The amino acid positions described herein are based on a VEGF molecule lacking a leader sequence such as the leader sequence of SEQ ID NO.: 3. The amino acid sequences of VEGF-A isoforms with leader sequence are the sequences of SEQ ID NOs.: 2, 5, 7, 9, 12, 14, 16 and 18.
[0044] The various isoforms of VEGF-A share a common amino-terminal domain consisting of 110 amino acids. VEGF-A isoforms have a receptor binding domain encoded by exons 2-5. The most notable difference between the isoforms are found in the neuropilin and heparin binding domains which are encoded by exons 6a, 6b, 7a and 7b.
[0045] The most common VEGF-A isoform is VEGF165. The nucleic acid encoding VEGF165 is the sequence of SEQ ID NO.: 1. Recently, an endogenous splice variant referred to as VEGF165b was described which contains sequences encoded by exon 9, instead of exon 8, at the carboxy terminus. The nucleic acid molecule encoding this protein is the sequence of SEQ ID NO.: 11. VEGF165b (SEQ ID NO.: 12 with leader sequence; SEQ ID NO.: 13 without leader sequence) inhibited VEGF signaling in endothelial cells when added with VEGF165 (see Woolard et al., 2004, Cancer Research. 64: 7822-7835; see also U.S. 2005/0054036 which is herein incorporated by reference in its entirety).
[0046] In one embodiment of the invention, the VEGF analogs are VEGF-A analogs. VEGF-A analogs include "modified VEGF-A proteins", "VEGF-A receptor antagonists", "VEGF-A chimeras", "VEGF-A fusion proteins" and "VEGF-A single chain molecules." A VEGF-A analog is a VEGF-A molecule containing at least one modified VEGF-A subunit.
[0047] VEGF-B exists in two isoforms, VEGF-B167 (SEQ ID NO.: 48) and VEGF-B186 (SEQ ID NO.: 50) (Makinen et al., 1999, 3. Biol. Chem. 274: 21217-21222). In one embodiment of the invention, the VEGF analog is a VEGF-B analog. VEGF-B analogs include "modified VEGF-B proteins", "VEGF-B analogs", "VEGF-B receptor antagonists", "VEGF-B chimeras", "VEGF-B fusion proteins" and "VEGF-B single chain molecules." A VEGF-B analog is a VEGF-B molecule containing at least one modified VEGF-B subunit.
[0048] VEGF-C is produced as a propeptide (SEQ ID NO.: 51) that is proteolytically cleaved to form a 21-kd active protein (Nicosia, 1998, Am. J. Path. 153: 11-16). In one embodiment of the invention, the VEGF analog is a VEGF-C analog. VEGF-C analogs include "modified VEGF-C proteins", "VEGF-C analogs", "VEGF-C receptor antagonists", "VEGF-C chimeras", "VEGF-C fusion proteins" and "VEGF-C single chain molecules." A VEGF-C analog is a VEGF-C molecule containing at least one modified VEGF-C subunit.
[0049] VEGF-D is also produced as a propeptide (SEQ ID NO.: 52) that is proteolytically cleaved to form an active protein. VEGF-D is 48% identical to VEGF-C(Nicosia, supra). In one embodiment of the invention, the VEGF analog is a VEGF-D analog. VEGF-D analogs include "modified VEGF-D proteins", "VEGF-D analogs", "VEGF-D receptor antagonists", "VEGF-D chimeras", "VEGF-D fusion proteins" and "VEGF-D single chain molecules." A VEGF-D analog is a VEGF-D molecule containing at least one modified VEGF-D subunit.
[0050] Placenta growth factor (PlGF) exists in three isoforms, PlGF-1 (SEQ ID NO.: 54), PlGF-2 (SEQ ID NO.: 56) and PlGF-3 (SEQ ID NO.: 58). PlGF-2 contains an exon 6 encoded peptide which bestows heparin and neuropilin-1 binding properties absent in the other two isoforms. Both PlGF-1 and PlGF-2 have been reported as being capable of inducing endothelial cell migration (Migdal et al., 1998, J. Biol. Chem. 273: 22272-22278). In one embodiment of the invention, the VEGF analog is a PlGF analog. In another embodiment, the VEGF analog is PlGF-1 or PlGF-2. PlGF analogs include "modified PlGF proteins", "PlGF analogs", "PlGF receptor antagonists", "PlGF chimeras", "PlGF fusion proteins" and "PlGF single chain molecules." PlGF analogs are PlGF molecules with at least one modified PlGF subunit.
[0051] The VEGF analogs of the invention are modified animal or human VEGF molecules. In one embodiment of the invention, the VEGF analogs are mammalian VEGF molecules. In another embodiment of the invention, the VEGF analogs are avian VEGF molecules. The VEGF analogs of the present invention include, but are not limited to, modified primate, canine, feline, bovine, equinine, porcine, ovine, murine, rat and rabbit VEGF molecules. In one embodiment, the animal VEGF analog is a VEGF-A analog. For instance, the animal VEGF-A analog of the invention can be an animal VEGF165 or VEGF165b analog.
[0052] The modified VEGF molecules of species other than human have substitutions at positions corresponding to those in the modified human VEGF molecules disclosed herein and may be identified using any alignment program, including but not limited to DNASIS, ALIONment, SIM and GCG programs such as Gap, BestFit, FrameAlign, and Compare. As can be appreciated by one of skill in the art, the corresponding amino acid to be replaced with a basic amino acid may not be identical to the one in human VEGF-A. For instance, a skilled artisan would appreciate that a glutamate (E) may correspond to a different acidic amino acid in an animal such as aspartate (D).
[0053] In another embodiment, the corresponding amino acid is identified as being located in the same general position within a defined structure, for instance, on an outer loop structure. The structure of a protein can be predicted using software based on the amino acids of the protein. Accordingly, one of skill in the art can use software that predicts protein folding and loop structure to identify the corresponding position in a related protein.
[0054] Design of VEGF Receptor Antagonists
[0055] The VEGF receptor antagonists encompassed by the present invention may be designed by comparing the amino acid sequences of the VEGF of interest to that of other species to identify basic residues in the proteins of VEGF of other species. For instance, a VEGF-A molecule of instance can be designed by comparing a human VEGF-A to that of another species. Such methods are disclosed in U.S. Pat. No. 6,361,992, which is herein incorporated by reference in its entirety. Consideration may also be given to the relative biological activity of VEGF from various species as to which species to choose for comparison and amino acid substitution. Further homology modeling based on the structure of related glycoproteins is useful to identify surface-exposed amino acid residues. Homology modeling can be performed by methods generally know in the art, including, but not limited to, the use of protein modeling computer software.
[0056] The present invention also provides a modified VEGF protein, wherein the modified VEGF comprises an amino acid(s) substituted at a position(s) corresponding to the same amino acid position in a VEGF protein from another species having an increased binding affinity and/or decreased bioactivity over the wild-type VEGF. For example, snake venom VEGF-F binds to KDR with high affinity and strongly stimulates proliferation of vascular endothelial cells in vitro. One can compare human VEGF-A to snake venom VEGF, design human VEGF-A proteins with amino acid substitutions at one or more positions where the snake venom and human sequences differ, construct human VEGF-A proteins with the selected changes, and administer the modified human VEGF-A to humans. Although snake venom VEGF-F demonstrates an increase in KDR binding affinity and bioactivity, i.e., binding affinity and bioactivity are correlated, compared to human VEGF, one of skill in the art would understand that amino acid substitutions could be empirically tested to identify amino acid substitutions which increase receptor binding affinity but decrease or have no effect on bioactivity. An amino acid substitution which increases receptor binding affinity and/or decreases or has no effect on bioactivity may then be combined with one or more other amino acid substitutions known to increase receptor binding affinity and/or decrease bioactivity.
[0057] In another embodiment of the invention, the modified VEGF molecule can contain one or more amino acids substituted at a position(s) corresponding to the same amino acid position in a VEGF homolog that naturally exists in arthropods. In arthropods, a single growth factor performs the tasks performed by PDGF and VEGF in higher organisms. One of skill in the art would understand that amino acid substitutions could be empirically tested to identify amino acid substitutions which increase receptor binding affinity but decrease or have no effect on bioactivity, or, alternatively, have little effect on receptor binding affinity but decrease bioactivity.
[0058] Further, the present invention provides a modified VEGF, wherein the modified VEGF comprises a basic amino acid(s) substituted at a position(s) corresponding to the same amino acid in a different VEGF or VEGF isoform or closely related glycoprotein such as proteins in the PDGF family from the same species or different species. For example, VEGF165 can be compared to PDGF from the same species and amino acid substitutions made to the VEGF protein based on any sequence divergence. A skilled artisan can compare two or more sequences of VEGF proteins or VEGF-related proteins using methods known in the art such as the use of alignment software, including but not limited to, DNASIS, ALIONment, SIM and GCG programs such as Gap, BestFit, FrameAlign, and Compare.
[0059] In another aspect of the invention, the amino acid substitutions described herein can be incorporated into closely related proteins such as VEGF-E (SEQ ID NO.: 60), VEGF-F (SEQ ID NO.: 62) and PDGF (SEQ ID NO.: 63 and SEQ ID NO.: 64). For instance, one or more basic amino acid substitutions selected from the group consisting of E67, E72, E73, 183 and Q87 can be compared to a PDGF isoform from the same species and amino acid substitutions made to the PDGF isoform.
[0060] The VEGF analogs of the invention may be designed to display a decreased receptor binding affinity to Flt-1 receptors compared to wild-type VEGF-A. Although these analogs display a decreased receptor binding affinity to Flt-1, they may have an increased or comparable receptor binding affinity to KDR compared to wild-type VEGF-A.
[0061] The VEGF analogs of the invention may be designed to display a decreased receptor binding affinity to co-receptors, including, but not limited to, neuropilin-1 or neuropilin-2 compared to that of wild-type VEGF. Analogs with decreased receptor binding affinity to neuropilin-1 or neuropilin-2 may have increased or similar receptor binding affinity to KDR, Flt-1 or VEGR3 compared to that of wild-type VEGF. For instance, VEGF-A analogs can be designed which exhibit decreased receptor binding affinity to neuropilin-1 and increased receptor binding affinity to KDR and/or Flt-1. In one embodiment of the invention, the VEGF-A displaying decreased receptor binding affinity to neuropilin-1 is an analog designed in the VEGF165b splice variant. In another embodiment, VEGF-B167 and PlGF-2 analogs can be designed which exhibit decreased receptor binding affinity to neuropilin-1 and increased binding affinity to Flt-1.
[0062] In one embodiment of the invention, VEGF analogs are designed to exhibit decreased receptor binding affinity to neuropilin-1 or neuropilin-2 compared to wild-type VEGF by disrupting the VEGF neuropilin binding site. This can be accomplished by reducing the number of cysteine amino acid residues in the neuropilin-1 receptor binding domain. For instance, VEGF165 analogs can be designed to disrupt the neuropilin 1 binding site in VEGF165 by substituting the cysteine residues at positions 146 and/or 160 of SEQ ID NO.: 4 with amino acids such as serine which cause a disruption of the disulfide bridge. The substitution of cysteine residues at positions 146 and 160 of SEQ ID NO.: 4 disrupts neuropilin-1 binding but does not disrupt heparin binding. Mutations at positions 146 and/or 160 can be coupled with one or more mutations to increase, maintain or restore receptor binding affinity to KDR, Flt-1 and/or VEGFR3 as described herein.
[0063] Similarly, the present invention includes VEGF analogs which exhibit decreased receptor binding affinity to neuropilin-2 compared to wild-type VEGF. For instance, the invention includes VEGF-C and VEGF-D analogs which exhibit reduced binding affinity to neuropilin-2 but increased or similar binding affinity to KDR and/or VEGFR3 compared to wild-type VEGF-C or VEGF-D, respectively.
[0064] The invention also includes VEGF analogs which exhibit enhanced stability and resistance to proteases. In one embodiment, amino acids substitutions at positions A111 and A148 of SEQ ID NO.: 4 are incorporated in a VEGF-A analog to improve resistance to proteases. The invention also includes VEGF-C and VEGF-D analogs which contain mutations preventing the cleavage of the VEGF-C propeptide or VEGF-D propeptide, respectively. For instance, the present invention includes VEGF-C and VEGF-D analogs that contain one or more mutations which induce resistance to serine protease plasmin and/or other members of the plasminogen family.
[0065] In another embodiment of the invention, VEGF analogs which exhibit increased receptor binding affinity to one or more VEGF receptors, preferably KDR, can be created in a naturally occurring VEGF molecule which exhibits antagonistic properties. For instance, VEGF165b, an isoform isolated from kidney tissue, can be modified to incorporate the amino acid substitutions associated with an increase in receptor binding ability and decrease in bioactivity of the protein. Similarly, a skilled artisan could incorporate the amino acid substitutions of the present invention in synthetic or new isoforms of VEGF which contain the properties of VEGF165b. In particular, the mutations of the invention can be used with other VEGF proteins which contain the amino acids SLTRKD (SEQ ID NO.: 70), i.e., the amino acids coded for by what has been termed exon 9, in addition to or in place of the amino acids coded for by exon 8 (CDKPRR; SEQ ID NO.: 71).
[0066] Amino Acid Substitutions
[0067] The VEGF analogs of the present invention contain one or more basic amino acid substitutions which confer enhanced receptor binding affinity and decreased bioactivity. In one embodiment of the invention, the VEGF analogs are VEGF receptor antagonists, including but not limited to VEGF-A antagonists.
[0068] A modified VEGF molecule of the invention may have a basic amino acid substitution in one or more subunits, i.e., monomers, of VEGF. Basic amino acids comprise the amino acids lysine (K), arginine (R) and histidine (H), and any other basic amino acids which may be a modification of any of these three amino acids, synthetic basic amino acids not normally found in nature, or any other amino acids which are positively charged at a neutral pH. Preferred amino acids, among others, are selected from the group consisting of lysine and arginine.
[0069] In one embodiment, a modified VEGF molecule of the invention comprises at least one modified subunit, wherein the modified subunit comprises a basic amino acid substitution at position I83 of wild-type human VEGF165 (SEQ ID NO.: 4), VEGF121 (SEQ ID NO.: 6), VEGF145 (SEQ ID NO.: 8), VEGF148 (SEQ ID NO.: 10), VEGF165b (SEQ ID NO.: 13), VEGF183 (SEQ ID NO.: 15), VEGF189 (SEQ ID NO.: 17) or VEGF206 (SEQ ID NO.: 19). For instance, the invention includes an I83K amino acid substitution in SEQ ID NOs.: 4, 6, 8, 10, 13, 15, 17 or 19 corresponding to the amino acid sequences of VEGF-A isoforms.
[0070] The invention also includes a basic amino acid substitution in the position corresponding to position 83 in other VEGF molecules, i.e., VEGF-B, VEGF-C, VEGF-D and PlGF, such as position 183 of VEGF-B167 (SEQ ID NO.: 48) or VEGF-B186 (SEQ ID NO.: 50) and position 191 of PlGF-1 (SEQ ID NO.: 54), PlGF-2 (SEQ ID NO.: 56) or PlGF-3 (SEQ ID NO.: 58).
[0071] The invention includes modified VEGF molecules in animals other than humans, wherein the VEGF molecule contains, in one or more subunits, a basic amino acid substitution in the position corresponding to position 83 in human VEGF-A. In one embodiment, the modified animal VEGF is a modified VEGF-A molecule. For instance, the present invention includes a basic amino acid substitution at position 183 in primate (SEQ ID NO.: 22), position 182 in bovine (SEQ ID NO.: 25), position 182 in canine (SEQ ID NO.: 28), position 183 in chicken (SEQ ID NO.: 31), position 182 in equine (SEQ ID NO.: I82), position 182 in murine (SEQ ID NO.: 37), position 182 in porcine (SEQ ID NO.: 40), position 182 of rat (SEQ ID NO.: 43) and position 182 in ovine (SEQ ID NO.: 46).
[0072] The invention also envisions a modified VEGF-related protein, including, but not limited to VEGF-E, VEGF-F and PDGF, containing an amino acid substitution corresponding to position 183 of SEQ ID NO.: 4. For instance, VEGF-F (SEQ ID NO.: 62) can be modified to include an 183 amino acid substitution.
[0073] The modified VEGF molecule of the invention can contain basic amino acid substitutions which further increase the binding affinity or decrease bioactivity of VEGF compared to wild-type VEGF such as wild-type VEGF-A. VEGF molecules with basic amino acid substitutions at one or more of positions 44, 67, 72, 73 and/or 87 of VEGF165 (SEQ ID NO.: 4), VEGF121 (SEQ ID NO.: 6), VEGF145 (SEQ ID NO.: 8), VEGF148 (SEQ ID NO.: 10), VEGF165b (SEQ ID NO.: 13), VEGF183 (SEQ ID NO.: 15), VEGF189 (SEQ ID NO.: 17) and VEGF206 (SEQ ID NO.: 19) can increase binding affinity for KDR compared to wild-type VEGF. For instance, the invention includes the basic amino acid modifications E44R, E44K, E72R, E72K, E73R, E73K, Q87R, Q87K and E67K.
[0074] In one embodiment of the invention, basic amino substitutions corresponding to positions 44, 67, 72, 73 and/or 87 of SEQ ID NO.: 4 are coupled with the basic amino acid substitution corresponding to position 83 of SEQ ID NO.: 4 to produce a VEGF receptor antagonists. For instance, the modified amino acids of the present invention include basic amino acid substitutions at positions 72+73+83, 44+83, 72+83, 73+83, 44+72+83, 44+73+83, 44+72+73+83, 44+83+87, 83+87, 67+72+73+83; 44+67+83, 67+72+83, 67+73+83, 44+67+72+83, 44+67+73+83, 44+67+72+73+83, 44+67+83+87 and 67+83+87.
[0075] In another embodiment of the invention, the analog is a VEGF165b molecule containing one or more basic amino acids at positions E44, E67, E72, E73 and Q87 and optionally a basic amino acid substitution at position I83. When the VEGF-A isoform is VEGF165b, it is possible to generate a VEGF analog of the invention with increased binding affinity and decreased bioactivity compared to wild-type VEGF-A, including VEGF165, by incorporating a single amino acid modification that would otherwise only result in an increase in receptor binding affinity in other VEGF165.
[0076] As can be appreciated by a skilled artisan, the invention includes VEGF proteins and VEGF-related proteins other that VEGF-A that contain basic amino acid modifications corresponding to those of positions E44, E67, E72, E73 and/or Q87 of VEGF-A (SEQ ID NO.: 4). For instance, the invention includes a modified VEGF-B analog (SEQ ID NOs.: 48 and 50) containing one or more basic amino acid substitutions at positions A44, E67, G72, Q73 and S87 and a modified VEGF-F analog (SEQ ID NO.: 62) containing one or more basic amino acid substitutions at positions E44, E67, E72, E73 and Q87.
[0077] A modified animal, i.e., non-human, VEGF-A molecule of the invention can likewise contain additional amino acid modifications to increase binding affinity or decrease bioactivity of the modified animal VEGF molecule compared to wild-type animal VEGF. The invention includes the use of these modifications in conjunction with an amino acid substitution that corresponds to 183 of SEQ ID NO.: 4 as described above. For instance, the present invention includes one or more basic amino acid substitutions selected from the group of positions E44, E67, E72, E73, I83 and I87 of primate (long-tailed macaque) VEGF-A (SEQ ID NO.: 22); one or more basic amino acid substitutions selected from the group of positions E43, E66, E71, E72, I82 and Q86 of bovine VEGF-A (SEQ ID NO.: 25); one or more basic amino acid substitutions selected from the group of positions E43, E66, E71, E72, I82 and Q86 of canine VEGF-A (SEQ ID NO.: 28); one or more basic amino acid substitutions selected from the group of positions E44, E67, D72, V73, I83 and Q87 of avian (chicken) VEGF-A (SEQ ID NO.: 31); one or more basic amino acid substitutions selected from the group of positions E43, E66, A71, E72, I82 and Q86 of equine VEGF-A (SEQ ID NO.: 34); one or more basic amino acid substitutions selected from the group of positions E43, E66, S71, E72, I82 and Q86 of murine VEGF-A (SEQ ID NO.: 37); one or more basic amino acid substitutions selected from the group of positions E43, E66, E71, E72, I82 and Q86 of porcine VEGF-A (SEQ ID No.: 40); one or more basic amino acid substitutions selected from the group of positions E43, E66, S71, E72, I82 and Q86 of rat VEGF-A (SEQ ID NO.: 43); and one or more basic amino acid substitutions selected from the group of positions E43, E66, E71, E72, I82 and Q86 of ovine VEGF-A (SEQ ID NO.: 46).
[0078] VEGF analogs containing one or more basic amino acid substitutions can also be combined with amino acid substitutions designed to disrupt a co-receptor binding site. In one embodiment, the VEGF analogs of the invention contain a disrupted neuropilin-1 binding site. The neuropilin-1 binding site comprises amino acids 111 to 165 of VEGF165 (SEQ ID NO.: 04). This domain overlaps the heparin binding domain encoded by exons 6 and 7. The invention includes any amino acid modifications in or near (i.e., within about 5 amino acids) that disrupt the neuropilin-1 binding site domain but which do not disrupt the ability of the heparin binding domain to bind heparin sulfate. Such amino acid modifications can be determined empirically by a skilled artisan.
[0079] In one embodiment of the invention, the neuropilin-1 binding domain is disrupted by reducing the number of cysteine amino acid residues in the domain, i.e., by reducing the number of cysteine amino acid residues between amino acids 111 to 165 of VEGF-A. For instance, VEGF165 analogs can be designed to disrupt the neuropilin 1 binding site by substituting the cysteine residues at positions 146 and/or 160 of SEQ ID NO.: 4 with amino acids such as serine which cause a disruption of the disulfide bridge. The substitution of cysteine residues at positions 146 and 160 of SEQ ID NO.: 4 disrupts neuropilin-1 binding but does not disrupt heparin binding. The neuropilin-1 binding site can also be disrupted by ending the amino acid peptide at position 146 or 160.
[0080] The invention can also included modifications of amino acids surrounding amino acids at positions 146 and 160 of SEQ ID NO.: 4 such that the cysteine residues of positions 146 and 160 are unable to form a disulfide bridge. For instance, the invention includes, but is not limited to, one or more amino acid substitutions at positions 136 through 165 which are capable of disrupting the formation of a disulfide bridge.
[0081] A modified VEGF analog of the invention containing one or more of the basic amino acid substitutions corresponding to E44, E67, E72, E73, I83 and Q87 of SEQ ID NO.: 4 described herein. For instance, the invention includes VEGF analogs with amino acid substitutions at positions E44B+C146X, E44B+C160X, E44B+C146X+C160X, E67B+C146X, E67B+C160X, E67B+C146X+C160X, E44B+E67B+C146X, E44B+E67B+C160X, E44B+E67B+C146X+C160X, E72B+C146X, E72B+C160X, E72B+C146X+C160X, E73B+C146X, E73B+C160X, E73B+C146X+C160X, E72B+E73B+C146X, E72B+E73B+C160X, E72B+E73B+C146X+C160X, I83B+C146X, I83B+C160X, I83B+C146X+C160X, Q87B+C146X, Q87B+C160X, Q87B+C146X+C160X, E44B+E67B+E72B+C146X, E44B+E67B+E72B+C160X, E44B+E67B+E72+C146X+C160X, E44B+E67B+E73B+C146X, E44B+E67B+E73B+C160X, E44B+E67B+E73B+C146X+C160X, E44B+E67B+E72B+E73B+C146X, E44B+E67B+E72B+E73B+C160X, E44B+E67B+E72B+E73B+C146X+C160X, E67B+E72B+E73B+C146X, E67B+E72B+E73B+C160X, E67B+E72B+E73B+C146X+C160X, E44B+E72B+E73B+C146X, E44B+E72B+E73B+C160X, E44B+E72B+E73B+C146X+C160X, E44B+I83B+C146X, E44B+I83B+C160X, E44B+I83B+C146X+C160X, E67B+I83B+C146X, E67B+I83B+C160X, E67B+I83B+C146X+C160X, E44B+E67B+I83B+C146X, E44B+E67B+I83B+C160X, E44B+E67B+I83B+C146X+C160X, E72B+I83B+C146X, E72B+I83B+C160X, E72B+I83B+C146X+C160X, E73B+I83B+C146X, E73B+I83B+C160X, E73B+I83B+C146X+C160X, E72B+E73B+I83B+C146X, E72B+E73B+I83B+C160X, E72B+E73B+I83B+C146X+C160X, I83B+Q87B+C146X, I83B+Q87B+C160X, I83B+Q87B+C146X+C160X, E44B+E67B+E72B+I83B+C146X, E44B+E67B+E72B+I83B+C160X, E44B+E67B+E72+183B+C146X+C160X, E44B+E67B+E73B+I83B+C146X, E44B+E67B+E73B+I83B+C160X, E44B+E67B+E73B+I83B+C146X+C160X, E44B+E67B+E72B+E73B+I83B+C146X, E44B+E67B+E72B+E73B+I83B+C160X, E44B+E67B+E72B+E73B+I83B+C146X+C160X, E67B+E72B+E73B+I83B+C146X, E67B+E72B+E73B+I83B+C160X, E67B+E72B+E73B+I83B+C146X+C160X, E44B+E72B+E73B+I83B+C146X, E44B+E72B+E73B+I83B+C160X and E44B+E72B+E73B+I83B+C146X+C160X, wherein B is a basic amino acid and X is any amino acid other than cysteine. In one embodiment, X is serine.
[0082] The modified proteins of the invention may also contain further substitutions, particularly conservative substitutions that do not alter the enhanced properties of the protein. Typically, however, such modified proteins will contain less than five substitutions at positions other than those listed above, and may exhibit complete amino acid sequence identity with the corresponding wild-type VEGF subunits in positions other that the positions listed above.
[0083] As can be appreciated by a skilled artisan, all amino acid substitutions and peptide modifications disclosed in the present invention can be incorporated in any VEGF protein or related protein, regardless of species, because of the high degree of homology between VEGF proteins and related proteins. A skilled artisan can correlate the amino acid substitutions described herein using methods known in the art, including, but not limited to, the use of amino acid sequence alignment software.
[0084] VEGF Analogs with Increased Serum Half-Life
[0085] The VEGF analogs of the invention may have an increased plasma half-life as compared to wild-type VEGF. In one embodiment, the modification(s) which increases or maintains receptor binding affinity and decreases bioactivity as compared to wild-type VEGF also increases the plasma half-life of the VEGF as compared to wild-type VEGF. In another embodiment, the modified VEGF proteins of the invention are further modified such that the plasma half-life is increased as compared to wild type VEGF.
[0086] There are many modifications known in the art that can be used to increase the half-life of proteins, in particular glycoproteins. For instance, the modified VEGF proteins of the invention may further comprise at least one sequence with a potential glycosylation site including sequences comprising N-glycosylation and/or O-glycosylation sites on either the alpha or beta chain. Sequences providing potential glycosylation recognition sites may be either an N-terminal or C-terminal extension on either subunit. Exemplary modified proteins contain an N-terminal extension on a subunit that is selected from the group consisting of ANITV (SEQ ID NO.: 72) and ANITVNITV (SEQ ID NO.: 73).
[0087] Increased half-life may also be provided by the use of a peptide extensions such as a carboxyl terminal extension peptide of hCG. See U.S. Ser. No. 09/519,728 which is herein incorporated by reference in its entirety. A subunit of a VEGF analog may be covalently bound by any method known in the art to a CTEP, e.g., by a peptide bond or by a heterobifunctional reagent able to form a covalent bond between the amino terminus and carboxyl terminus of a protein, including but not limited to a peptide linker.
[0088] In another embodiment of the invention, the basic amino acid substitutions of the invention are coupled with one or more amino acid substitutions that enhance stability and increase serum half-life by eliminating one or more proteolytic cleavage sites. In one embodiment, the additional amino acid substitutions reduce proteolytic cleavage. In another embodiment, the additional amino acid substitutions prevent proteolytic cleavage. The invention includes VEGF analogs that contain one or more mutations which induce resistance to plasmin and other members of the plasminogen family. In one embodiment of the invention, at least one subunit of a VEGF molecule contains an amino acid substitution corresponding to amino acid positions A111 and/or A148 such as A111P and/or A148P of VEGF165 (SEQ ID NO.: 4) or VEGF165b (SEQ ID NO.: 13). For instance, the invention includes VEGF121, VEGF145, VEGF148, VEGF183, VEGF189 and VEGF206 containing an amino acid substitution at position A111. The invention includes one or more mutations in VEGF-B, VEGF-C, VEGF-D and PlGF which inhibit or reduce protease cleavage. For instance, the invention includes amino acid substitutions which prevent the cleavage of VEGF-C and VEGF-D necessary for bioactivity.
[0089] In another embodiment, half-life can be increased by linking VEGF monomers and by constructing fusion proteins. Increasing the size of a VEGF analog without interfering with binding sites can increase the half-life of the molecule.
[0090] Increased half-life may be provided by crosslinking, including but not limited to pegylation or conjugation of other appropriate chemical groups. Such methods are known in the art, for instance as described in U.S. Pat. No. 5,612,034, U.S. Pat. No. 6,225,449, and U.S. Pat. No. 6,555,660, each of which is incorporated by reference in its entirety. Half-life may also be increased by increasing the number of negatively charged residues within the molecule, for instance, the number of glutamate and/or aspartate residues. Such alteration may be accomplished by site directed mutagenesis or by an insertion of an amino acid sequence containing one or more negatively charged residues into said modified VEGF, including insertions selected from the group consisting of GEFT and GEFTT, among others.
[0091] The half-life of a protein is a measurement of protein stability and indicates the time necessary for a one-half reduction in the concentration of the protein. The serum half-life of the modified VEGF molecules described herein may be determined by any method suitable for measuring VEGF levels in samples from a subject over time, for example, but not limited to, immunoassays using anti-VEGF antibodies to measure VEGF levels in serum samples taken over a period of time after administration of the modified VEGF, or by detection of labeled VEGF molecules, i.e., radiolabeled molecules, in samples taken from a subject after administration of the labeled VEGF.
[0092] The rate of absorption of a VEGF analog of the present invention may result in increased or decreased duration of action. A VEGF analog with an increased rate of absorption and decreased duration of action may be beneficial for patients receiving a VEGF analog pharmaceutical composition by way of subcutaneous administration or other route of administration generally associated with a slow rate of absorption and/or increased duration of action by counteracting the absorption qualities associated with the route of administration.
[0093] Linker
[0094] The VEGF analog of the invention can contain two or more monomers separated by a linker peptide. A linker peptide can be used to form a VEGF analog in a single chain conformation. A skilled artisan can appreciate that various types of linkers can be used in the present invention to form a VEGF single chain molecule that is capable of binding a VEGF receptor and which acts as a VEGF receptor antagonist. A linker peptide should not hinder the ability of the single chain molecule to bind a VEGF receptor.
[0095] The linker peptide can range from about 2 to about 50 or more amino acids in length. For instance, the linker can consist of about 2 amino acids, about 3 amino acids, about 4 amino acids, about 5 amino acids, about 6 amino acids, about 7 amino acids, about 8 amino acids, about 9 amino acids, about 10 amino acids, about 10-15 amino acids, or about 15-20 amino acids. In one embodiment of the invention, the linker is Gly-Ser or contains Gly-Ser. In another embodiment, the linker is a glycine-rich polypeptide chain.
[0096] VEGF molecules containing a linker can be constructed using the methods described herein. A skilled artisan would be able to appreciate that VEGF analog molecules of the invention containing linker peptides can include any of the mutations described herein, in one or more monomers. Further, a VEGF analog containing one or more linker peptides can link more than one type of VEGF protein or isoform. For instance, the present invention includes, but is not limited to, a modified VEGF single chain molecule with a wild-type VEGF165 monomer linked to a modified VEGF165 monomer containing an I83B substitution; a wild-type VEGF165 monomer linked to a modified VEGF165b containing an I83B substitution; and a modified VEGF165 monomer fused to a modified VEGF-F monomer.
[0097] VEGF Fusion Proteins
[0098] The present invention also includes fusion proteins, i.e., chimeras, containing one or more modified VEGF proteins or fragments. "Fusion protein" and "chimera" are used interchangeably herein. As used herein, a VEGF moiety is a VEGF protein or protein fragment containing one or more of the basic amino acid substitutions of the invention. A VEGF fusion protein can have one or more VEGF moieties.
[0099] Such a fusion protein may be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the fusion protein by any of the means described herein. Alternatively, such a fusion protein may be made by protein synthesis techniques, for example, using a peptide synthesizer.
[0100] The fusion protein of the invention contains at least one VEGF protein or protein fragment containing one or more basic amino acid substitutions described herein. In one embodiment the fusion protein contains a basic amino acid substitution at position 183 of VEGF165 (SEQ ID NO. 4), VEGF165b (SEQ ID NO. 13), VEGF121 (SEQ ID NO.: 6), VEGF145 (SEQ ID NO.: 8), VEGF148 (SEQ ID NO.: 10), VEGF183 (SEQ ID NO.: 15), VEGF189 (SEQ ID NO.: 17) or VEGF206 (SEQ ID NO.: 19). In another embodiment, the fusion protein contains at least one basic amino acid substitution at a position corresponding to I83K of SEQ ID NO.: 4 in another VEGF protein, for instance, an isoform of VEGF-B, VEGF-C, VEGF-D or PlGF. As can be appreciated by a skilled artisan, human or animal VEGF proteins or fragments thereof may be used for the fusion proteins of the invention.
[0101] In one embodiment of the invention, two different VEGF protein subunits or fragments thereof are fused. For instance, the invention includes a VEGF-A subunit or fragment thereof fused to a VEGF-B subunit or fragment thereof, a VEGF-C subunit or fragment thereof, a VEGF-D subunit or fragment thereof, or a PlGF subunit or fragment thereof; a VEGF-B subunit or fragment thereof fused to a VEGF-A subunit or fragment thereof, a VEGF-C subunit or fragment thereof, a VEGF-D subunit or fragment thereof, or a PlGF subunit or fragment thereof., a VEGF-C subunit or fragment thereof fused to a VEGF-A subunit or fragment thereof, a VEGF-B subunit or fragment thereof, a VEGF-D subunit or fragment thereof, or a PlGF subunit or fragment thereof; a VEGF-D subunit or fragment thereof fused to a VEGF-A subunit or fragment thereof, a VEGF-B subunit or fragment thereof, a VEGF-C subunit or fragment thereof, or a PlGF subunit or fragment thereof; and a PlGF subunit or fragment thereof fused to a VEGF-A subunit or fragment thereof, a VEGF-B subunit or fragment thereof, a VEGF-C subunit or fragment thereof, or a VEGF-D subunit or fragment thereof.
[0102] The invention includes fusion proteins comprised of two or more different isoforms of the same VEGF protein or fragments thereof. For instance, the invention includes a fusion protein comprised of a VEGF165 subunit or fragment thereof fused to a VEGF121 subunit or fragment thereof, a VEGF145 subunit or fragment thereof, a VEGF148 subunit or fragment or subunit thereof, a VEGF165b subunit or fragment thereof, a VEGF183 subunit or fragment thereof, a VEGF189 subunit or fragment thereof, or a VEGF206 subunit or fragment thereof. The invention also includes a a VEGF165b subunit or fragment thereof fused to a VEGF121 subunit or fragment thereof, a VEGF145 subunit or fragment thereof, a VEGF148 subunit or fragment or subunit thereof, a VEGF165 subunit or fragment thereof, a VEGF183 subunit or fragment thereof, a VEGF189 subunit or fragment thereof, or a VEGF206 subunit or fragment thereof.
[0103] The basic amino acid substitutions of the invention may be present in one or more subunits of the protein. For example, a fusion protein containing a VEGF165 subunit and VEGF165b subunit may only contain an amino acid substitution in the VEGF165 subunit. The invention includes a wild-type VEGF165 subunit fused by way of a GS linker to a VEGF165 containing an I83K amino acid substitution. As can be appreciated by one of skill in the art, the fusion proteins of the present invention containing one mutated subunit can be created in both orientations, i.e., the subunit containing the mutation can be at either the N- or C-terminus of the fusion protein.
[0104] In another embodiment of the invention, a VEGF subunit or fragment thereof is fused to a related protein subunit or fragment thereof. For instance, a VEGF subunit or fragment thereof can be fused to a PDGF subunit or other glycoprotein subunit or fragment thereof.
[0105] As can be appreciated by one of ordinary skill in the art, the fusion proteins described herein can be constructed using human or animal VEGF sequences. Further, a fusion protein can be constructed using a human VEGF subunit fused to an animal VEGF subunit.
[0106] A VEGF fusion protein should be understood to be a VEGF analog. All modifications disclosed herein, for instance, modifications to further increase receptor binding affinity, modifications to increase half-life and stability, modifications to reduce or inhibit protease cleavage, and modifications to disrupt a co-receptor binding site such as a neuropilin-1 binding site can be incorporated in one or more subunits of the VEGF fusion protein.
[0107] The fusion proteins of the invention can also contain a linker separating the two or more VEGF subunits or VEGF-related protein subunits. The linker can be covalently linked to and between the peptides of the fusion protein.
[0108] VEGF and Toxin Fusion Proteins
[0109] The present invention provides fusion proteins comprising a toxin and one or more modified VEGF subunits, i.e., monomers, containing one or more of the basic amino acid substitutions described herein. For instance, the VEGF monomer, i.e., subunit, of a VEGF-toxin fusion protein can contain a basic amino acid at one or more amino acid positions corresponding to the amino acid positions from the group consisting of 44, 67, 72, 73, 83 and 87 (SEQ ID NO.: 4 or SEQ ID NO.: 13). The VEGF and toxin fusion proteins of the invention may optionally contain a linker sequence separating the toxin and one or more VEGF subunits.
[0110] As used herein, the term "toxin" refers to a poisonous substance of biological origin. The toxin of the invention may be a soluble toxin as known in the art. The fusion proteins comprising a soluble toxin may be used to target tumors. Such fusion proteins may also be used for diagnostic purposes.
[0111] Examples of toxins include, but are not limited to, Pseudomonas exotoxins (PE), Diphtheria toxins (DT), ricin toxin, abrin toxin, anthrax toxins, shiga toxin, botulism toxin, tetanus toxin, cholera toxin, maitotoxin, palytoxin, ciguatoxin, textilotoxin, batrachotoxin, alpha conotoxin, taipoxin, tetrodotoxin, alpha tityustoxin, saxitoxin, anatoxin, microcystin, aconitine, exfoliatin toxins A and B, enterotoxins, toxic shock syndrome toxin (TSST-1), Y. pestis toxin, gas gangrene toxin, and others.
[0112] In one embodiment, the present invention provides a pharmaceutical composition comprising a soluble toxin fused to a modified VEGF and a pharmaceutically acceptable carrier. In another embodiment, the present invention provides the use of a modified VEGF fusion protein comprising a soluble toxin for the manufacture of a medicament for the treatment or prevention of diseases or conditions associated with angiogenesis.
[0113] Without wishing to be bound by a theory, it is believed that the VEGF-toxin fusion protein of the invention prevents or reduces angiogenesis, the growth of tumors and/or the spread of cancer by targeting and killing the VEGF receptor and surrounding endothelial and tumor cells.
[0114] Expression and/or Synthesis of VEGF Receptor Antagonists
[0115] The present invention includes nucleic acids encoding the modified VEGF proteins of the invention, as well as vectors and host cells for expressing the nucleic acids.
[0116] As used herein, the terms "nucleic acid" or "polynucleotide" refer to deoxyribonucleotides or ribonucleotides and polymers thereof in either single or double stranded form. The invention includes a nucleic acid molecule which codes for a modified VEGF molecule of the invention. For instance, the invention includes a nucleic acid molecule that codes for a modified VEGF165 molecule. The nucleic acid molecule of SEQ ID NO.: 1 which codes for wild-type VEGF165 can be mutated by methods known in the art such that the mutated VEGF165 nucleic acid molecule codes for the modified protein. Similarly, the nucleic acid molecule of SEQ ID NO.: 11 which codes for wild-type VEGF165b can be mutated by methods known in the art such that it codes for a VEGF165b molecule of the invention.
[0117] Once a nucleic acid encoding a particular modified VEGF of interest, or a region of that nucleic acid encoding a portion of the protein containing a basic amino acid substitution, is constructed, modified, or isolated, that nucleic acid can then be cloned into an appropriate vector, which can direct the in vivo or in vitro synthesis of the modified VEGF protein. Alternatively, the nucleic acid encoding a VEGF analog of the invention may be cloned or modified directly in the expression vector of interest. The vector is contemplated to have the necessary functional elements that direct and regulate transcription of the inserted gene, or hybrid gene. These functional elements include, but are not limited to, a promoter, regions upstream or downstream of the promoter, such as enhancers that may regulate the transcriptional activity of the promoter, an origin of replication, appropriate restriction sites to facilitate cloning of inserts adjacent to the promoter, antibiotic resistance genes or other markers which can serve to select for cells containing the vector or the vector containing the insert, RNA splice junctions, a transcription termination region, or any other region which may serve to facilitate the expression of the inserted gene or hybrid gene. (See generally, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (1989)). Appropriate promoters for the expression of nucleic acids in different host cells are well known in the art, and are readily interchanged depending on the vector-host system used for expression. Exemplary vectors and host cells are described in U.S. Pat. No. 6,361,992, which is herein incorporated by reference in its entirety.
[0118] There are numerous E. coli (Escherichia coli) expression vectors known to one of ordinary skill in the art which are useful for the expression of the nucleic acid insert. Other vectors suitable for use include expression vectors from bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species. These expression vectors will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any number of a variety of well-known promoters will be present, such as the lactose promoter system, a tryptophan (Trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences for example, for initiating and completing transcription and translation. If necessary, an amino terminal methionine can be provided by insertion of a Met codon 5' and in-frame with the downstream nucleic acid insert. Also, the carboxy-terminal extension of the nucleic acid insert can be removed using standard oligonucleotide mutagenesis procedures.
[0119] Additionally, yeast expression systems can be used. There are several advantages to yeast expression systems. First, evidence exists that proteins produced in a yeast secretion systems exhibit correct disulfide pairing. Second, post-translational glycosylation is efficiently carried out by yeast secretory systems. The Saccharomyces cerevisiae pre-pro-alpha-factor leader region (encoded by the MF''-1 gene) is routinely used to direct protein secretion from yeast. (Brake, et al.," varies-Factor-Directed Synthesis and Secretion of Mature Foreign Proteins in Saccharomyces cerevisiae." Proc. Nat. Acad. Sci., 81:4642-4646 (1984)). The leader region of pre-pro-alpha-factor contains a signal peptide and a pro-segment which includes a recognition sequence for a yeast protease encoded by the KFX2 gene. This enzyme cleaves the precursor protein on the carboxyl side of a Lys-Arg dipeptide cleavage signal sequence. The VEGF coding sequence can be fused in-frame to the pre-pro-alpha-factor leader region. This construct is then put under the control of a strong transcription promoter, such as the alcohol dehydrogenase I promoter or a glycolytic promoter. The nucleic acid coding sequence is followed by a translation termination codon which is followed by transcription termination signals. Alternatively, the nucleic acid coding sequences can be fused to a second protein coding sequence, such as Sj26 or beta-galactosidase, which may be used to facilitate purification of the fusion protein by affinity chromatography. The insertion of protease cleavage sites to separate the components of the fusion protein is applicable to constructs used for expression in yeast. Efficient post-translational glycosolation and expression of recombinant proteins can also be achieved in Baculovirus systems.
[0120] Mammalian cells permit the expression of proteins in an environment that favors important post-translational modifications such as folding and cysteine pairing, addition of complex carbohydrate structures, and secretion of active protein. Vectors useful for the expression of active proteins in mammalian cells are characterized by insertion of the protein coding sequence between a strong viral or other promoter and a polyadenylation signal. The vectors can contain genes conferring hygromycin resistance, gentamicin resistance, or other genes or phenotypes suitable for use as selectable markers, or methotrexate resistance for gene amplification. The chimeric protein coding sequence can be introduced into a Chinese hamster ovary (CHO) cell line using a methotrexate resistance-encoding vector, or other cell lines using suitable selection markers. Presence of the vector DNA in transformed cells can be confirmed by Southern blot analysis. Production of RNA corresponding to the insert coding sequence can be confirmed by Northern blot analysis. A number of other suitable host cell lines capable of secreting intact human proteins have been developed in the art, and include the CHO cell lines, HeLa cells, myeloma cell lines, Jurkat cells, etc. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary information processing sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Exemplary expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, Bovine Papilloma Virus, etc. The vectors containing the nucleic acid segments of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transformation is commonly utilized for prokaryotic cells, whereas calcium phosphate, DEAE dextran, or lipofectin mediated transfection or electroporation may be used for other cellular hosts.
[0121] Expression of the gene or hybrid gene can be either in vivo or in vitro. In vivo synthesis comprises transforming prokaryotic or eukaryotic cells that can serve as host cells for the vector. For instance, techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (ibid.), Hinnen et al. (Proc. Natl. Acad. Sci. USA 75: 1929-1933, 1978), Yelton et al., (Proc. Natl. Acad. Sci. USA 81: 1740-1747, 1984), and Russell (Nature 301: 167-169, 1983). Other techniques for introducing cloned DNA sequences into fungal cells, such as electroporation (Becker and Guarente, Methods in Enzymol. 194: 182-187, 1991) may be used. The genotype of the host cell will generally contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art.
[0122] Cloned DNA sequences comprising modified VEGF and VEGF fusion proteins of the invention may be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14: 725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7: 603, 1981; Graham and Van der Eb, Virology 52: 456, 1973.) Other techniques for introducing cloned DNA sequences into mammalian cells, such as electroporation (Neumann et al., EMBO J. 1: 841-845, 1982), or lipofection may also be used. In order to identify cells that have integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable selectable marker. A preferred amplifiable selectable marker is the DHFR gene. A particularly preferred amplifiable marker is the DHFR' (see U.S. Pat. No. 6,291,212) cDNA (Simonsen and Levinson, Proc. Natl. Acad. Sci. USA 80: 2495-2499, 1983). Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, Mass.) and the choice of selectable markers is well within the level of ordinary skill in the art.
[0123] Alternatively, expression of the gene can occur in an in vitro expression system. For example, in vitro transcription systems are commercially available which are routinely used to synthesize relatively large amounts of mRNA. In such in vitro transcription systems, the nucleic acid encoding the modified VEGF would be cloned into an expression vector adjacent to a transcription promoter. For example, the Bluescript II cloning and expression vectors contain multiple cloning sites which are flanked by strong prokaryotic transcription promoters. (Stratagene Cloning Systems, La Jolla, Calif.). Kits are available which contain all the necessary reagents for in vitro synthesis of an RNA from a DNA template such as the Bluescript vectors. (Stratagene Cloning Systems, La Jolla, Calif.). RNA produced in vitro by a system such as this can then be translated in vitro to produce the desired VEGF analog (Stratagene Cloning Systems, La Jolla, Calif.).
[0124] Another method of producing a VEGF receptor antagonist is to link two peptides or polypeptides together by protein chemistry techniques. Peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert-butyloxycarbonoyl) chemistry. (Applied Biosystems, Inc., Foster City, Calif.). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to a hybrid VEGF protein can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of a hybrid peptide can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form a hybrid peptide. (Grant, G. A., "Synthetic Peptides: A User Guide," W. H. Freeman and Co., N.Y. (1992) and Bodansky, M and Trost, B., Ed., "Principles of Peptide Synthesis," Springer-Verlag Inc., N.Y. (1993)). Alternatively, the peptide or polypeptide can by independently synthesized in vivo as described above. Once isolated, these independent peptides or polypeptides may be linked to form a VEGF via similar peptide condensation reactions. For example, enzymatic or chemical ligation of cloned or synthetic peptide segments can allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen, L., et al., Biochemistry, 30:4151 (1991); Dawson, at al., "Synthesis of Proteins by Native Chemical Ligation," Science, 266:776-779 (1994)).
[0125] The invention also provides fragments of modified VEGF which have antagonist activity. The polypeptide fragments of the present invention can be recombinant proteins obtained by cloning nucleic acids encoding the peptides in an expression system capable of producing the peptides. For example, amino or carboxy-terminal amino acids can be sequentially removed from either the native or the VEGF protein and the respective activity tested in one of many available assays described above. In another example, the modified proteins of the invention may have a portion of either amino terminal or carboxy terminal amino acids, or even an internal region of the protein, replaced with a polypeptide fragment or other moiety, such as biotin, which can facilitate in the purification of the modified VEGF. For example, a modified VEGF can be fused to a maltose binding protein, through either peptide chemistry of cloning the respective nucleic acids encoding the two polypeptide fragments into an expression vector such that the expression of the coding region results in a hybrid polypeptide. The hybrid polypeptide can be affinity purified by passing it over an amylose affinity column, and the modified VEGF can then be separated from the maltose binding region by cleaving the hybrid polypeptide with the specific protease factor Xa. (See, for example, New England Biolabs Product Catalog, 1996, pg. 164).
[0126] The VEGF analog of the invention can be a heterodimer or a homodimer. In one embodiment, the VEGF analog is a fusion protein containing one or more VEGF subunits. The VEGF fusion protein of the invention can be a single chain protein containing two or more VEGF subunits separated by linking peptides. In another embodiment, the VEGF analog of the invention is a fusion protein containing one or more VEGF subunits fused to a toxin. The VEGF analog and VEGF analog fusion protein of the invention can be isolated and purified by means known in the art.
[0127] All of the VEGF analogs of the invention contain at least one basic amino acid substitution in at least one VEGF subunit. In one embodiment of the invention, the VEGF analogs of the invention contain at least two basic amino acid substitutions, at least 3 basic amino acid substitutions, at least 4 basic amino acid substitutions or at least 5 basic amino acid substitutions in at least one or at least two VEGF subunits.
[0128] The invention includes VEGF analogs containing VEGF active fragments, i.e., peptides that are not full length proteins. Active fragments of the modified VEGF of the invention can also be synthesized directly or obtained by chemical or mechanical disruption of larger modified VEGF protein. An active fragment is defined as an amino acid sequence of at least about 5 consecutive amino acids, at least 10 consecutive amino acids, at least 20 consecutive amino acids, at least 30 consecutive amino acids, at least 40 consecutive amino acids, at least 50 consecutive amino acids, at least 60 consecutive amino acids, at least 70 consecutive amino acids, at least 80 consecutive amino acids, at least 90 consecutive amino acids, at least 100 consecutive amino acids, at least 110 consecutive amino acids, at least 120 consecutive amino acids, at least 130 consecutive amino acids, at least 140 consecutive amino acids, at least 150 consecutive amino acids, or at least 160 consecutive amino acids derived from the natural amino acid sequence, which has the relevant activity, e.g., binding or regulatory activity. The fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the peptide is not significantly altered or impaired compared to the modified VEGF. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its biolongevity and/or bioactivity, etcetera. In any case, the peptide must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etcetera. Functional or active regions of the VEGF may be identified by mutagenesis of a specific region of the hormone, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the receptor (Zoller, M. J. et al.).
[0129] Methods of Use
[0130] The invention encompasses methods for reducing VEGF-mediated angiogenesis, comprising contacting a cell expressing kinase domain receptor (KDR) with the VEGF analogs, including VEGF-A165 and VEGF-A165b analogs, described herein such that VEGF-mediated angiogenesis is reduced. KDR-expressing cells to be targeted by the methods of the invention can include either or both prokaryotic and eukaryotic cells. Such cells may be maintained in vitro, or they may be present in vivo, for instance in a patient or subject diagnosed with cancer or another angiogenesis-related disease.
[0131] The present invention includes methods of treating a patient diagnosed with an angiogenesis-related disease or condition with a therapeutically effective amount of any of the VEGF receptor antagonists described herein, comprising administering said VEGF analog or fusion protein to said patient such that said angiogenesis-related disease or condition is reduced or inhibited. In order to measure the reduction of angiogenesis, the patient's results may be compared to that of a patient administered a placebo. Exemplary angiogenesis-related diseases are described throughout this application, and include but are not limited to diseases selected from the group consisting of tumors and neoplasias, hemangiomas, rheumatoid arthritis, osteoarthritis, septic arthritis, asthma, atherosclerosis, idiopathic pulmonary fibrosis, vascular restenosis, arteriovenous malformations, meningioma, neovascular glaucoma, psoriasis, Kaposi's Syndrome, angiofibroma, hemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic granuloma, retrolental fibroplasias, scleroderma, trachoma, von Hippel-Lindau disease, vascular adhesion pathologies, synovitis, dermatitis, endometriosis, pterygium, diabetic retinopathy, neovascularization associated with corneal injury or grafts, wounds, sores, and ulcers (skin, gastric and duodenal).
[0132] A patient suffering from a disease caused by or exacerbated by an increase in angiogenesis, a decrease in angiogenesis, or otherwise dysregulated angiogenesis can be treated with a VEGF analog alone or in combination with a known VEGF receptor antagonist, an anti-angiogenesis therapy, an anti-cancer therapy, or other therapy known to treat the disease or condition. As used herein, "therapy" includes but is not limited to a known drug. Known VEGF receptor antagonists or anti-angiogenesis therapies include but are not limited to agents that either interrupt VEGF/KDR interaction and/or block the KDR signal transduction pathway such as peptides that block binding of VEGF to KDR, antibodies to VEGF, antibodies to KDR, soluble receptors, tyrosine kinase inhibitors, anti-VEGF immunotoxins, ribozymes, antisense mediated VEGF suppression, and undersulfated, low molecular weight glycol-split heparin.
[0133] If a VEGF analog of the invention is used in combination with another therapy, the coupling of the therapies results in a synergistic effect. In addition, a VEGF analog of the present invention can be combined with a drug associated with an undesirable side effect. By coupling a VEGF analog with such a drug, the effective dosage of the drug with the side effect can be lowered to reduce the probability of the side effect from occurring.
[0134] The invention includes methods of treating a patient diagnosed with cancer with a therapeutically effective amount of any of the VEGF receptor antagonists described herein, comprising administering said antagonist to said patient such that the spread of said cancer is reduced or inhibited, i.e., metastasis is reduced or inhibited. The invention includes methods of treating a patient diagnosed with cancer with a therapeutically effective amount of any of the VEGF receptor antagonists described herein, comprising administering said antagonist to said patient such that the growth of a tumor is reduced or inhibited. In one embodiment, the VEGF analog functions by inhibiting angiogenesis by reducing or preventing VEGF-induced angiogenesis. In another embodiment, the VEGF analog is a VEGF-toxin fusion protein that prevents or reduces angiogenesis by targeting or killing tumor cells, vascular cells such as endothelial cells and/or VEGF receptors.
[0135] Cancers treatable by the methods of the present invention include all solid tumor and metastatic cancers, including but not limited to those selected from the group consisting of bladder, breast, liver, bone, kidney, colon, ovarian, prostate, pancreatic, lung, brain and skin cancers. The invention includes but is not limited to treatment of cancer with a VEGF analog of the present invention, alone, in combination with chemotherapy, or in combination with radiation therapy by methods known in the art (see U.S. Pat. No. 6,596,712). For instance, a VEGF analog may be used with cesium, iridium, iodine, or cobalt radiation.
[0136] The present invention includes methods of treating a patient diagnosed with infertility with a therapeutically effective amount of any of the VEGF receptor antagonists described herein, comprising administering said antagonist to said patient such that infertility is deemed treated by one of skill in the art. Infertility can be measured by quantitative and qualitative parameters known in the art such as quantity of oocytes, fertilization rate, blastocyst formation rate, and embryo formation rate. Such infertility diseases include any disease associated with the expression of VEGF that compromises a patient's fertility including but not limited to unexplained female infertility, endometriosis, and unexplained male infertility. The invention includes but is not limited to treatment of infertility by administration of a VEGF analog alone or in combination with other anti-VEGF treatments, anti-angiogenesis treatments, and/or infertility treatments.
[0137] The present invention also includes methods of treating a patient diagnosed with an angiogenesis-associated eye disease with a therapeutically effective amount of any of the VEGF receptor antagonists described herein, comprising administering said antagonist to said patient such that said eye disease is reduced or inhibited. Such eye diseases include any eye disease associated with abnormal intraocular neovascularization, including but not limited to retinopathy of prematurity, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. The invention includes but is not limited to treatment of angiogenesis-related eye diseases by administration of a VEGF analog alone or in combination with other anti-VEGF treatments, anti-angiogenesis treatments, and/or other eye disease treatments. For example, a VEGF analog of the present invention could be administered to a patient in conjunction with Pfizer's Macugen (pegaptanib) which is a pegylated anti-VEGF aptamer which acts by binding to and inhibiting the activity of VEGF for the treatment of diabetic macular edema, retinal vein occlusion, and age-related macular degeneration.
[0138] The present invention also includes methods of treating a patient diagnosed with an angiogenesis-associated inflammatory condition or autoimmune disease with a therapeutically effective amount of any of the VEGF receptor antagonists described herein, comprising administering said antagonist to said patient such that said inflammatory condition is reduced or inhibited. Such inflammatory conditions or diseases include any inflammatory disorder associated with expression of VEGF and activation of cells by VEGF, including but not limited to all types of arthritis and particularly rheumatoid arthritis and osteoarthritis, asthma, pulmonary fibrosis and dermatitis. The invention includes but is not limited to treatment of angiogenesis-related inflammatory conditions or autoimmune disease by administration of a VEGF analog alone or in combination with other anti-VEGF treatments, anti-angiogenesis treatments, inflammation therapeutics, and/or autoimmune disease therapeutics.
[0139] In another embodiment of the present invention, the modified VEGF protein of the invention is used as a diagnostic. The VEGF analogs of the invention or VEGF receptors can displayed on a synthetic surface, such as in a protein or peptide array. Such an array is well known in the art and can be used to screen for VEGF analogs which bind to KDR and other receptors known to be involved in angiogenesis. The VEGF analogs disclosed herein can be used as positive controls to assess the ability of putative VEGF analogs to bind to KDR and other receptors known to be involved in angiogenesis. The invention also includes an array comprising the VEGF analogs of the present invention to screen for putative VEGF receptors which may be involved in angiogenesis.
[0140] Assays suitable for characterizing the analogs described herein are described in PCT/US/99/05908, which is herein incorporated by reference in its entirety. For instance, various immunoassays may be used including but not limited to competitive binding assays and non-competitive assay systems using techniques such as radioimmunoassays, ELISA, sandwich immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays, western blots, precipitation reactions, agglutination assays, complement fixation assays, immunofluorescence assays, Protein A assays, and immunoelectrophoresis assays, etcetera.
[0141] Pharmaceutical Formulations
[0142] The invention provides methods of diagnosis and treatment by administration to a subject of an effective amount of a therapeutic of the invention. The subject may be an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human. In a specific embodiment, a non-human mammal is the subject.
[0143] The pharmaceutical compositions of the invention comprise an effective amount of one or more modified VEGF proteins of the present invention in combination with the pharmaceutically acceptable carrier. The compositions may further comprise other known drugs suitable for the treatment of the particular disease being targeted. An effective amount of the VEGF receptor antagonist of the present invention is that amount that blocks, inhibits or reduces VEGF stimulation of endothelial cells compared to that which would occur in the absence of the compound; in other words, an amount that decreases the angiogenic activity of the endothelium, compared to that which would occur in the absence of the compound. The effective amount (and the manner of administration) will be determined on an individual basis and will be based on the specific therapeutic VEGF receptor antagonist being used and a consideration of the subject (size, age, general health), the condition being treated (cancer, arthritis, eye disease, etc.), the severity of the symptoms to be treated, the result sought, the specific carrier or pharmaceutical formulation being used, the route of administration, and other factors as would be apparent to those skilled in the art. The effective amount can be determined by one of ordinary skill in the art using techniques as are known in the art. Therapeutically effective amounts of the compounds described herein can be determined using in vitro tests, animal models or other dose-response studies, as are known in the art. The VEGF proteins of the present invention can be used alone or in conjunction with other therapies. The therapeutically effective amount may be reduced when a VEGF analog is used in conjunction with another therapy.
[0144] The pharmaceutical compositions of the invention may be prepared, packaged, or sold in formulations suitable for intradermal, intravenous, subcutaneous, oral, rectal, vaginal, parenteral, intraperitoneal, topical, pulmonary, intranasal, buccal, ophthalmic, intrathecal, epidural or another route of administration. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. For example, the pharmaceutical compositions of the invention can be administered locally to a tumor via microinfusion. Further, administration may be by a single dose or a series of doses.
[0145] For pharmaceutical uses, the VEGF analogs of the present invention may be used in combination with a pharmaceutically acceptable carrier, and can optionally include a pharmaceutically acceptable diluent or excipient. Further, the VEGF analogs of the present invention may be used in combination with other known therapies, including but not limited to anti-VEGF therapies, anti-angiogenesis therapies, anti-cancer therapies, infertility therapies, autoimmune disease therapies, inflammation therapies, ocular disease therapies, and skin disease therapies.
[0146] The present invention thus also provides pharmaceutical compositions suitable for administration to a subject. The carrier can be a liquid, so that the composition is adapted for parenteral administration, or can be solid, i.e., a tablet or pill formulated for oral administration. Further, the carrier can be in the form of a nebulizable liquid or solid so that the composition is adapted for inhalation. When administered parenterally, the composition should be pyrogen free and in an acceptable parenteral carrier. Active compounds can alternatively be formulated or encapsulated in liposomes, using known methods. Other contemplated formulations include projected nanoparticles and immunologically based formulations.
[0147] Liposomes are completely closed lipid bilayer membranes which contain entrapped aqueous volume. Liposomes are vesicles which may be unilamellar (single membrane) or multilamellar (onion-like structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer). The bilayer is composed of two lipid monolayers having a hydrophobic "tail" region and a hydrophilic "head" region. In the membrane bilayer, the hydrophobic (nonpolar) "tails" of the lipid monolayers orient toward the center of the bilayer, whereas the hydrophilic (polar) "heads" orient toward the aqueous phase.
[0148] The liposomes of the present invention may be formed by any of the methods known in the art. Several methods may be used to form the liposomes of the present invention. For example, multilamellar vesicles (MLVs), stable plurilamellar vesicles (SPLVs), small unilamellar vesicles (SUV), or reverse phase evaporation vesicles (REVs) may be used. Preferably, however, MLVs are extruded through filters forming large unilamellar vesicles (LUVs) of sizes dependent upon the filter size utilized. In general, polycarbonate filters of 30, 50, 60, 100, 200 or 800 nm pores may be used. In this method, disclosed in Cullis et al., U.S. Pat. No. 5,008,050, relevant portions of which are incorporated by reference herein, the liposome suspension may be repeatedly passed through the extrusion device resulting in a population of liposomes of homogeneous size distribution.
[0149] For example, the filtering may be performed through a straight-through membrane filter (a Nuclepore polycarbonate filter) or a tortuous path filter (e.g. a Nuclepore Membrafil filter (mixed cellulose esters) of 0.1 μm size), or by alternative size reduction techniques such as homogenization. The size of the liposomes may vary from about 0.03 to above about 2 microns in diameter; preferably about 0.05 to 0.3 microns and most preferably about 0.1 to about 0.2 microns. The size range includes liposomes that are MLVs, SPLVs, or LUVs.
[0150] Lipids which can be used in the liposome formulations of the present invention include synthetic or natural phospholipids and may include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidic acid (PA), phosphatidylinositol (PI), sphingomyelin (SPM) and cardiolipin, among others, either alone or in combination, and also in combination with cholesterol. The phospholipids useful in the present invention may also include dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG). In other embodiments, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), or hydrogenated soy phosphatidylcholine (HSPC) may also be used. Dimyristoylphosphatidylcholine (DMPC) and diarachidonoylphosphatidylcholine (DAPC) may similarly be used.
[0151] During preparation of the liposomes, organic solvents may also be used to suspend the lipids. Suitable organic solvents for use in the present invention include those with a variety of polarities and dielectric properties, which solubilize the lipids, for example, chloroform, methanol, ethanol, dimethylsulfoxide (DMSO), methylene chloride, and solvent mixtures such as benzene:methanol (70:30), among others. As a result, solutions (mixtures in which the lipids and other components are uniformly distributed throughout) containing the lipids are formed. Solvents are generally chosen on the basis of their biocompatability, low toxicity, and solubilization abilities.
[0152] To encapsulate the VEGF receptor antagonist(s) of the inventions into the liposomes, the methods described in U.S. Pat. No. 5,380,531, relevant portions of which are incorporated by reference herein, may be used with the analog(s) of the present invention.
[0153] Liposomes containing the VEGF analog(s) of the present invention may be used therapeutically in mammals, especially humans, in the treatment of a number of disease states or pharmacological conditions which require sustained release formulations as well as repeated administration. The mode of administration of the liposomes containing the agents of the present invention may determine the sites and cells in the organism to which the VEGF analog may be delivered.
[0154] The liposomes of the present invention may be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. The preparations may be injected parenterally, for example, intravenously. For parenteral administration, they can be used, for example, in the form of a sterile aqueous solution which may contain other solutes, for example, enough salts or glucose to make the solution isotonic, should isotonicity be necessary or desired. The liposomes of the present invention may also be employed subcutaneously or intramuscularly. Other uses, depending upon the particular properties of the preparation, may be envisioned by those skilled in the art.
[0155] For the oral mode of administration, the liposomal formulations of the present invention can be used in the form of tablets, capsules, lozenges, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like. In the case of tablets, carriers which can be used include lactose, sodium citrate and salts of phosphoric acid. Various disintegrants such as starch, lubricating agents, and talc are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high molecular weight polyethylene glycols. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added.
[0156] For the topical mode of administration, the pharmaceutical formulations of the present invention may be incorporated into dosage forms such as a solution, suspension, gel, oil, ointment or salve, and the like. Preparation of such topical formulations are described in the art of pharmaceutical formulations as exemplified, for example, by Gennaro et al. (1995) Remington's Pharmaceutical Sciences, Mack Publishing. For topical application, the compositions could also be administered as a powder or spray, particularly in aerosol form. For administration to humans in the treatment of disease states or pharmacological conditions, the prescribing physician will ultimately determine the appropriate dosage of the agent for a given human subject, and this can be expected to vary according to the age, weight and response of the individual as well as the pharmacokinetics of the agent used.
[0157] The pharmaceutical compositions of the invention further comprise a depot formulation of biopolymers such as biodegradable microspheres. Biodegradable microspheres are used to control drug release rates and to target drugs to specific sites in the body, thereby optimizing their therapeutic response, decreasing toxic side effects, and eliminating the inconvenience of repeated injections. Biodegradable microspheres have the advantage over large polymer implants in that they do not require surgical procedures for implantation and removal.
[0158] The biodegradable microspheres used in the context of the invention are formed with a polymer which delays the release of the proteins and maintains, at the site of action, a therapeutically effective concentration for a prolonged period of time. The polymer can be chosen from ethylcellulose, polystyrene, poly(ε-caprolactone), poly(lactic acid) and poly(lactic acid-co-glycolic acid) (PLGA). PLGA copolymer is one of the synthetic biodegradable and biocompatible polymers that has reproducible and slow-release characteristics. An advantage of PLGA copolymers is that their degradation rate ranges from months to years and is a function of the polymer molecular weight and the ratio of polylactic acid to polyglycolic acid residues. Several products using PLGA for parenteral applications are currently on the market, including Lupron Depot and Zoladex in the United States and Enantone Depot, Decapeptil, and Pariodel LA in Europe (see Yonsei, Med J. 2000 December; 41(6):720-34 for review).
[0159] The pharmaceutical compositions of the invention may further be prepared, packaged, or sold in a formulation suitable for nasal administration as increased permeability has been shown through the tight junction of the nasal epithelium (Pietro and Woolley, The Science behind Nastech's intranasal drug delivery technology. Manufacturing Chemist, August, 2003). Such formulations may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, and preferably from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder or using a self-propelling solvent/powder-dispensing container such as a device comprising the active ingredient dissolved or suspended in a low-boiling propellant in a sealed container. Preferably, such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. More preferably, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions preferably include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
[0160] Pharmaceutical compositions of the invention formulated for nasal delivery may also provide the active ingredient in the form of droplets of a solution or suspension. Such formulations may be prepared, packaged, or sold as aqueous or dilute alcoholic solutions or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration preferably have an average diameter in the range from about 0.1 to about 200 nanometers.
[0161] Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered in the manner in which snuff is taken i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nose.
[0162] Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may further comprise one or more of the additional ingredients described herein.
[0163] In some embodiments, the compositions of the invention may be administered by inhalation. For inhalation therapy, the active ingredients may be in a solution useful for administration by metered dose inhalers or in a form suitable for a dry powder inhaler. In another embodiment, the compositions are suitable for administration by bronchial lavage.
[0164] Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof.
[0165] The VEGF receptor antagonists of the present invention can be administered acutely (i.e., during the onset or shortly after events leading to inflammation), or can be administered during the course of a degenerative disease to reduce or ameliorate the progression of symptoms that would otherwise occur. The timing and interval of administration is varied according to the subject's symptoms, and can be administered at an interval of several hours to several days, over a time course of hours, days, weeks or longer, as would be determined by one skilled in the art. A typical daily regime can be from about 0.01 μg/kg body weight per day, from about 1 mg/kg body weight per day, from about 10 mg/kg body weight per day, from about 100 mg/kg body weight per day, and from about 1 g/kg body weight per day.
[0166] The VEGF receptor antagonists of the invention may be administered intravenously, orally, intranasally, intraocularly, intramuscularly, intrathecally, or by any suitable route in view of the VEGF protein, the protein formulation and the disease to be treated. Modified VEGF for the treatment of inflammatory arthritis can be injected directly into the synovial fluid. Modified VEGF for the treatment of solid tumors may be injected directly into the tumor. Modified VEGF for the treatment of skin diseases may be applied topically, for instance in the form of a lotion or spray. Intrathecal administration, i.e. for the treatment of brain tumors, can comprise injection directly into the brain. Alternatively, modified VEGF may be coupled or conjugated to a second molecule (a "carrier"), which is a peptide or non-proteinaceous moiety selected for its ability to penetrate the blood-brain barrier and transport the active agent across the blood-brain barrier. Examples of suitable carriers are disclosed in U.S. Pat. Nos. 4,902,505; 5,604,198; and 5,017,566, which are herein incorporated by reference in their entirety.
[0167] An alternative method of administering the VEGF receptor antagonists of the present invention is carried out by administering to the subject a vector carrying a nucleic acid sequence encoding the modified VEGF protein, where the vector is capable of directing expression and secretion of the protein. Suitable vectors are typically viral vectors, including DNA viruses, RNA viruses, and retroviruses. Techniques for utilizing vector delivery systems and carrying out gene therapy are known in the art (see Lundstrom, 2003, Trends Biotechnol. 21(3):117-22, for a recent review).
[0168] Transgenic Animals
[0169] The production of transgenic non-human animals that contain a modified VEGF construct with increased receptor binding affinity and optionally antagonistic properties is contemplated in one embodiment of the present invention.
[0170] The successful production of transgenic, non-human animals has been described in a number of patents and publications, such as, for example U.S. Pat. No. 6,291,740 (issued Sep. 18, 2001); U.S. Pat. No. 6,281,408 (issued Aug. 28, 2001); and U.S. Pat. No. 6,271,436 (issued Aug. 7, 2001) the contents of which are hereby incorporated by reference in their entireties.
[0171] The ability to alter the genetic make-up of animals, such as domesticated mammals including cows, pigs, goats, horses, cattle, and sheep, allows a number of commercial applications. These applications include the production of animals which express large quantities of exogenous proteins in an easily harvested form (e.g., expression into the milk or blood), the production of animals with increased weight gain, feed efficiency, carcass composition, milk production or content, disease resistance and resistance to infection by specific microorganisms and the production of animals having enhanced growth rates or reproductive performance. Animals which contain exogenous DNA sequences in their genome are referred to as transgenic animals.
[0172] The most widely used method for the production of transgenic animals is the microinjection of DNA into the pronuclei of fertilized embryos (Wall et al., J. Cell. Biochem. 49:113
[1992]). Other methods for the production of transgenic animals include the infection of embryos with retroviruses or with retroviral vectors. Infection of both pre- and post-implantation mouse embryos with either wild-type or recombinant retroviruses has been reported (Janenich, Proc. Natl. Acad. Sci. USA 73:1260
[1976]; Janenich et al., Cell 24:519
[1981]; Stuhlmann et al., Proc. Natl. Acad. Sci. USA 81:7151
[1984]; Jahner et al., Proc. Natl. Acad Sci. USA 82:6927
[1985]; Van der Putten et al., Proc. Natl. Acad Sci. USA 82:6148-6152
[1985]; Stewart et al., EMBO J. 6:383-388
[1987]).
[0173] An alternative means for infecting embryos with retroviruses is the injection of virus or virus-producing cells into the blastocoele of mouse embryos (Jahner, D. et al., Nature 298:623
[1982]). The introduction of transgenes into the germline of mice has been reported using intrauterine retroviral infection of the midgestation mouse embryo (Jahner et al., supra
[1982]). Infection of bovine and ovine embryos with retroviruses or retroviral vectors to create transgenic animals has been reported. These protocols involve the micro-injection of retroviral particles or growth arrested (i.e., mitomycin C-treated) cells which shed retroviral particles into the perivitelline space of fertilized eggs or early embryos (PCT International Application WO 90/08832
[1990]; and Haskell and Bowen, Mol. Reprod. Dev., 40:386
[1995]. PCT International Application WO 90/08832 describes the injection of wild-type feline leukemia virus B into the perivitelline space of sheep embryos at the 2 to 8 cell stage. Fetuses derived from injected embryos were shown to contain multiple sites of integration.
[0174] U.S. Pat. No. 6,291,740 (issued Sep. 18, 2001) describes the production of transgenic animals by the introduction of exogenous DNA into pre-maturation oocytes and mature, unfertilized oocytes (i.e., pre-fertilization oocytes) using retroviral vectors which transduce dividing cells (e.g., vectors derived from murine leukemia virus [MLV]). This patent also describes methods and compositions for cytomegalovirus promoter-driven, as well as mouse mammary tumor LTR expression of various recombinant proteins.
[0175] U.S. Pat. No. 6,281,408 (issued Aug. 28, 2001) describes methods for producing transgenic animals using embryonic stem cells. Briefly, the embryonic stem cells are used in a mixed cell co-culture with a formula to generate transgenic animals. Foreign genetic material is introduced into the embryonic stem cells prior to co-culturing by, for example, electroporation, microinjection or retroviral delivery. ES cells transfected in this manner are selected for integrations of the gene via a selection marker such as neomycin.
[0176] U.S. Pat. No. 6,271,436 (issued Aug. 7, 2001) describes the production of transgenic animals using methods including isolation of primordial germ cells, culturing these cells to produce primordial germ cell-derived cell lines, transforming both the primordial germ cells and the cultured cell lines, and using these transformed cells and cell lines to generate transgenic animals. The efficiency at which transgenic animals are generated is greatly increased, thereby allowing the use of homologous recombination in producing transgenic non-rodent animal species.
[0177] Kits Containing Modified VEGF Proteins
[0178] In a further embodiment, the present invention provides kits containing a VEGF analog and/or VEGF analog fusion proteins, which can be used, for instance, for therapeutic or non-therapeutic applications. The kit comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which includes a VEGF analog or VEGF fusion protein that is effective for therapeutic or non-therapeutic applications, such as described above. The label on the container indicates that the composition is used for a specific therapy or non-therapeutic application, and may also indicate directions for either in vivo or in vitro use, such as those described above.
[0179] The kit of the invention will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. The kit of the invention may also include a control consisting of wild-type VEGF such as wild-type VEGF165 or VEGF165b.
[0180] The following examples are provided to describe and illustrate the present invention. As such, they should not be construed to limit the scope of the invention. Those in the art will appreciate that many other embodiments also fall within the scope of the invention, as it is described herein above and in the claims.
EXAMPLES
Example 1
Design of VEGF Receptor Antagonists
[0181] VEGF-A antagonists of the present invention were designed to increase receptor binding affinity and decrease bioactivity as compared to wild-type VEGF-A. One method by which this was done was by adding a positive charge to the loops of VEGF-A. This approach to design super-antagonists involves a combination of different methods known in the art including but not limited to homology modeling, sequence comparisons, charge scanning mutagenesis, and linking monomers and introduction of mutations in the context of linked monomers.
[0182] Vammin, or snake venom VEGF, has been shown to bind to KDR-IgG with high affinity and strongly stimulate proliferation of vascular endothelial cells in vitro (see Yamazaki et al., 2003, J. Biol. Chem. 278, 51985-51988, which is herein incorporated by reference in its entirety). VEGF-A receptor antagonists were designed based on VEGF165 homology to vammin. VEGF165 has glutamate residues at positions 72 and 73, whereas vammin contains a glycine and lysine residue at these positions, respectively. By modifying VEGF-A to contain two basic amino acid residues at positions 72 and 73, the modified VEGF-A demonstrated a significant increase in receptor binding affinity compared to wild-type VEGF-A (FIG. 3A).
Example 2
Characterization of VEGF Receptor Antagonists
[0183] VEGF analogs I83K, E44R, E72RE73R, E67K and Q87K were created and assayed for their ability to bind to KDR and to decrease cell proliferation compared to wild-type VEGF.
[0184] Methods
[0185] VEGF analogs expressed by yeast cells were incubated with immobilized KDR-Fc and the ability of the analogs to bind to KDR-Fc was assayed. The binding assay was performed as follows:
[0186] 1. Nunc MaxiSorp® 96 microwell plates were coated with 150 ng/well KDR-Fc (R & D System, Inc.) and 100 μl 50 mM sodium bicarbonate buffer (15 mM Na2CO3+35 mM NaHCO3) at pH 9.6. A separate plate was used for each VEGF analog and wild-type VEGF tested.
[0187] 2. The plates were incubated at 4° C. overnight.
[0188] 3. The next day, the wells were washed three times in washing buffer (0.05% tween in PBS).
[0189] 4. The wells were blocked with PBS with 3% BSA, 0.03% tween for 1 hour at room temperature.
[0190] 5. After blocking, the wells were washed three times in washing buffer (0.05% tween in PBS).
[0191] 6. VEGF-A (wild-type or mutant) were added at different concentrations to the wells in 50 μl binding buffer (1% BSA and 0.03% tween in PBS).
[0192] 7. 125I-labeled VEGF-A (wild-type or mutant) at 70,000 cpm/well (PerkinElmer) was added to each well in 50 μl binding buffer (1% BSA and 0.03% tween in PBS).
[0193] 8. The contents of the wells were mixed and incubated for 2 hours at room temperature with slow shaking.
[0194] 9. The wells were washed three times with washing buffer (0.05% tween in PBS).
[0195] 10. To each well, 120 μl of lysis buffer (0.2 M NaOH+0.5% SDS) was added. Plate was shaken vigorously for 20 minutes at room temperature.
[0196] 11. The lysis buffer from each well was transferred to an individual tube. The wells were washed with lysis buffer two times additional times and combined with the lysis solution buffer in the corresponding tube.
[0197] 12. The measure of binding for wild-type VEGF-A and various VEGF-A mutants was determined by counting with a gamma counter.
[0198] The ability of HUVEC endothelial cells to proliferate in the presence of the VEGF analogs was assayed as follows:
[0199] 1. HUVEC endothelial cells (passage 6) were seeded into 96 well plates at 3,000 cells/well using Media-200 with growth factors and incubated overnight.
[0200] 2. After overnight incubation, the media was removed and Media 199 (Invitrogen) with 2% dialysis FBS (Invitrogen) was added.
[0201] 3. Cells were incubated for 20 hours.
[0202] 4. Wild-type VEGF-A and VEGF-A analogs were serial diluted in Media 199 with 2% dialysis FBS in the 96-well plates, starting at 200 ng/well.
[0203] 5. The media was removed from each well and replaced with 200 μl/well diluted VEGF media.
[0204] 6. Cells were incubated at 37° C. for 72 hours.
[0205] 7. Cell proliferation was analyzed using Promega's CellTiter-Glo® Luminescent Cell Viability Assay. Briefly, CellTiter buffer was thawed, transferred into CellTiter-Glo substrate, and mixed well to make substrate mixture. 100 μl growth media was removed from each well into a new 96 well plate and mixed well with 100 μl substrate mixture. The plates were shaken for 2 minutes and incubated at room temperature for an additional ten minutes.
[0206] 8. Plates were read for luminescent signal using a plate reader with integration time set at 250 mS (Tecan).
[0207] Analysis
[0208] The receptor binding affinity of the I83K analog to KDR-Fc was slightly less than that of wild-type VEGF-A (FIG. 1A). However, the I83K analog demonstrated a significant decrease in endothelial cell proliferation compared to wild-type VEGF-A (FIG. 1B). VEGF-A analogs E44R, EE72/73RR, E67K and Q87K all demonstrated an increase in receptor cell binding affinity compared to wild-type VEGF-A (FIGS. 2A, 3A, 4, 5 and 6). However, analogs E44R and EE72/73RR demonstrated little to no change in endothelial cell proliferation (FIGS. 2B and 3B). These results show that VEGF165 analogs comprising I83K can effectively function as a VEGF-A receptor antagonist. Further, although VEGF-A analogs E44R and EE72/73RR were unable to decrease endothelial cell proliferation alone, when added to I83K, these modifications have the potential of further increasing receptor binding affinity.
[0209] All publications, patents and patent applications discussed in this application are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain preferred embodiments, thereof, and may details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.
Sequence CWU
1
1
731576DNAHomo sapiens 1atgaactttc tgctgtcttg ggtgcattgg agccttgcct
tgctgctcta cctccaccat 60gccaagtggt cccaggctgc acccatggca gaaggaggag
ggcagaatca tcacgaagtg 120gtgaagttca tggatgtcta tcagcgcagc tactgccatc
caatcgagac cctggtggac 180atcttccagg agtaccctga tgagatcgag tacatcttca
agccatcctg tgtgcccctg 240atgcgatgcg ggggctgctg caatgacgag ggcctggagt
gtgtgcccac tgaggagtcc 300aacatcacca tgcagattat gcggatcaaa cctcaccaag
gccagcacat aggagagatg 360agcttcctac agcacaacaa atgtgaatgc agaccaaaga
aagatagagc aagacaagaa 420aatccctgtg ggccttgctc agagcggaga aagcatttgt
ttgtacaaga tccgcagacg 480tgtaaatgtt cctgcaaaaa cacagactcg cgttgcaagg
cgaggcagct tgagttaaac 540gaacgtactt gcagatgtga caagccgagg cggtga
5762191PRTHomo sapiens 2Met Asn Phe Leu Leu Ser
Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5
10 15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala
Pro Met Ala Glu Gly 20 25
30 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr
Gln 35 40 45 Arg
Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu 50
55 60 Tyr Pro Asp Glu Ile Glu
Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu 65 70
75 80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly
Leu Glu Cys Val Pro 85 90
95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
100 105 110 Gln Gly
Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys 115
120 125 Glu Cys Arg Pro Lys Lys Asp
Arg Ala Arg Gln Glu Asn Pro Cys Gly 130 135
140 Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln
Asp Pro Gln Thr 145 150 155
160 Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln
165 170 175 Leu Glu Leu
Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg 180
185 190 326PRTHomo sapiens 3Met Asn Phe Leu Leu
Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5
10 15 Tyr Leu His His Ala Lys Trp Ser Gln Ala
20 25 4165PRTHomo sapiens 4Ala Pro Met
Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys 1 5
10 15 Phe Met Asp Val Tyr Gln Arg Ser
Tyr Cys His Pro Ile Glu Thr Leu 20 25
30 Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr
Ile Phe Lys 35 40 45
Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 50
55 60 Gly Leu Glu Cys
Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65 70
75 80 Met Arg Ile Lys Pro His Gln Gly Gln
His Ile Gly Glu Met Ser Phe 85 90
95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg
Ala Arg 100 105 110
Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe
115 120 125 Val Gln Asp Pro
Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser 130
135 140 Arg Cys Lys Ala Arg Gln Leu Glu
Leu Asn Glu Arg Thr Cys Arg Cys 145 150
155 160 Asp Lys Pro Arg Arg 165
5147PRTHomo sapiens 5Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala
Leu Leu Leu 1 5 10 15
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
20 25 30 Gly Gly Gln Asn
His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35
40 45 Arg Ser Tyr Cys His Pro Ile Glu Thr
Leu Val Asp Ile Phe Gln Glu 50 55
60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys
Val Pro Leu 65 70 75
80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
85 90 95 Thr Glu Glu Ser
Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100
105 110 Gln Gly Gln His Ile Gly Glu Met Ser
Phe Leu Gln His Asn Lys Cys 115 120
125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn Cys
Asp Lys 130 135 140
Pro Arg Arg 145 6121PRTHomo sapiens 6Ala Pro Met Ala Glu Gly Gly
Gly Gln Asn His His Glu Val Val Lys 1 5
10 15 Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His
Pro Ile Glu Thr Leu 20 25
30 Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe
Lys 35 40 45 Pro
Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 50
55 60 Gly Leu Glu Cys Val Pro
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65 70
75 80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile
Gly Glu Met Ser Phe 85 90
95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg
100 105 110 Gln Glu
Asn Cys Asp Lys Pro Arg Arg 115 120
7171PRTHomo sapiens 7Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala
Leu Leu Leu 1 5 10 15
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
20 25 30 Gly Gly Gln Asn
His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35
40 45 Arg Ser Tyr Cys His Pro Ile Glu Thr
Leu Val Asp Ile Phe Gln Glu 50 55
60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys
Val Pro Leu 65 70 75
80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
85 90 95 Thr Glu Glu Ser
Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100
105 110 Gln Gly Gln His Ile Gly Glu Met Ser
Phe Leu Gln His Asn Lys Cys 115 120
125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys
Ser Val 130 135 140
Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr 145
150 155 160 Lys Ser Trp Ser Val
Cys Asp Lys Pro Arg Arg 165 170
8145PRTHomo sapiens 8Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu
Val Val Lys 1 5 10 15
Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu
20 25 30 Val Asp Ile Phe
Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys 35
40 45 Pro Ser Cys Val Pro Leu Met Arg Cys
Gly Gly Cys Cys Asn Asp Glu 50 55
60 Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr
Met Gln Ile 65 70 75
80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe
85 90 95 Leu Gln His Asn
Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg 100
105 110 Gln Glu Lys Lys Ser Val Arg Gly Lys
Gly Lys Gly Gln Lys Arg Lys 115 120
125 Arg Lys Lys Ser Arg Tyr Lys Ser Trp Ser Val Cys Asp Lys
Pro Arg 130 135 140
Arg 145 9174PRTHomo sapiens 9Met Asn Phe Leu Leu Ser Trp Val His Trp Ser
Leu Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
20 25 30 Gly Gly
Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35
40 45 Arg Ser Tyr Cys His Pro Ile
Glu Thr Leu Val Asp Ile Phe Gln Glu 50 55
60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser
Cys Val Pro Leu 65 70 75
80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
85 90 95 Thr Glu Glu
Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100
105 110 Gln Gly Gln His Ile Gly Glu Met
Ser Phe Leu Gln His Asn Lys Cys 115 120
125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn
Pro Cys Gly 130 135 140
Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr 145
150 155 160 Cys Lys Cys Ser
Cys Lys Asn Thr Asp Ser Arg Cys Lys Met 165
170 10148PRTHomo sapiens 10Ala Pro Met Ala Glu Gly Gly
Gly Gln Asn His His Glu Val Val Lys 1 5
10 15 Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His
Pro Ile Glu Thr Leu 20 25
30 Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe
Lys 35 40 45 Pro
Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 50
55 60 Gly Leu Glu Cys Val Pro
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65 70
75 80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile
Gly Glu Met Ser Phe 85 90
95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg
100 105 110 Gln Glu
Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe 115
120 125 Val Gln Asp Pro Gln Thr Cys
Lys Cys Ser Cys Lys Asn Thr Asp Ser 130 135
140 Arg Cys Lys Met 145 11606DNAHomo
sapiens 11atgaactttc tgctgtcttg ggtgcattgg agccttgcct tgctgctcta
cctccaccat 60gccaagtggt cccaggctgc acccatggca gaaggaggag ggcagaatca
tcacgaagtg 120gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac
cctggtggac 180atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg
tgtgcccctg 240atgcgatgcg ggggctgctg caatgacgag ggcctggagt gtgtgcccac
tgaggagtcc 300aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat
aggagagatg 360agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc
aagacaagaa 420aatccctgtg ggccttgctc agagcggaga aagcatttgt ttgtacaaga
tccgcagacg 480tgtaaatgtt cctgcaaaaa cacagactcg cgttgcaagg cgaggcagct
tgagttaaac 540gaacgtactt gcagatctct caccaggaaa gactgataca gaacgatcga
tacagaaacc 600acgctg
60612191PRTHomo sapiens 12Met Asn Phe Leu Leu Ser Trp Val His
Trp Ser Leu Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala
Glu Gly 20 25 30
Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
35 40 45 Arg Ser Tyr Cys
His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu 50
55 60 Tyr Pro Asp Glu Ile Glu Tyr Ile
Phe Lys Pro Ser Cys Val Pro Leu 65 70
75 80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu
Glu Cys Val Pro 85 90
95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
100 105 110 Gln Gly Gln
His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys 115
120 125 Glu Cys Arg Pro Lys Lys Asp Arg
Ala Arg Gln Glu Asn Pro Cys Gly 130 135
140 Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp
Pro Gln Thr 145 150 155
160 Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln
165 170 175 Leu Glu Leu Asn
Glu Arg Thr Cys Arg Ser Leu Thr Arg Lys Asp 180
185 190 13165PRTHomo sapiens 13Ala Pro Met Ala Glu
Gly Gly Gly Gln Asn His His Glu Val Val Lys 1 5
10 15 Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys
His Pro Ile Glu Thr Leu 20 25
30 Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe
Lys 35 40 45 Pro
Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 50
55 60 Gly Leu Glu Cys Val Pro
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65 70
75 80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile
Gly Glu Met Ser Phe 85 90
95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg
100 105 110 Gln Glu
Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe 115
120 125 Val Gln Asp Pro Gln Thr Cys
Lys Cys Ser Cys Lys Asn Thr Asp Ser 130 135
140 Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg
Thr Cys Arg Ser 145 150 155
160 Leu Thr Arg Lys Asp 165 14209PRTHomo sapiens 14Met
Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1
5 10 15 Tyr Leu His His Ala Lys
Trp Ser Gln Ala Ala Pro Met Ala Glu Gly 20
25 30 Gly Gly Gln Asn His His Glu Val Val Lys
Phe Met Asp Val Tyr Gln 35 40
45 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe
Gln Glu 50 55 60
Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu 65
70 75 80 Met Arg Cys Gly Gly
Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro 85
90 95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile
Met Arg Ile Lys Pro His 100 105
110 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys
Cys 115 120 125 Glu
Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val 130
135 140 Arg Gly Lys Gly Lys Gly
Gln Lys Arg Lys Arg Lys Lys Ser Arg Pro 145 150
155 160 Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu
Phe Val Gln Asp Pro 165 170
175 Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala
180 185 190 Arg Gln
Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg 195
200 205 Arg 15183PRTHomo sapiens
15Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys 1
5 10 15 Phe Met Asp Val
Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu 20
25 30 Val Asp Ile Phe Gln Glu Tyr Pro Asp
Glu Ile Glu Tyr Ile Phe Lys 35 40
45 Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn
Asp Glu 50 55 60
Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65
70 75 80 Met Arg Ile Lys Pro
His Gln Gly Gln His Ile Gly Glu Met Ser Phe 85
90 95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro
Lys Lys Asp Arg Ala Arg 100 105
110 Gln Glu Lys Lys Ser Val Arg Gly Lys Gly Lys Gly Gln Lys Arg
Lys 115 120 125 Arg
Lys Lys Ser Arg Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His 130
135 140 Leu Phe Val Gln Asp Pro
Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr 145 150
155 160 Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu
Asn Glu Arg Thr Cys 165 170
175 Arg Cys Asp Lys Pro Arg Arg 180
16215PRTHomo sapiens 16Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu
Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
20 25 30 Gly Gly Gln
Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35
40 45 Arg Ser Tyr Cys His Pro Ile Glu
Thr Leu Val Asp Ile Phe Gln Glu 50 55
60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys
Val Pro Leu 65 70 75
80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
85 90 95 Thr Glu Glu Ser
Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100
105 110 Gln Gly Gln His Ile Gly Glu Met Ser
Phe Leu Gln His Asn Lys Cys 115 120
125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys
Ser Val 130 135 140
Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr 145
150 155 160 Lys Ser Trp Ser Val
Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His 165
170 175 Leu Phe Val Gln Asp Pro Gln Thr Cys Lys
Cys Ser Cys Lys Asn Thr 180 185
190 Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr
Cys 195 200 205 Arg
Cys Asp Lys Pro Arg Arg 210 215 17189PRTHomo sapiens
17Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys 1
5 10 15 Phe Met Asp Val
Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu 20
25 30 Val Asp Ile Phe Gln Glu Tyr Pro Asp
Glu Ile Glu Tyr Ile Phe Lys 35 40
45 Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn
Asp Glu 50 55 60
Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65
70 75 80 Met Arg Ile Lys Pro
His Gln Gly Gln His Ile Gly Glu Met Ser Phe 85
90 95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro
Lys Lys Asp Arg Ala Arg 100 105
110 Gln Glu Lys Lys Ser Val Arg Gly Lys Gly Lys Gly Gln Lys Arg
Lys 115 120 125 Arg
Lys Lys Ser Arg Tyr Lys Ser Trp Ser Val Pro Cys Gly Pro Cys 130
135 140 Ser Glu Arg Arg Lys His
Leu Phe Val Gln Asp Pro Gln Thr Cys Lys 145 150
155 160 Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys
Ala Arg Gln Leu Glu 165 170
175 Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg
180 185 18232PRTHomo sapiens 18Met Asn
Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5
10 15 Tyr Leu His His Ala Lys Trp
Ser Gln Ala Ala Pro Met Ala Glu Gly 20 25
30 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met
Asp Val Tyr Gln 35 40 45
Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
50 55 60 Tyr Pro Asp
Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu 65
70 75 80 Met Arg Cys Gly Gly Cys Cys
Asn Asp Glu Gly Leu Glu Cys Val Pro 85
90 95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met
Arg Ile Lys Pro His 100 105
110 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys
Cys 115 120 125 Glu
Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val 130
135 140 Arg Gly Lys Gly Lys Gly
Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr 145 150
155 160 Lys Ser Trp Ser Val Tyr Val Gly Ala Arg Cys
Cys Leu Met Pro Trp 165 170
175 Ser Leu Pro Gly Pro His Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys
180 185 190 His Leu
Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn 195
200 205 Thr Asp Ser Arg Cys Lys Ala
Arg Gln Leu Glu Leu Asn Glu Arg Thr 210 215
220 Cys Arg Cys Asp Lys Pro Arg Arg 225
230 19206PRTHomo sapiens 19Ala Pro Met Ala Glu Gly Gly Gly
Gln Asn His His Glu Val Val Lys 1 5 10
15 Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile
Glu Thr Leu 20 25 30
Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys
35 40 45 Pro Ser Cys Val
Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 50
55 60 Gly Leu Glu Cys Val Pro Thr Glu
Glu Ser Asn Ile Thr Met Gln Ile 65 70
75 80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly
Glu Met Ser Phe 85 90
95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg
100 105 110 Gln Glu Lys
Lys Ser Val Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys 115
120 125 Arg Lys Lys Ser Arg Tyr Lys Ser
Trp Ser Val Tyr Val Gly Ala Arg 130 135
140 Cys Cys Leu Met Pro Trp Ser Leu Pro Gly Pro His Pro
Cys Gly Pro 145 150 155
160 Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr Cys
165 170 175 Lys Cys Ser Cys
Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu 180
185 190 Glu Leu Asn Glu Arg Thr Cys Arg Cys
Asp Lys Pro Arg Arg 195 200 205
20576DNAMacaca fascicularis 20atgaactttc tgctgtcttg ggtgcattgg
agccttgcct tgctgctgta cctccaccat 60gccaagtggt cccaggctgc acccatggca
gaaggaggag ggcagaatca tcacgaagtg 120gtgaagttca tggatgtcta tcagcgcagc
tactgccatc caatcgagac cctggtggac 180atcttccagg agtaccctga tgagattgag
tacatcttca agccatcctg tgtgcccctg 240atgcgatgtg ggggctgctg caatgacgag
ggcctggagt gtgtgcccac tgaggagtcc 300aacatcacca tgcagattat gcggatcaaa
cctcaccaag gccagcacat aggagagatg 360agcttcctac agcacaacaa atgtgaatgc
agaccaaaga aagatagagc aagacaagaa 420aatccctgtg ggccttgctc agagcggaga
aagcatttgt ttgtacaaga tccgcagacg 480tgtaaatgtt cctgcaaaaa cacagactcg
cgttgcaagg cgaggcagct tgagttaaac 540gaacgtactt gcagatgtga caagccgagg
cggtga 57621191PRTMacaca fascicularis 21Met
Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1
5 10 15 Tyr Leu His His Ala Lys
Trp Ser Gln Ala Ala Pro Met Ala Glu Gly 20
25 30 Gly Gly Gln Asn His His Glu Val Val Lys
Phe Met Asp Val Tyr Gln 35 40
45 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe
Gln Glu 50 55 60
Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu 65
70 75 80 Met Arg Cys Gly Gly
Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro 85
90 95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile
Met Arg Ile Lys Pro His 100 105
110 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys
Cys 115 120 125 Glu
Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly 130
135 140 Pro Cys Ser Glu Arg Arg
Lys His Leu Phe Val Gln Asp Pro Gln Thr 145 150
155 160 Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg
Cys Lys Ala Arg Gln 165 170
175 Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg
180 185 190 22165PRTMacaca
fascicularis 22Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val
Val Lys 1 5 10 15
Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu
20 25 30 Val Asp Ile Phe Gln
Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys 35
40 45 Pro Ser Cys Val Pro Leu Met Arg Cys
Gly Gly Cys Cys Asn Asp Glu 50 55
60 Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr
Met Gln Ile 65 70 75
80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe
85 90 95 Leu Gln His Asn
Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg 100
105 110 Gln Glu Asn Pro Cys Gly Pro Cys Ser
Glu Arg Arg Lys His Leu Phe 115 120
125 Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr
Asp Ser 130 135 140
Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys 145
150 155 160 Asp Lys Pro Arg Arg
165 23573DNABos taurus 23atgaactttc tgctctcttg ggtacattgg
agccttgcct tgctgctcta ccttcaccat 60gccaagtggt cccaggctgc acccatggca
gaaggagggc agaaacccca cgaagtggtg 120aagttcatgg atgtctacca gcgcagcttc
tgccgtccca tcgagaccct ggtggacatc 180ttccaggagt acccagatga gattgagttc
attttcaagc cgtcctgtgt gcccctgatg 240cggtgcgggg gctgctgtaa tgacgaaagt
ctggagtgtg tgcccactga ggagttcaac 300atcaccatgc agattatgcg gatcaaacct
caccaaagcc agcacatagg agagatgagc 360ttcctacagc ataacaaatg tgaatgcaga
ccaaagaaag ataaagcaag gcaagaaaat 420ccctgtgggc cttgctcaga gcggagaaag
catttgtttg tacaagatcc gcagacgtgt 480aaatgttcct gcaaaaacac agactcgcgt
tgcaaggcga ggcagcttga gttaaacgaa 540cgtacttgca gatgtgacaa gccgaggcgg
tga 57324190PRTBos taurus 24Met Asn Phe
Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5
10 15 Tyr Leu His His Ala Lys Trp Ser
Gln Ala Ala Pro Met Ala Glu Gly 20 25
30 Gly Gln Lys Pro His Glu Val Val Lys Phe Met Asp Val
Tyr Gln Arg 35 40 45
Ser Phe Cys Arg Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr 50
55 60 Pro Asp Glu Ile
Glu Phe Ile Phe Lys Pro Ser Cys Val Pro Leu Met 65 70
75 80 Arg Cys Gly Gly Cys Cys Asn Asp Glu
Ser Leu Glu Cys Val Pro Thr 85 90
95 Glu Glu Phe Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro
His Gln 100 105 110
Ser Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu
115 120 125 Cys Arg Pro Lys
Lys Asp Lys Ala Arg Gln Glu Asn Pro Cys Gly Pro 130
135 140 Cys Ser Glu Arg Arg Lys His Leu
Phe Val Gln Asp Pro Gln Thr Cys 145 150
155 160 Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys
Ala Arg Gln Leu 165 170
175 Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg
180 185 190 25164PRTBos taurus 25Ala
Pro Met Ala Glu Gly Gly Gln Lys Pro His Glu Val Val Lys Phe 1
5 10 15 Met Asp Val Tyr Gln Arg
Ser Phe Cys Arg Pro Ile Glu Thr Leu Val 20
25 30 Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile
Glu Phe Ile Phe Lys Pro 35 40
45 Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp
Glu Ser 50 55 60
Leu Glu Cys Val Pro Thr Glu Glu Phe Asn Ile Thr Met Gln Ile Met 65
70 75 80 Arg Ile Lys Pro His
Gln Ser Gln His Ile Gly Glu Met Ser Phe Leu 85
90 95 Gln His Asn Lys Cys Glu Cys Arg Pro Lys
Lys Asp Lys Ala Arg Gln 100 105
110 Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe
Val 115 120 125 Gln
Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg 130
135 140 Cys Lys Ala Arg Gln Leu
Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp 145 150
155 160 Lys Pro Arg Arg 26645DNACanis familiaris
26atgaactttc tgctctcttg ggtgcattgg agccttgcct tgctgctcta cctccaccat
60gccaagtggt cccaggctgc gcctatggca ggaggagagc acaaacccca cgaagtggtg
120aagttcatgg acgtctacca gcgcagctac tgccgtccca ttgagaccct ggtggacatc
180ttccaggagt accctgacga gatcgagtac atcttcaagc catcctgcgt gcccctgatg
240cggtgtgggg gctgctgtaa tgatgagggc ctagagtgcg tgcccactga ggagttcaac
300atcaccatgc agattatgcg gatcaaacct catcaaggcc agcacatagg ggagatgagt
360ttcctgcagc atagcaaatg tgaatgcaga ccaaagaaag atagagcaag gcaagaaaaa
420aaatcaattc gaggaaaggg gaaggggcaa aaaagaaagc gcaagaaatc ccggtataaa
480ccctggagcg ttccctgtgg gccttgctca gagcggagaa agcatttgtt tgtacaagat
540ccgcagacgt gtaaatgttc ctgcaaaaac acagactcgc gttgcaaggc gaggcagctt
600gagttaaacg aacgtacttg cagatgtgac aagccgaggc ggtga
64527214PRTCanis familiaris 27Met Asn Phe Leu Leu Ser Trp Val His Trp Ser
Leu Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Gly Gly
20 25 30 Glu His
Lys Pro His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg 35
40 45 Ser Tyr Cys Arg Pro Ile Glu
Thr Leu Val Asp Ile Phe Gln Glu Tyr 50 55
60 Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys
Val Pro Leu Met 65 70 75
80 Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr
85 90 95 Glu Glu Phe
Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln 100
105 110 Gly Gln His Ile Gly Glu Met Ser
Phe Leu Gln His Ser Lys Cys Glu 115 120
125 Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys
Ser Ile Arg 130 135 140
Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr Lys 145
150 155 160 Pro Trp Ser Val
Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu 165
170 175 Phe Val Gln Asp Pro Gln Thr Cys Lys
Cys Ser Cys Lys Asn Thr Asp 180 185
190 Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr
Cys Arg 195 200 205
Cys Asp Lys Pro Arg Arg 210 28188PRTCanis familiaris
28Ala Pro Met Ala Gly Gly Glu His Lys Pro His Glu Val Val Lys Phe 1
5 10 15 Met Asp Val Tyr
Gln Arg Ser Tyr Cys Arg Pro Ile Glu Thr Leu Val 20
25 30 Asp Ile Phe Gln Glu Tyr Pro Asp Glu
Ile Glu Tyr Ile Phe Lys Pro 35 40
45 Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp
Glu Gly 50 55 60
Leu Glu Cys Val Pro Thr Glu Glu Phe Asn Ile Thr Met Gln Ile Met 65
70 75 80 Arg Ile Lys Pro His
Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu 85
90 95 Gln His Ser Lys Cys Glu Cys Arg Pro Lys
Lys Asp Arg Ala Arg Gln 100 105
110 Glu Lys Lys Ser Ile Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys
Arg 115 120 125 Lys
Lys Ser Arg Tyr Lys Pro Trp Ser Val Pro Cys Gly Pro Cys Ser 130
135 140 Glu Arg Arg Lys His Leu
Phe Val Gln Asp Pro Gln Thr Cys Lys Cys 145 150
155 160 Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala
Arg Gln Leu Glu Leu 165 170
175 Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg 180
185 29651DNAGallus gallus 29atgaactttc
tgctcacttg gatccactgg gggctggcgg cgctgctcta tctgcagagc 60gcggagttgt
cgaaggctgc tccggccctg ggggatgggg agcggaagcc caacgaagtt 120atcaaattcc
tggaagtcta cgaacgcagc ttctgcagga caattgagac cctggtggac 180attttccagg
agtaccctga tgaggtggag tacatattca ggccatcctg tgtgcctctg 240atgagatgtg
cgggttgctg cggcgatgag ggcctagaat gtgtccctgt ggatgtgtac 300aacgtcacga
tggagatcgc aagaattaaa ccccatcaga gtcagcacat agcgcacatg 360agcttcttac
agcacagtaa atgtgactgc agaccaaaga aagatgtcaa aaataaacaa 420gaaaaaaaat
caaagcgagg aaaggggaag ggtcaaaaga gaaagcgcaa gaaaggccgg 480tacaaaccac
ccagctttca ctgtgagcct tgctcagaga ggagaaagca cttgtttgta 540caagatcccc
agacctgtaa atgttcctgc aaattcacag actcacgttg caagtcgagg 600cagcttgagt
taaacgagcg cacttgcaga tgtgaaaaac cgagacggtg a
65130216PRTGallus gallus 30Met Asn Phe Leu Leu Thr Trp Ile His Trp Gly
Leu Ala Ala Leu Leu 1 5 10
15 Tyr Leu Gln Ser Ala Glu Leu Ser Lys Ala Ala Pro Ala Leu Gly Asp
20 25 30 Gly Glu
Arg Lys Pro Asn Glu Val Ile Lys Phe Leu Glu Val Tyr Glu 35
40 45 Arg Ser Phe Cys Arg Thr Ile
Glu Thr Leu Val Asp Ile Phe Gln Glu 50 55
60 Tyr Pro Asp Glu Val Glu Tyr Ile Phe Arg Pro Ser
Cys Val Pro Leu 65 70 75
80 Met Arg Cys Ala Gly Cys Cys Gly Asp Glu Gly Leu Glu Cys Val Pro
85 90 95 Val Asp Val
Tyr Asn Val Thr Met Glu Ile Ala Arg Ile Lys Pro His 100
105 110 Gln Ser Gln His Ile Ala His Met
Ser Phe Leu Gln His Ser Lys Cys 115 120
125 Asp Cys Arg Pro Lys Lys Asp Val Lys Asn Lys Gln Glu
Lys Lys Ser 130 135 140
Lys Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Gly Arg 145
150 155 160 Tyr Lys Pro Pro
Ser Phe His Cys Glu Pro Cys Ser Glu Arg Arg Lys 165
170 175 His Leu Phe Val Gln Asp Pro Gln Thr
Cys Lys Cys Ser Cys Lys Phe 180 185
190 Thr Asp Ser Arg Cys Lys Ser Arg Gln Leu Glu Leu Asn Glu
Arg Thr 195 200 205
Cys Arg Cys Glu Lys Pro Arg Arg 210 215
31190PRTGallus gallus 31Ala Pro Ala Leu Gly Asp Gly Glu Arg Lys Pro Asn
Glu Val Ile Lys 1 5 10
15 Phe Leu Glu Val Tyr Glu Arg Ser Phe Cys Arg Thr Ile Glu Thr Leu
20 25 30 Val Asp Ile
Phe Gln Glu Tyr Pro Asp Glu Val Glu Tyr Ile Phe Arg 35
40 45 Pro Ser Cys Val Pro Leu Met Arg
Cys Ala Gly Cys Cys Gly Asp Glu 50 55
60 Gly Leu Glu Cys Val Pro Val Asp Val Tyr Asn Val Thr
Met Glu Ile 65 70 75
80 Ala Arg Ile Lys Pro His Gln Ser Gln His Ile Ala His Met Ser Phe
85 90 95 Leu Gln His Ser
Lys Cys Asp Cys Arg Pro Lys Lys Asp Val Lys Asn 100
105 110 Lys Gln Glu Lys Lys Ser Lys Arg Gly
Lys Gly Lys Gly Gln Lys Arg 115 120
125 Lys Arg Lys Lys Gly Arg Tyr Lys Pro Pro Ser Phe His Cys
Glu Pro 130 135 140
Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr Cys 145
150 155 160 Lys Cys Ser Cys Lys
Phe Thr Asp Ser Arg Cys Lys Ser Arg Gln Leu 165
170 175 Glu Leu Asn Glu Arg Thr Cys Arg Cys Glu
Lys Pro Arg Arg 180 185 190
32573DNAEquus caballus 32atgaactttc tgctctcttg ggtgcattgg agccttgcct
tgctgctcta cctccaccat 60gccaagtggt cccaggctgc acccatggca gaaggagagc
ataaaaccca tgaagtggtg 120aagttcatgg acgtctacca gcgcagctac tgccgtccaa
tcgagaccct ggtggacatc 180ttccaggagt accccgatga gatcgagtac atcttcaagc
catcctgtgt gcccctgatg 240cggtgtgggg gctgctgcaa cgacgagggc ctagagtgcg
tgcccactgc ggagttcaac 300atcaccatgc agattatgcg gatcaaacct caccaaagcc
aacacatagg agagatgagt 360ttcctacagc atagcaaatg tgaatgcaga ccaaagaaag
ataaagcaag gcaagaaaat 420ccctgtgggc cttgctcaga gcggagaaag catttgtttg
tacaagatcc gcagacgtgt 480aaatgttcct gcaaaaacac agactcgcgt tgcaaggcga
ggcagcttga gttaaacgaa 540cgtacttgca gatgtgacaa gccgaggcgg tga
57333190PRTEquus caballus 33Met Asn Phe Leu Leu
Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5
10 15 Tyr Leu His His Ala Lys Trp Ser Gln Ala
Ala Pro Met Ala Glu Gly 20 25
30 Glu His Lys Thr His Glu Val Val Lys Phe Met Asp Val Tyr Gln
Arg 35 40 45 Ser
Tyr Cys Arg Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr 50
55 60 Pro Asp Glu Ile Glu Tyr
Ile Phe Lys Pro Ser Cys Val Pro Leu Met 65 70
75 80 Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu
Glu Cys Val Pro Thr 85 90
95 Ala Glu Phe Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln
100 105 110 Ser Gln
His Ile Gly Glu Met Ser Phe Leu Gln His Ser Lys Cys Glu 115
120 125 Cys Arg Pro Lys Lys Asp Lys
Ala Arg Gln Glu Asn Pro Cys Gly Pro 130 135
140 Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp
Pro Gln Thr Cys 145 150 155
160 Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu
165 170 175 Glu Leu Asn
Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg 180
185 190 34164PRTEquus caballus 34Ala Pro Met Ala Glu
Gly Glu His Lys Thr His Glu Val Val Lys Phe 1 5
10 15 Met Asp Val Tyr Gln Arg Ser Tyr Cys Arg
Pro Ile Glu Thr Leu Val 20 25
30 Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys
Pro 35 40 45 Ser
Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly 50
55 60 Leu Glu Cys Val Pro Thr
Ala Glu Phe Asn Ile Thr Met Gln Ile Met 65 70
75 80 Arg Ile Lys Pro His Gln Ser Gln His Ile Gly
Glu Met Ser Phe Leu 85 90
95 Gln His Ser Lys Cys Glu Cys Arg Pro Lys Lys Asp Lys Ala Arg Gln
100 105 110 Glu Asn
Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val 115
120 125 Gln Asp Pro Gln Thr Cys Lys
Cys Ser Cys Lys Asn Thr Asp Ser Arg 130 135
140 Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr
Cys Arg Cys Asp 145 150 155
160 Lys Pro Arg Arg 35573DNAMus musculus 35atgaactttc tgctgtcttg
ggtgcactgg accctggctt tactgctgta cctccaccat 60gccaagtggt cccaggctgc
acccacgaca gaaggagagc agaagtccca tgaagtgatc 120aagttcatgg acgtctacca
gcgaagctac tgccgtccaa ttgagaccct ggtggacatc 180ttccaggagt accccgacga
gatagagtac atcttcaagc cgtcctgtgt gccgctgatg 240cgctgtgcag gctgctgtaa
cgatgaagcc ctggagtgcg tgcccacgtc agagagcaac 300atcaccatgc agatcatgcg
gatcaaacct caccaaagcc agcacatagg agagatgagc 360ttcctacagc acagccgatg
tgaatgcaga ccaaagaaag acaggacaaa gccagaaaat 420cactgtgagc cttgttcaga
gcggagaaag catttgtttg tccaagatcc gcagacgtgt 480aaatgttcct gcaaaaacac
agactcgcgt tgcaaggcga ggcagcttga gttaaacgaa 540cgtacttgca gatgtgacaa
gccgaggcgg tga 57336214PRTMus musculus
36Met Asn Phe Leu Leu Ser Trp Val His Trp Thr Leu Ala Leu Leu Leu 1
5 10 15 Tyr Leu His His
Ala Lys Trp Ser Gln Ala Ala Pro Thr Thr Glu Gly 20
25 30 Glu Gln Lys Ser His Glu Val Ile Lys
Phe Met Asp Val Tyr Gln Arg 35 40
45 Ser Tyr Cys Arg Pro Ile Glu Thr Leu Val Asp Ile Phe Gln
Glu Tyr 50 55 60
Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met 65
70 75 80 Arg Cys Ala Gly Cys
Cys Asn Asp Glu Ala Leu Glu Cys Val Pro Thr 85
90 95 Ser Glu Ser Asn Ile Thr Met Gln Ile Met
Arg Ile Lys Pro His Gln 100 105
110 Ser Gln His Ile Gly Glu Met Ser Phe Leu Gln His Ser Arg Cys
Glu 115 120 125 Cys
Arg Pro Lys Lys Asp Arg Thr Lys Pro Glu Lys Lys Ser Val Arg 130
135 140 Gly Lys Gly Lys Gly Gln
Lys Arg Lys Arg Lys Lys Ser Arg Phe Lys 145 150
155 160 Ser Trp Ser Val His Cys Glu Pro Cys Ser Glu
Arg Arg Lys His Leu 165 170
175 Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp
180 185 190 Ser Arg
Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg 195
200 205 Cys Asp Lys Pro Arg Arg
210 37188PRTMus musculus 37Ala Pro Thr Thr Glu Gly Glu
Gln Lys Ser His Glu Val Ile Lys Phe 1 5
10 15 Met Asp Val Tyr Gln Arg Ser Tyr Cys Arg Pro
Ile Glu Thr Leu Val 20 25
30 Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys
Pro 35 40 45 Ser
Cys Val Pro Leu Met Arg Cys Ala Gly Cys Cys Asn Asp Glu Ala 50
55 60 Leu Glu Cys Val Pro Thr
Ser Glu Ser Asn Ile Thr Met Gln Ile Met 65 70
75 80 Arg Ile Lys Pro His Gln Ser Gln His Ile Gly
Glu Met Ser Phe Leu 85 90
95 Gln His Ser Arg Cys Glu Cys Arg Pro Lys Lys Asp Arg Thr Lys Pro
100 105 110 Glu Lys
Lys Ser Val Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg 115
120 125 Lys Lys Ser Arg Phe Lys Ser
Trp Ser Val His Cys Glu Pro Cys Ser 130 135
140 Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln
Thr Cys Lys Cys 145 150 155
160 Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu
165 170 175 Asn Glu Arg
Thr Cys Arg Cys Asp Lys Pro Arg Arg 180 185
38573DNASus scrofa 38atgaactttc tgctgtcttg ggtgcattgg
agccttgcct tgctgctcta cctccaccat 60gccaagtggt cccaggctgc acccatggca
gaaggagacc agaaacccca cgaagtggtg 120aagttcatgg acgtctacca gcgcagctac
tgccgtccaa tcgagaccct ggtggacatc 180ttccaggagt accccgatga gatcgagtac
atcttcaagc cgtcctgtgt gcccctgatg 240cggtgcgggg gctgctgcaa cgacgaaggt
ctggagtgtg tgcccactga ggagttcaac 300atcaccatgc agattatgcg gatcaaacct
caccaaggcc agcacatagg agagatgagc 360ttcctacagc acaacaaatg tgaatgcaga
ccaaagaaag atagagcgag gcaagaaaat 420ccctgtgggc cttgctcaga gcggagaaag
catttgtttg tacaagatcc gcagacgtgt 480aaatgttcct gcaaaaacac agactcgcgt
tgcaaggcga ggcagcttga gttaaacgaa 540cgtacttgca gatgtgacaa gccgaggcgg
tga 57339190PRTSus scrofa 39Met Asn Phe
Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5
10 15 Tyr Leu His His Ala Lys Trp Ser
Gln Ala Ala Pro Met Ala Glu Gly 20 25
30 Asp Gln Lys Pro His Glu Val Val Lys Phe Met Asp Val
Tyr Gln Arg 35 40 45
Ser Tyr Cys Arg Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr 50
55 60 Pro Asp Glu Ile
Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met 65 70
75 80 Arg Cys Gly Gly Cys Cys Asn Asp Glu
Gly Leu Glu Cys Val Pro Thr 85 90
95 Glu Glu Phe Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro
His Gln 100 105 110
Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu
115 120 125 Cys Arg Pro Lys
Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly Pro 130
135 140 Cys Ser Glu Arg Arg Lys His Leu
Phe Val Gln Asp Pro Gln Thr Cys 145 150
155 160 Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys
Ala Arg Gln Leu 165 170
175 Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg
180 185 190 40164PRTSus scrofa 40Ala
Pro Met Ala Glu Gly Asp Gln Lys Pro His Glu Val Val Lys Phe 1
5 10 15 Met Asp Val Tyr Gln Arg
Ser Tyr Cys Arg Pro Ile Glu Thr Leu Val 20
25 30 Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile
Glu Tyr Ile Phe Lys Pro 35 40
45 Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp
Glu Gly 50 55 60
Leu Glu Cys Val Pro Thr Glu Glu Phe Asn Ile Thr Met Gln Ile Met 65
70 75 80 Arg Ile Lys Pro His
Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu 85
90 95 Gln His Asn Lys Cys Glu Cys Arg Pro Lys
Lys Asp Arg Ala Arg Gln 100 105
110 Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe
Val 115 120 125 Gln
Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg 130
135 140 Cys Lys Ala Arg Gln Leu
Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp 145 150
155 160 Lys Pro Arg Arg 41573DNARattus norvegicus
41atgaactttc tgctctcttg ggtgcactgg accctggctt tactgctgta cctccaccat
60gccaagtggt cccaggctgc acccacgaca gaaggggagc agaaagccca tgaagtggtg
120aagttcatgg acgtctacca gcgcagctat tgccgtccga ttgagaccct ggtggacatc
180ttccaggagt accccgatga gatagagtat atcttcaagc cgtcctgtgt gcccctaatg
240cggtgtgcgg gctgctgcaa tgatgaagcc ctggagtgcg tgcccacgtc ggagagcaac
300gtcactatgc agatcatgcg gatcaaacct caccaaagcc agcacatagg agagatgagc
360ttcctgcagc atagcagatg tgaatgcaga ccaaagaaag atagaacaaa gccagaaaat
420cactgtgagc cttgttcaga gcggagaaag catttgtttg tccaagatcc gcagacgtgt
480aaatgttcct gcaaaaacac agactcgcgt tgcaaggcga ggcagcttga gttaaacgaa
540cgtacttgca gatgtgacaa gccaaggcgg tga
57342214PRTRattus norvegicus 42Met Asn Phe Leu Leu Ser Trp Val His Trp
Thr Leu Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Thr Thr Glu
Gly 20 25 30 Glu
Gln Lys Ala His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg 35
40 45 Ser Tyr Cys Arg Pro Ile
Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr 50 55
60 Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser
Cys Val Pro Leu Met 65 70 75
80 Arg Cys Ala Gly Cys Cys Asn Asp Glu Ala Leu Glu Cys Val Pro Thr
85 90 95 Ser Glu
Ser Asn Val Thr Met Gln Ile Met Arg Ile Lys Pro His Gln 100
105 110 Ser Gln His Ile Gly Glu Met
Ser Phe Leu Gln His Ser Arg Cys Glu 115 120
125 Cys Arg Pro Lys Lys Asp Arg Thr Lys Pro Glu Lys
Lys Ser Val Arg 130 135 140
Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Phe Lys 145
150 155 160 Ser Trp Ser
Val His Cys Glu Pro Cys Ser Glu Arg Arg Lys His Leu 165
170 175 Phe Val Gln Asp Pro Gln Thr Cys
Lys Cys Ser Cys Lys Asn Thr Asp 180 185
190 Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg
Thr Cys Arg 195 200 205
Cys Asp Lys Pro Arg Arg 210 43188PRTRattus
norvegicus 43Ala Pro Thr Thr Glu Gly Glu Gln Lys Ala His Glu Val Val Lys
Phe 1 5 10 15 Met
Asp Val Tyr Gln Arg Ser Tyr Cys Arg Pro Ile Glu Thr Leu Val
20 25 30 Asp Ile Phe Gln Glu
Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro 35
40 45 Ser Cys Val Pro Leu Met Arg Cys Ala
Gly Cys Cys Asn Asp Glu Ala 50 55
60 Leu Glu Cys Val Pro Thr Ser Glu Ser Asn Val Thr Met
Gln Ile Met 65 70 75
80 Arg Ile Lys Pro His Gln Ser Gln His Ile Gly Glu Met Ser Phe Leu
85 90 95 Gln His Ser Arg
Cys Glu Cys Arg Pro Lys Lys Asp Arg Thr Lys Pro 100
105 110 Glu Lys Lys Ser Val Arg Gly Lys Gly
Lys Gly Gln Lys Arg Lys Arg 115 120
125 Lys Lys Ser Arg Phe Lys Ser Trp Ser Val His Cys Glu Pro
Cys Ser 130 135 140
Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys 145
150 155 160 Ser Cys Lys Asn Thr
Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu 165
170 175 Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro
Arg Arg 180 185 44441DNAOvis
aries 44atgaactttc tgctctcttg ggtgcattgg agccttgcct tgctgctcta ccttcaccat
60gccaagtggt cccaggctgc acccatggca gaaggagggc agaaacccca tgaagtgatg
120aagttcatgg atgtctacca gcgcagcttc tgccgtccca ttgagaccct ggtggacatc
180ttccaggagt acccagatga gattgagttc attttcaagc cgtcctgtgt gcccctgatg
240cggtgcgggg gctgctgtaa tgacgaaagt ctggagtgtg tgcccactga ggagttcaac
300atcaccatgc agattatgcg gatcaaacct caccaaagcc agcacatagg agagatgagt
360ttcctacagc ataacaaatg tgaatgcaga ccaaagaaag ataaagcaag gcaagaaaaa
420tgtgacaagc cgaggcggtg a
44145146PRTOvis aries 45Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu
Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
20 25 30 Gly Gln Lys
Pro His Glu Val Met Lys Phe Met Asp Val Tyr Gln Arg 35
40 45 Ser Phe Cys Arg Pro Ile Glu Thr
Leu Val Asp Ile Phe Gln Glu Tyr 50 55
60 Pro Asp Glu Ile Glu Phe Ile Phe Lys Pro Ser Cys Val
Pro Leu Met 65 70 75
80 Arg Cys Gly Gly Cys Cys Asn Asp Glu Ser Leu Glu Cys Val Pro Thr
85 90 95 Glu Glu Phe Asn
Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln 100
105 110 Ser Gln His Ile Gly Glu Met Ser Phe
Leu Gln His Asn Lys Cys Glu 115 120
125 Cys Arg Pro Lys Lys Asp Lys Ala Arg Gln Glu Lys Cys Asp
Lys Pro 130 135 140
Arg Arg 145 46120PRTOvis aries 46Ala Pro Met Ala Glu Gly Gly Gln Lys
Pro His Glu Val Met Lys Phe 1 5 10
15 Met Asp Val Tyr Gln Arg Ser Phe Cys Arg Pro Ile Glu Thr
Leu Val 20 25 30
Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Phe Ile Phe Lys Pro
35 40 45 Ser Cys Val Pro
Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Ser 50
55 60 Leu Glu Cys Val Pro Thr Glu Glu
Phe Asn Ile Thr Met Gln Ile Met 65 70
75 80 Arg Ile Lys Pro His Gln Ser Gln His Ile Gly Glu
Met Ser Phe Leu 85 90
95 Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Lys Ala Arg Gln
100 105 110 Glu Lys Cys
Asp Lys Pro Arg Arg 115 120 47188PRTHomo sapiens
47Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu 1
5 10 15 Ala Pro Ala Gln
Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln 20
25 30 Arg Lys Val Val Ser Trp Ile Asp Val
Tyr Thr Arg Ala Thr Cys Gln 35 40
45 Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly
Thr Val 50 55 60
Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly 65
70 75 80 Cys Cys Pro Asp Asp
Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln 85
90 95 Val Arg Met Gln Ile Leu Met Ile Arg Tyr
Pro Ser Ser Gln Leu Gly 100 105
110 Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys
Lys 115 120 125 Lys
Asp Ser Ala Val Lys Pro Asp Ser Pro Arg Pro Leu Cys Pro Arg 130
135 140 Cys Thr Gln His His Gln
Arg Pro Asp Pro Arg Thr Cys Arg Cys Arg 145 150
155 160 Cys Arg Arg Arg Ser Phe Leu Arg Cys Gln Gly
Arg Gly Leu Glu Leu 165 170
175 Asn Pro Asp Thr Cys Arg Cys Arg Lys Leu Arg Arg 180
185 48167PRTHomo sapiens 48Pro Val Ser Gln
Pro Asp Ala Pro Gly His Gln Arg Lys Val Val Ser 1 5
10 15 Trp Ile Asp Val Tyr Thr Arg Ala Thr
Cys Gln Pro Arg Glu Val Val 20 25
30 Val Pro Leu Thr Val Glu Leu Met Gly Thr Val Ala Lys Gln
Leu Val 35 40 45
Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly Cys Cys Pro Asp Asp 50
55 60 Gly Leu Glu Cys Val
Pro Thr Gly Gln His Gln Val Arg Met Gln Ile 65 70
75 80 Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu
Gly Glu Met Ser Leu Glu 85 90
95 Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys Lys Asp Ser Ala
Val 100 105 110 Lys
Pro Asp Ser Pro Arg Pro Leu Cys Pro Arg Cys Thr Gln His His 115
120 125 Gln Arg Pro Asp Pro Arg
Thr Cys Arg Cys Arg Cys Arg Arg Arg Ser 130 135
140 Phe Leu Arg Cys Gln Gly Arg Gly Leu Glu Leu
Asn Pro Asp Thr Cys 145 150 155
160 Arg Cys Arg Lys Leu Arg Arg 165
49207PRTHomo sapiens 49Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala
Leu Leu Gln Leu 1 5 10
15 Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln
20 25 30 Arg Lys Val
Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln 35
40 45 Pro Arg Glu Val Val Val Pro Leu
Thr Val Glu Leu Met Gly Thr Val 50 55
60 Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg
Cys Gly Gly 65 70 75
80 Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln
85 90 95 Val Arg Met Gln
Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly 100
105 110 Glu Met Ser Leu Glu Glu His Ser Gln
Cys Glu Cys Arg Pro Lys Lys 115 120
125 Lys Asp Ser Ala Val Lys Pro Asp Arg Ala Ala Thr Pro His
His Arg 130 135 140
Pro Gln Pro Arg Ser Val Pro Gly Trp Asp Ser Ala Pro Gly Ala Pro 145
150 155 160 Ser Pro Ala Asp Ile
Thr His Pro Thr Pro Ala Pro Gly Pro Ser Ala 165
170 175 His Ala Ala Pro Ser Thr Thr Ser Ala Leu
Thr Pro Gly Pro Ala Ala 180 185
190 Ala Ala Ala Asp Ala Ala Ala Ser Ser Val Ala Lys Gly Gly Ala
195 200 205 50186PRTHomo
sapiens 50Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln Arg Lys Val Val Ser
1 5 10 15 Trp Ile
Asp Val Tyr Thr Arg Ala Thr Cys Gln Pro Arg Glu Val Val 20
25 30 Val Pro Leu Thr Val Glu Leu
Met Gly Thr Val Ala Lys Gln Leu Val 35 40
45 Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly Cys
Cys Pro Asp Asp 50 55 60
Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln Val Arg Met Gln Ile 65
70 75 80 Leu Met Ile
Arg Tyr Pro Ser Ser Gln Leu Gly Glu Met Ser Leu Glu 85
90 95 Glu His Ser Gln Cys Glu Cys Arg
Pro Lys Lys Lys Asp Ser Ala Val 100 105
110 Lys Pro Asp Arg Ala Ala Thr Pro His His Arg Pro Gln
Pro Arg Ser 115 120 125
Val Pro Gly Trp Asp Ser Ala Pro Gly Ala Pro Ser Pro Ala Asp Ile 130
135 140 Thr His Pro Thr
Pro Ala Pro Gly Pro Ser Ala His Ala Ala Pro Ser 145 150
155 160 Thr Thr Ser Ala Leu Thr Pro Gly Pro
Ala Ala Ala Ala Ala Asp Ala 165 170
175 Ala Ala Ser Ser Val Ala Lys Gly Gly Ala 180
185 51419PRTHomo sapiens 51Met His Leu Leu Gly Phe
Phe Ser Val Ala Cys Ser Leu Leu Ala Ala 1 5
10 15 Ala Leu Leu Pro Gly Pro Arg Glu Ala Pro Ala
Ala Ala Ala Ala Phe 20 25
30 Glu Ser Gly Leu Asp Leu Ser Asp Ala Glu Pro Asp Ala Gly Glu
Ala 35 40 45 Thr
Ala Tyr Ala Ser Lys Asp Leu Glu Glu Gln Leu Arg Ser Val Ser 50
55 60 Ser Val Asp Glu Leu Met
Thr Val Leu Tyr Pro Glu Tyr Trp Lys Met 65 70
75 80 Tyr Lys Cys Gln Leu Arg Lys Gly Gly Trp Gln
His Asn Arg Glu Gln 85 90
95 Ala Asn Leu Asn Ser Arg Thr Glu Glu Thr Ile Lys Phe Ala Ala Ala
100 105 110 His Tyr
Asn Thr Glu Ile Leu Lys Ser Ile Asp Asn Glu Trp Arg Lys 115
120 125 Thr Gln Cys Met Pro Arg Glu
Val Cys Ile Asp Val Gly Lys Glu Phe 130 135
140 Gly Val Ala Thr Asn Thr Phe Phe Lys Pro Pro Cys
Val Ser Val Tyr 145 150 155
160 Arg Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr
165 170 175 Ser Thr Ser
Tyr Leu Ser Lys Thr Leu Phe Glu Ile Thr Val Pro Leu 180
185 190 Ser Gln Gly Pro Lys Pro Val Thr
Ile Ser Phe Ala Asn His Thr Ser 195 200
205 Cys Arg Cys Met Ser Lys Leu Asp Val Tyr Arg Gln Val
His Ser Ile 210 215 220
Ile Arg Arg Ser Leu Pro Ala Thr Leu Pro Gln Cys Gln Ala Ala Asn 225
230 235 240 Lys Thr Cys Pro
Thr Asn Tyr Met Trp Asn Asn His Ile Cys Arg Cys 245
250 255 Leu Ala Gln Glu Asp Phe Met Phe Ser
Ser Asp Ala Gly Asp Asp Ser 260 265
270 Thr Asp Gly Phe His Asp Ile Cys Gly Pro Asn Lys Glu Leu
Asp Glu 275 280 285
Glu Thr Cys Gln Cys Val Cys Arg Ala Gly Leu Arg Pro Ala Ser Cys 290
295 300 Gly Pro His Lys Glu
Leu Asp Arg Asn Ser Cys Gln Cys Val Cys Lys 305 310
315 320 Asn Lys Leu Phe Pro Ser Gln Cys Gly Ala
Asn Arg Glu Phe Asp Glu 325 330
335 Asn Thr Cys Gln Cys Val Cys Lys Arg Thr Cys Pro Arg Asn Gln
Pro 340 345 350 Leu
Asn Pro Gly Lys Cys Ala Cys Glu Cys Thr Glu Ser Pro Gln Lys 355
360 365 Cys Leu Leu Lys Gly Lys
Lys Phe His His Gln Thr Cys Ser Cys Tyr 370 375
380 Arg Arg Pro Cys Thr Asn Arg Gln Lys Ala Cys
Glu Pro Gly Phe Ser 385 390 395
400 Tyr Ser Glu Glu Val Cys Arg Cys Val Pro Ser Tyr Trp Lys Arg Pro
405 410 415 Gln Met
Ser 52354PRTHomo sapiens 52Met Tyr Arg Glu Trp Val Val Val Asn Val Phe
Met Met Leu Tyr Val 1 5 10
15 Gln Leu Val Gln Gly Ser Ser Asn Glu His Gly Pro Val Lys Arg Ser
20 25 30 Ser Gln
Ser Thr Leu Glu Arg Ser Glu Gln Gln Ile Arg Ala Ala Ser 35
40 45 Ser Leu Glu Glu Leu Leu Arg
Ile Thr His Ser Glu Asp Trp Lys Leu 50 55
60 Trp Arg Cys Arg Leu Arg Leu Lys Ser Phe Thr Ser
Met Asp Ser Arg 65 70 75
80 Ser Ala Ser His Arg Ser Thr Arg Phe Ala Ala Thr Phe Tyr Asp Ile
85 90 95 Glu Thr Leu
Lys Val Ile Asp Glu Glu Trp Gln Arg Thr Gln Cys Ser 100
105 110 Pro Arg Glu Thr Cys Val Glu Val
Ala Ser Glu Leu Gly Lys Ser Thr 115 120
125 Asn Thr Phe Phe Lys Pro Pro Cys Val Asn Val Phe Arg
Cys Gly Gly 130 135 140
Cys Cys Asn Glu Glu Ser Leu Ile Cys Met Asn Thr Ser Thr Ser Tyr 145
150 155 160 Ile Ser Lys Gln
Leu Phe Glu Ile Ser Val Pro Leu Thr Ser Val Pro 165
170 175 Glu Leu Val Pro Val Lys Val Ala Asn
His Thr Gly Cys Lys Cys Leu 180 185
190 Pro Thr Ala Pro Arg His Pro Tyr Ser Ile Ile Arg Arg Ser
Ile Gln 195 200 205
Ile Pro Glu Glu Asp Arg Cys Ser His Ser Lys Lys Leu Cys Pro Ile 210
215 220 Asp Met Leu Trp Asp
Ser Asn Lys Cys Lys Cys Val Leu Gln Glu Glu 225 230
235 240 Asn Pro Leu Ala Gly Thr Glu Asp His Ser
His Leu Gln Glu Pro Ala 245 250
255 Leu Cys Gly Pro His Met Met Phe Asp Glu Asp Arg Cys Glu Cys
Val 260 265 270 Cys
Lys Thr Pro Cys Pro Lys Asp Leu Ile Gln His Pro Lys Asn Cys 275
280 285 Ser Cys Phe Glu Cys Lys
Glu Ser Leu Glu Thr Cys Cys Gln Lys His 290 295
300 Lys Leu Phe His Pro Asp Thr Cys Ser Cys Glu
Asp Arg Cys Pro Phe 305 310 315
320 His Thr Arg Pro Cys Ala Ser Gly Lys Thr Ala Cys Ala Lys His Cys
325 330 335 Arg Phe
Pro Lys Glu Lys Arg Ala Ala Gln Gly Pro His Ser Arg Lys 340
345 350 Asn Pro 53149PRTHomo
sapiens 53Met Pro Val Met Arg Leu Phe Pro Cys Phe Leu Gln Leu Leu Ala Gly
1 5 10 15 Leu Ala
Leu Pro Ala Val Pro Pro Gln Gln Trp Ala Leu Ser Ala Gly 20
25 30 Asn Gly Ser Ser Glu Val Glu
Val Val Pro Phe Gln Glu Val Trp Gly 35 40
45 Arg Ser Tyr Cys Arg Ala Leu Glu Arg Leu Val Asp
Val Val Ser Glu 50 55 60
Tyr Pro Ser Glu Val Glu His Met Phe Ser Pro Ser Cys Val Ser Leu 65
70 75 80 Leu Arg Cys
Thr Gly Cys Cys Gly Asp Glu Asn Leu His Cys Val Pro 85
90 95 Val Glu Thr Ala Asn Val Thr Met
Gln Leu Leu Lys Ile Arg Ser Gly 100 105
110 Asp Arg Pro Ser Tyr Val Glu Leu Thr Phe Ser Gln His
Val Arg Cys 115 120 125
Glu Cys Arg Pro Leu Arg Glu Lys Met Lys Pro Glu Arg Cys Gly Asp 130
135 140 Ala Val Pro Arg
Arg 145 54131PRTHomo sapiens 54Leu Pro Ala Val Pro Pro
Gln Gln Trp Ala Leu Ser Ala Gly Asn Gly 1 5
10 15 Ser Ser Glu Val Glu Val Val Pro Phe Gln Glu
Val Trp Gly Arg Ser 20 25
30 Tyr Cys Arg Ala Leu Glu Arg Leu Val Asp Val Val Ser Glu Tyr
Pro 35 40 45 Ser
Glu Val Glu His Met Phe Ser Pro Ser Cys Val Ser Leu Leu Arg 50
55 60 Cys Thr Gly Cys Cys Gly
Asp Glu Asn Leu His Cys Val Pro Val Glu 65 70
75 80 Thr Ala Asn Val Thr Met Gln Leu Leu Lys Ile
Arg Ser Gly Asp Arg 85 90
95 Pro Ser Tyr Val Glu Leu Thr Phe Ser Gln His Val Arg Cys Glu Cys
100 105 110 Arg Pro
Leu Arg Glu Lys Met Lys Pro Glu Arg Cys Gly Asp Ala Val 115
120 125 Pro Arg Arg 130
55170PRTHomo sapiens 55Met Pro Val Met Arg Leu Phe Pro Cys Phe Leu Gln
Leu Leu Ala Gly 1 5 10
15 Leu Ala Leu Pro Ala Val Pro Pro Gln Gln Trp Ala Leu Ser Ala Gly
20 25 30 Asn Gly Ser
Ser Glu Val Glu Val Val Pro Phe Gln Glu Val Trp Gly 35
40 45 Arg Ser Tyr Cys Arg Ala Leu Glu
Arg Leu Val Asp Val Val Ser Glu 50 55
60 Tyr Pro Ser Glu Val Glu His Met Phe Ser Pro Ser Cys
Val Ser Leu 65 70 75
80 Leu Arg Cys Thr Gly Cys Cys Gly Asp Glu Asn Leu His Cys Val Pro
85 90 95 Val Glu Thr Ala
Asn Val Thr Met Gln Leu Leu Lys Ile Arg Ser Gly 100
105 110 Asp Arg Pro Ser Tyr Val Glu Leu Thr
Phe Ser Gln His Val Arg Cys 115 120
125 Glu Cys Arg Pro Leu Arg Glu Lys Met Lys Pro Glu Arg Arg
Arg Pro 130 135 140
Lys Gly Arg Gly Lys Arg Arg Arg Glu Lys Gln Arg Pro Thr Asp Cys 145
150 155 160 His Leu Cys Gly Asp
Ala Val Pro Arg Arg 165 170 56152PRTHomo
sapiens 56Leu Pro Ala Val Pro Pro Gln Gln Trp Ala Leu Ser Ala Gly Asn Gly
1 5 10 15 Ser Ser
Glu Val Glu Val Val Pro Phe Gln Glu Val Trp Gly Arg Ser 20
25 30 Tyr Cys Arg Ala Leu Glu Arg
Leu Val Asp Val Val Ser Glu Tyr Pro 35 40
45 Ser Glu Val Glu His Met Phe Ser Pro Ser Cys Val
Ser Leu Leu Arg 50 55 60
Cys Thr Gly Cys Cys Gly Asp Glu Asn Leu His Cys Val Pro Val Glu 65
70 75 80 Thr Ala Asn
Val Thr Met Gln Leu Leu Lys Ile Arg Ser Gly Asp Arg 85
90 95 Pro Ser Tyr Val Glu Leu Thr Phe
Ser Gln His Val Arg Cys Glu Cys 100 105
110 Arg Pro Leu Arg Glu Lys Met Lys Pro Glu Arg Arg Arg
Pro Lys Gly 115 120 125
Arg Gly Lys Arg Arg Arg Glu Lys Gln Arg Pro Thr Asp Cys His Leu 130
135 140 Cys Gly Asp Ala
Val Pro Arg Arg 145 150 57221PRTHomo sapiens
57Met Pro Val Met Arg Leu Phe Pro Cys Phe Leu Gln Leu Leu Ala Gly 1
5 10 15 Leu Ala Leu Pro
Ala Val Pro Pro Gln Gln Trp Ala Leu Ser Ala Gly 20
25 30 Asn Gly Ser Ser Glu Val Glu Val Val
Pro Phe Gln Glu Val Trp Gly 35 40
45 Arg Ser Tyr Cys Arg Ala Leu Glu Arg Leu Val Asp Val Val
Ser Glu 50 55 60
Tyr Pro Ser Glu Val Glu His Met Phe Ser Pro Ser Cys Val Ser Leu 65
70 75 80 Leu Arg Cys Thr Gly
Cys Cys Gly Asp Glu Asn Leu His Cys Val Pro 85
90 95 Val Glu Thr Ala Asn Val Thr Met Gln Leu
Leu Lys Ile Arg Ser Gly 100 105
110 Asp Arg Pro Ser Tyr Val Glu Leu Thr Phe Ser Gln His Val Arg
Cys 115 120 125 Glu
Cys Arg His Ser Pro Gly Arg Gln Ser Pro Asp Met Pro Gly Asp 130
135 140 Phe Arg Ala Asp Ala Pro
Ser Phe Leu Pro Pro Arg Arg Ser Leu Pro 145 150
155 160 Met Leu Phe Arg Met Glu Trp Gly Cys Ala Leu
Thr Gly Ser Gln Ser 165 170
175 Ala Val Trp Pro Ser Ser Pro Val Pro Glu Glu Ile Pro Arg Met His
180 185 190 Pro Gly
Arg Asn Gly Lys Lys Gln Gln Arg Lys Pro Leu Arg Glu Lys 195
200 205 Met Lys Pro Glu Arg Cys Gly
Asp Ala Val Pro Arg Arg 210 215 220
58203PRTHomo sapiens 58Leu Pro Ala Val Pro Pro Gln Gln Trp Ala Leu Ser
Ala Gly Asn Gly 1 5 10
15 Ser Ser Glu Val Glu Val Val Pro Phe Gln Glu Val Trp Gly Arg Ser
20 25 30 Tyr Cys Arg
Ala Leu Glu Arg Leu Val Asp Val Val Ser Glu Tyr Pro 35
40 45 Ser Glu Val Glu His Met Phe Ser
Pro Ser Cys Val Ser Leu Leu Arg 50 55
60 Cys Thr Gly Cys Cys Gly Asp Glu Asn Leu His Cys Val
Pro Val Glu 65 70 75
80 Thr Ala Asn Val Thr Met Gln Leu Leu Lys Ile Arg Ser Gly Asp Arg
85 90 95 Pro Ser Tyr Val
Glu Leu Thr Phe Ser Gln His Val Arg Cys Glu Cys 100
105 110 Arg His Ser Pro Gly Arg Gln Ser Pro
Asp Met Pro Gly Asp Phe Arg 115 120
125 Ala Asp Ala Pro Ser Phe Leu Pro Pro Arg Arg Ser Leu Pro
Met Leu 130 135 140
Phe Arg Met Glu Trp Gly Cys Ala Leu Thr Gly Ser Gln Ser Ala Val 145
150 155 160 Trp Pro Ser Ser Pro
Val Pro Glu Glu Ile Pro Arg Met His Pro Gly 165
170 175 Arg Asn Gly Lys Lys Gln Gln Arg Lys Pro
Leu Arg Glu Lys Met Lys 180 185
190 Pro Glu Arg Cys Gly Asp Ala Val Pro Arg Arg 195
200 59345PRTHomo sapiens 59Met Ser Leu Phe Gly
Leu Leu Leu Leu Thr Ser Ala Leu Ala Gly Gln 1 5
10 15 Arg Gln Gly Thr Gln Ala Glu Ser Asn Leu
Ser Ser Lys Phe Gln Phe 20 25
30 Ser Ser Asn Lys Glu Gln Asn Gly Val Gln Asp Pro Gln His Glu
Arg 35 40 45 Ile
Ile Thr Val Ser Thr Asn Gly Ser Ile His Ser Pro Arg Phe Pro 50
55 60 His Thr Tyr Pro Arg Asn
Thr Val Leu Val Trp Arg Leu Val Ala Val 65 70
75 80 Glu Glu Asn Val Trp Ile Gln Leu Thr Phe Asp
Glu Arg Phe Gly Leu 85 90
95 Glu Asp Pro Glu Asp Asp Ile Cys Lys Tyr Asp Phe Val Glu Val Glu
100 105 110 Glu Pro
Ser Asp Gly Thr Ile Leu Gly Arg Trp Cys Gly Ser Gly Thr 115
120 125 Val Pro Gly Lys Gln Ile Ser
Lys Gly Asn Gln Ile Arg Ile Arg Phe 130 135
140 Val Ser Asp Glu Tyr Phe Pro Ser Glu Pro Gly Phe
Cys Ile His Tyr 145 150 155
160 Asn Ile Val Met Pro Gln Phe Thr Glu Ala Val Ser Pro Ser Val Leu
165 170 175 Pro Pro Ser
Ala Leu Pro Leu Asp Leu Leu Asn Asn Ala Ile Thr Ala 180
185 190 Phe Ser Thr Leu Glu Asp Leu Ile
Arg Tyr Leu Glu Pro Glu Arg Trp 195 200
205 Gln Leu Asp Leu Glu Asp Leu Tyr Arg Pro Thr Trp Gln
Leu Leu Gly 210 215 220
Lys Ala Phe Val Phe Gly Arg Lys Ser Arg Val Val Asp Leu Asn Leu 225
230 235 240 Leu Thr Glu Glu
Val Arg Leu Tyr Ser Cys Thr Pro Arg Asn Phe Ser 245
250 255 Val Ser Ile Arg Glu Glu Leu Lys Arg
Thr Asp Thr Ile Phe Trp Pro 260 265
270 Gly Cys Leu Leu Val Lys Arg Cys Gly Gly Asn Cys Ala Cys
Cys Leu 275 280 285
His Asn Cys Asn Glu Cys Gln Cys Val Pro Ser Lys Val Thr Lys Lys 290
295 300 Tyr His Glu Val Leu
Gln Leu Arg Pro Lys Thr Gly Val Arg Gly Leu 305 310
315 320 His Lys Ser Leu Thr Asp Val Ala Leu Glu
His His Glu Glu Cys Asp 325 330
335 Cys Val Cys Arg Gly Ser Thr Gly Gly 340
345 60326PRTHomo sapiens 60Thr Gln Ala Glu Ser Asn Leu Ser Ser
Lys Phe Gln Phe Ser Ser Asn 1 5 10
15 Lys Glu Gln Asn Gly Val Gln Asp Pro Gln His Glu Arg Ile
Ile Thr 20 25 30
Val Ser Thr Asn Gly Ser Ile His Ser Pro Arg Phe Pro His Thr Tyr
35 40 45 Pro Arg Asn Thr
Val Leu Val Trp Arg Leu Val Ala Val Glu Glu Asn 50
55 60 Val Trp Ile Gln Leu Thr Phe Asp
Glu Arg Phe Gly Leu Glu Asp Pro 65 70
75 80 Glu Asp Asp Ile Cys Lys Tyr Asp Phe Val Glu Val
Glu Glu Pro Ser 85 90
95 Asp Gly Thr Ile Leu Gly Arg Trp Cys Gly Ser Gly Thr Val Pro Gly
100 105 110 Lys Gln Ile
Ser Lys Gly Asn Gln Ile Arg Ile Arg Phe Val Ser Asp 115
120 125 Glu Tyr Phe Pro Ser Glu Pro Gly
Phe Cys Ile His Tyr Asn Ile Val 130 135
140 Met Pro Gln Phe Thr Glu Ala Val Ser Pro Ser Val Leu
Pro Pro Ser 145 150 155
160 Ala Leu Pro Leu Asp Leu Leu Asn Asn Ala Ile Thr Ala Phe Ser Thr
165 170 175 Leu Glu Asp Leu
Ile Arg Tyr Leu Glu Pro Glu Arg Trp Gln Leu Asp 180
185 190 Leu Glu Asp Leu Tyr Arg Pro Thr Trp
Gln Leu Leu Gly Lys Ala Phe 195 200
205 Val Phe Gly Arg Lys Ser Arg Val Val Asp Leu Asn Leu Leu
Thr Glu 210 215 220
Glu Val Arg Leu Tyr Ser Cys Thr Pro Arg Asn Phe Ser Val Ser Ile 225
230 235 240 Arg Glu Glu Leu Lys
Arg Thr Asp Thr Ile Phe Trp Pro Gly Cys Leu 245
250 255 Leu Val Lys Arg Cys Gly Gly Asn Cys Ala
Cys Cys Leu His Asn Cys 260 265
270 Asn Glu Cys Gln Cys Val Pro Ser Lys Val Thr Lys Lys Tyr His
Glu 275 280 285 Val
Leu Gln Leu Arg Pro Lys Thr Gly Val Arg Gly Leu His Lys Ser 290
295 300 Leu Thr Asp Val Ala Leu
Glu His His Glu Glu Cys Asp Cys Val Cys 305 310
315 320 Arg Gly Ser Thr Gly Gly 325
61147PRTHomo sapiens 61Met Asn Phe Leu Leu Ser Trp Val His Trp Ser
Leu Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
20 25 30 Gly Gly
Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35
40 45 Arg Ser Tyr Cys His Pro Ile
Glu Thr Leu Val Asp Ile Phe Gln Glu 50 55
60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser
Cys Val Pro Leu 65 70 75
80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
85 90 95 Thr Glu Glu
Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100
105 110 Gln Gly Gln His Ile Gly Glu Met
Ser Phe Leu Gln His Asn Lys Cys 115 120
125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys
Cys Asp Lys 130 135 140
Pro Arg Arg 145 62121PRTHomo sapiens 62Ala Pro Met Ala Glu Gly
Gly Gly Gln Asn His His Glu Val Val Lys 1 5
10 15 Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His
Pro Ile Glu Thr Leu 20 25
30 Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe
Lys 35 40 45 Pro
Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 50
55 60 Gly Leu Glu Cys Val Pro
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 65 70
75 80 Met Arg Ile Lys Pro His Gln Gly Gln His Ile
Gly Glu Met Ser Phe 85 90
95 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg
100 105 110 Gln Glu
Lys Cys Asp Lys Pro Arg Arg 115 120
63211PRTHomo sapiens 63Met Arg Thr Leu Ala Cys Leu Leu Leu Leu Gly Cys
Gly Tyr Leu Ala 1 5 10
15 His Val Leu Ala Glu Glu Ala Glu Ile Pro Arg Glu Val Ile Glu Arg
20 25 30 Leu Ala Arg
Ser Gln Ile His Ser Ile Arg Asp Leu Gln Arg Leu Leu 35
40 45 Glu Ile Asp Ser Val Gly Ser Glu
Asp Ser Leu Asp Thr Ser Leu Arg 50 55
60 Ala His Gly Val His Ala Thr Lys His Val Pro Glu Lys
Arg Pro Leu 65 70 75
80 Pro Ile Arg Arg Lys Arg Ser Ile Glu Glu Ala Val Pro Ala Val Cys
85 90 95 Lys Thr Arg Thr
Val Ile Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro 100
105 110 Thr Ser Ala Asn Phe Leu Ile Trp Pro
Pro Cys Val Glu Val Lys Arg 115 120
125 Cys Thr Gly Cys Cys Asn Thr Ser Ser Val Lys Cys Gln Pro
Ser Arg 130 135 140
Val His His Arg Ser Val Lys Val Ala Lys Val Glu Tyr Val Arg Lys 145
150 155 160 Lys Pro Lys Leu Lys
Glu Val Gln Val Arg Leu Glu Glu His Leu Glu 165
170 175 Cys Ala Cys Ala Thr Thr Ser Leu Asn Pro
Asp Tyr Arg Glu Glu Asp 180 185
190 Thr Gly Arg Pro Arg Glu Ser Gly Lys Lys Arg Lys Arg Lys Arg
Leu 195 200 205 Lys
Pro Thr 210 64196PRTHomo sapiens 64Met Arg Thr Leu Ala Cys Leu
Leu Leu Leu Gly Cys Gly Tyr Leu Ala 1 5
10 15 His Val Leu Ala Glu Glu Ala Glu Ile Pro Arg
Glu Val Ile Glu Arg 20 25
30 Leu Ala Arg Ser Gln Ile His Ser Ile Arg Asp Leu Gln Arg Leu
Leu 35 40 45 Glu
Ile Asp Ser Val Gly Ser Glu Asp Ser Leu Asp Thr Ser Leu Arg 50
55 60 Ala His Gly Val His Ala
Thr Lys His Val Pro Glu Lys Arg Pro Leu 65 70
75 80 Pro Ile Arg Arg Lys Arg Ser Ile Glu Glu Ala
Val Pro Ala Val Cys 85 90
95 Lys Thr Arg Thr Val Ile Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro
100 105 110 Thr Ser
Ala Asn Phe Leu Ile Trp Pro Pro Cys Val Glu Val Lys Arg 115
120 125 Cys Thr Gly Cys Cys Asn Thr
Ser Ser Val Lys Cys Gln Pro Ser Arg 130 135
140 Val His His Arg Ser Val Lys Val Ala Lys Val Glu
Tyr Val Arg Lys 145 150 155
160 Lys Pro Lys Leu Lys Glu Val Gln Val Arg Leu Glu Glu His Leu Glu
165 170 175 Cys Ala Cys
Ala Thr Thr Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp 180
185 190 Thr Asp Val Arg 195
651338PRTHomo sapiens 65Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys
Ala Leu Leu Ser 1 5 10
15 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro
20 25 30 Glu Leu Ser
Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr 35
40 45 Leu His Leu Gln Cys Arg Gly Glu
Ala Ala His Lys Trp Ser Leu Pro 50 55
60 Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr
Lys Ser Ala 65 70 75
80 Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr
85 90 95 Ala Gln Ala Asn
His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val 100
105 110 Pro Thr Ser Lys Lys Lys Glu Thr Glu
Ser Ala Ile Tyr Ile Phe Ile 115 120
125 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile
Pro Glu 130 135 140
Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 145
150 155 160 Thr Ser Pro Asn Ile
Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 165
170 175 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp
Asp Ser Arg Lys Gly Phe 180 185
190 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys
Glu 195 200 205 Ala
Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 210
215 220 Gln Thr Asn Thr Ile Ile
Asp Val Gln Ile Ser Thr Pro Arg Pro Val 225 230
235 240 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn
Cys Thr Ala Thr Thr 245 250
255 Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys
260 265 270 Asn Lys
Arg Ala Ser Val Arg Arg Arg Ile Asp Gln Ser Asn Ser His 275
280 285 Ala Asn Ile Phe Tyr Ser Val
Leu Thr Ile Asp Lys Met Gln Asn Lys 290 295
300 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly
Pro Ser Phe Lys 305 310 315
320 Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Phe Ile Thr Val
325 330 335 Lys His Arg
Lys Gln Gln Val Leu Glu Thr Val Ala Gly Lys Arg Ser 340
345 350 Tyr Arg Leu Ser Met Lys Val Lys
Ala Phe Pro Ser Pro Glu Val Val 355 360
365 Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala
Arg Tyr Leu 370 375 380
Thr Arg Gly Tyr Ser Leu Ile Ile Lys Asp Val Thr Glu Glu Asp Ala 385
390 395 400 Gly Asn Tyr Thr
Ile Leu Leu Ser Ile Lys Gln Ser Asn Val Phe Lys 405
410 415 Asn Leu Thr Ala Thr Leu Ile Val Asn
Val Lys Pro Gln Ile Tyr Glu 420 425
430 Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu
Gly Ser 435 440 445
Arg Gln Ile Leu Thr Cys Thr Ala Tyr Gly Ile Pro Gln Pro Thr Ile 450
455 460 Lys Trp Phe Trp His
Pro Cys Asn His Asn His Ser Glu Ala Arg Cys 465 470
475 480 Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe
Ile Leu Asp Ala Asp Ser 485 490
495 Asn Met Gly Asn Arg Ile Glu Ser Ile Thr Gln Arg Met Ala Ile
Ile 500 505 510 Glu
Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg 515
520 525 Ile Ser Gly Ile Tyr Ile
Cys Ile Ala Ser Asn Lys Val Gly Thr Val 530 535
540 Gly Arg Asn Ile Ser Phe Tyr Ile Thr Asp Val
Pro Asn Gly Phe His 545 550 555
560 Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser
565 570 575 Cys Thr
Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp Ile Leu Leu 580
585 590 Arg Thr Val Asn Asn Arg Thr
Met His Tyr Ser Ile Ser Lys Gln Lys 595 600
605 Met Ala Ile Thr Lys Glu His Ser Ile Thr Leu Asn
Leu Thr Ile Met 610 615 620
Asn Val Ser Leu Gln Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn 625
630 635 640 Val Tyr Thr
Gly Glu Glu Ile Leu Gln Lys Lys Glu Ile Thr Ile Arg 645
650 655 Asp Gln Glu Ala Pro Tyr Leu Leu
Arg Asn Leu Ser Asp His Thr Val 660 665
670 Ala Ile Ser Ser Ser Thr Thr Leu Asp Cys His Ala Asn
Gly Val Pro 675 680 685
Glu Pro Gln Ile Thr Trp Phe Lys Asn Asn His Lys Ile Gln Gln Glu 690
695 700 Pro Gly Ile Ile
Leu Gly Pro Gly Ser Ser Thr Leu Phe Ile Glu Arg 705 710
715 720 Val Thr Glu Glu Asp Glu Gly Val Tyr
His Cys Lys Ala Thr Asn Gln 725 730
735 Lys Gly Ser Val Glu Ser Ser Ala Tyr Leu Thr Val Gln Gly
Thr Ser 740 745 750
Asp Lys Ser Asn Leu Glu Leu Ile Thr Leu Thr Cys Thr Cys Val Ala
755 760 765 Ala Thr Leu Phe
Trp Leu Leu Leu Thr Leu Leu Ile Arg Lys Met Lys 770
775 780 Arg Ser Ser Ser Glu Ile Lys Thr
Asp Tyr Leu Ser Ile Ile Met Asp 785 790
795 800 Pro Asp Glu Val Pro Leu Asp Glu Gln Cys Glu Arg
Leu Pro Tyr Asp 805 810
815 Ala Ser Lys Trp Glu Phe Ala Arg Glu Arg Leu Lys Leu Gly Lys Ser
820 825 830 Leu Gly Arg
Gly Ala Phe Gly Lys Val Val Gln Ala Ser Ala Phe Gly 835
840 845 Ile Lys Lys Ser Pro Thr Cys Arg
Thr Val Ala Val Lys Met Leu Lys 850 855
860 Glu Gly Ala Thr Ala Ser Glu Tyr Lys Ala Leu Met Thr
Glu Leu Lys 865 870 875
880 Ile Leu Thr His Ile Gly His His Leu Asn Val Val Asn Leu Leu Gly
885 890 895 Ala Cys Thr Lys
Gln Gly Gly Pro Leu Met Val Ile Val Glu Tyr Cys 900
905 910 Lys Tyr Gly Asn Leu Ser Asn Tyr Leu
Lys Ser Lys Arg Asp Leu Phe 915 920
925 Phe Leu Asn Lys Asp Ala Ala Leu His Met Glu Pro Lys Lys
Glu Lys 930 935 940
Met Glu Pro Gly Leu Glu Gln Gly Lys Lys Pro Arg Leu Asp Ser Val 945
950 955 960 Thr Ser Ser Glu Ser
Phe Ala Ser Ser Gly Phe Gln Glu Asp Lys Ser 965
970 975 Leu Ser Asp Val Glu Glu Glu Glu Asp Ser
Asp Gly Phe Tyr Lys Glu 980 985
990 Pro Ile Thr Met Glu Asp Leu Ile Ser Tyr Ser Phe Gln Val
Ala Arg 995 1000 1005
Gly Met Glu Phe Leu Ser Ser Arg Lys Cys Ile His Arg Asp Leu 1010
1015 1020 Ala Ala Arg Asn Ile
Leu Leu Ser Glu Asn Asn Val Val Lys Ile 1025 1030
1035 Cys Asp Phe Gly Leu Ala Arg Asp Ile Tyr
Lys Asn Pro Asp Tyr 1040 1045 1050
Val Arg Lys Gly Asp Thr Arg Leu Pro Leu Lys Trp Met Ala Pro
1055 1060 1065 Glu Ser
Ile Phe Asp Lys Ile Tyr Ser Thr Lys Ser Asp Val Trp 1070
1075 1080 Ser Tyr Gly Val Leu Leu Trp
Glu Ile Phe Ser Leu Gly Gly Ser 1085 1090
1095 Pro Tyr Pro Gly Val Gln Met Asp Glu Asp Phe Cys
Ser Arg Leu 1100 1105 1110
Arg Glu Gly Met Arg Met Arg Ala Pro Glu Tyr Ser Thr Pro Glu 1115
1120 1125 Ile Tyr Gln Ile Met
Leu Asp Cys Trp His Arg Asp Pro Lys Glu 1130 1135
1140 Arg Pro Arg Phe Ala Glu Leu Val Glu Lys
Leu Gly Asp Leu Leu 1145 1150 1155
Gln Ala Asn Val Gln Gln Asp Gly Lys Asp Tyr Ile Pro Ile Asn
1160 1165 1170 Ala Ile
Leu Thr Gly Asn Ser Gly Phe Thr Tyr Ser Thr Pro Ala 1175
1180 1185 Phe Ser Glu Asp Phe Phe Lys
Glu Ser Ile Ser Ala Pro Lys Phe 1190 1195
1200 Asn Ser Gly Ser Ser Asp Asp Val Arg Tyr Val Asn
Ala Phe Lys 1205 1210 1215
Phe Met Ser Leu Glu Arg Ile Lys Thr Phe Glu Glu Leu Leu Pro 1220
1225 1230 Asn Ala Thr Ser Met
Phe Asp Asp Tyr Gln Gly Asp Ser Ser Thr 1235 1240
1245 Leu Leu Ala Ser Pro Met Leu Lys Arg Phe
Thr Trp Thr Asp Ser 1250 1255 1260
Lys Pro Lys Ala Ser Leu Lys Ile Asp Leu Arg Val Thr Ser Lys
1265 1270 1275 Ser Lys
Glu Ser Gly Leu Ser Asp Val Ser Arg Pro Ser Phe Cys 1280
1285 1290 His Ser Ser Cys Gly His Val
Ser Glu Gly Lys Arg Arg Phe Thr 1295 1300
1305 Tyr Asp His Ala Glu Leu Glu Arg Lys Ile Ala Cys
Cys Ser Pro 1310 1315 1320
Pro Pro Asp Tyr Asn Ser Val Val Leu Tyr Ser Thr Pro Pro Ile 1325
1330 1335 661356PRTHomo
sapiens 66Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu
1 5 10 15 Thr Arg
Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro 20
25 30 Arg Leu Ser Ile Gln Lys Asp
Ile Leu Thr Ile Lys Ala Asn Thr Thr 35 40
45 Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp
Trp Leu Trp Pro 50 55 60
Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser 65
70 75 80 Asp Gly Leu
Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn 85
90 95 Asp Thr Gly Ala Tyr Lys Cys Phe
Tyr Arg Glu Thr Asp Leu Ala Ser 100 105
110 Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe
Ile Ala Ser 115 120 125
Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys 130
135 140 Thr Val Val Ile
Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser 145 150
155 160 Leu Cys Ala Arg Tyr Pro Glu Lys Arg
Phe Val Pro Asp Gly Asn Arg 165 170
175 Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr
Met Ile 180 185 190
Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser
195 200 205 Tyr Gln Ser Ile
Met Tyr Ile Val Val Val Val Gly Tyr Arg Ile Tyr 210
215 220 Asp Val Val Leu Ser Pro Ser His
Gly Ile Glu Leu Ser Val Gly Glu 225 230
235 240 Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu
Asn Val Gly Ile 245 250
255 Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu
260 265 270 Val Asn Arg
Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe 275
280 285 Leu Ser Thr Leu Thr Ile Asp Gly
Val Thr Arg Ser Asp Gln Gly Leu 290 295
300 Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys
Asn Ser Thr 305 310 315
320 Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met
325 330 335 Glu Ser Leu Val
Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala 340
345 350 Lys Tyr Leu Gly Tyr Pro Pro Pro Glu
Ile Lys Trp Tyr Lys Asn Gly 355 360
365 Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val
Leu Thr 370 375 380
Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu 385
390 395 400 Thr Asn Pro Ile Ser
Lys Glu Lys Gln Ser His Val Val Ser Leu Val 405
410 415 Val Tyr Val Pro Pro Gln Ile Gly Glu Lys
Ser Leu Ile Ser Pro Val 420 425
430 Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val
Tyr 435 440 445 Ala
Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu 450
455 460 Glu Cys Ala Asn Glu Pro
Ser Gln Ala Val Ser Val Thr Asn Pro Tyr 465 470
475 480 Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe
Gln Gly Gly Asn Lys 485 490
495 Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys
500 505 510 Thr Val
Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr 515
520 525 Lys Cys Glu Ala Val Asn Lys
Val Gly Arg Gly Glu Arg Val Ile Ser 530 535
540 Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln
Pro Asp Met Gln 545 550 555
560 Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser
565 570 575 Thr Phe Glu
Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro 580
585 590 Ile His Val Gly Glu Leu Pro Thr
Pro Val Cys Lys Asn Leu Asp Thr 595 600
605 Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr
Asn Asp Ile 610 615 620
Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr 625
630 635 640 Val Cys Leu Ala
Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val 645
650 655 Arg Gln Leu Thr Val Leu Glu Arg Val
Ala Pro Thr Ile Thr Gly Asn 660 665
670 Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val
Ser Cys 675 680 685
Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn 690
695 700 Glu Thr Leu Val Glu
Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg 705 710
715 720 Asn Leu Thr Ile Arg Arg Val Arg Lys Glu
Asp Glu Gly Leu Tyr Thr 725 730
735 Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe
Phe 740 745 750 Ile
Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu Ile Ile Ile Leu 755
760 765 Val Gly Thr Ala Val Ile
Ala Met Phe Phe Trp Leu Leu Leu Val Ile 770 775
780 Ile Leu Arg Thr Val Lys Arg Ala Asn Gly Gly
Glu Leu Lys Thr Gly 785 790 795
800 Tyr Leu Ser Ile Val Met Asp Pro Asp Glu Leu Pro Leu Asp Glu His
805 810 815 Cys Glu
Arg Leu Pro Tyr Asp Ala Ser Lys Trp Glu Phe Pro Arg Asp 820
825 830 Arg Leu Lys Leu Gly Lys Pro
Leu Gly Arg Gly Ala Phe Gly Gln Val 835 840
845 Ile Glu Ala Asp Ala Phe Gly Ile Asp Lys Thr Ala
Thr Cys Arg Thr 850 855 860
Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr His Ser Glu His Arg 865
870 875 880 Ala Leu Met
Ser Glu Leu Lys Ile Leu Ile His Ile Gly His His Leu 885
890 895 Asn Val Val Asn Leu Leu Gly Ala
Cys Thr Lys Pro Gly Gly Pro Leu 900 905
910 Met Val Ile Val Glu Phe Cys Lys Phe Gly Asn Leu Ser
Thr Tyr Leu 915 920 925
Arg Ser Lys Arg Asn Glu Phe Val Pro Tyr Lys Thr Lys Gly Ala Arg 930
935 940 Phe Arg Gln Gly
Lys Asp Tyr Val Gly Ala Ile Pro Val Asp Leu Lys 945 950
955 960 Arg Arg Leu Asp Ser Ile Thr Ser Ser
Gln Ser Ser Ala Ser Ser Gly 965 970
975 Phe Val Glu Glu Lys Ser Leu Ser Asp Val Glu Glu Glu Glu
Ala Pro 980 985 990
Glu Asp Leu Tyr Lys Asp Phe Leu Thr Leu Glu His Leu Ile Cys Tyr
995 1000 1005 Ser Phe Gln
Val Ala Lys Gly Met Glu Phe Leu Ala Ser Arg Lys 1010
1015 1020 Cys Ile His Arg Asp Leu Ala Ala
Arg Asn Ile Leu Leu Ser Glu 1025 1030
1035 Lys Asn Val Val Lys Ile Cys Asp Phe Gly Leu Ala Arg
Asp Ile 1040 1045 1050
Tyr Lys Asp Pro Asp Tyr Val Arg Lys Gly Asp Ala Arg Leu Pro 1055
1060 1065 Leu Lys Trp Met Ala
Pro Glu Thr Ile Phe Asp Arg Val Tyr Thr 1070 1075
1080 Ile Gln Ser Asp Val Trp Ser Phe Gly Val
Leu Leu Trp Glu Ile 1085 1090 1095
Phe Ser Leu Gly Ala Ser Pro Tyr Pro Gly Val Lys Ile Asp Glu
1100 1105 1110 Glu Phe
Cys Arg Arg Leu Lys Glu Gly Thr Arg Met Arg Ala Pro 1115
1120 1125 Asp Tyr Thr Thr Pro Glu Met
Tyr Gln Thr Met Leu Asp Cys Trp 1130 1135
1140 His Gly Glu Pro Ser Gln Arg Pro Thr Phe Ser Glu
Leu Val Glu 1145 1150 1155
His Leu Gly Asn Leu Leu Gln Ala Asn Ala Gln Gln Asp Gly Lys 1160
1165 1170 Asp Tyr Ile Val Leu
Pro Ile Ser Glu Thr Leu Ser Met Glu Glu 1175 1180
1185 Asp Ser Gly Leu Ser Leu Pro Thr Ser Pro
Val Ser Cys Met Glu 1190 1195 1200
Glu Glu Glu Val Cys Asp Pro Lys Phe His Tyr Asp Asn Thr Ala
1205 1210 1215 Gly Ile
Ser Gln Tyr Leu Gln Asn Ser Lys Arg Lys Ser Arg Pro 1220
1225 1230 Val Ser Val Lys Thr Phe Glu
Asp Ile Pro Leu Glu Glu Pro Glu 1235 1240
1245 Val Lys Val Ile Pro Asp Asp Asn Gln Thr Asp Ser
Gly Met Val 1250 1255 1260
Leu Ala Ser Glu Glu Leu Lys Thr Leu Glu Asp Arg Thr Lys Leu 1265
1270 1275 Ser Pro Ser Phe Gly
Gly Met Val Pro Ser Lys Ser Arg Glu Ser 1280 1285
1290 Val Ala Ser Glu Gly Ser Asn Gln Thr Ser
Gly Tyr Gln Ser Gly 1295 1300 1305
Tyr His Ser Asp Asp Thr Asp Thr Thr Val Tyr Ser Ser Glu Glu
1310 1315 1320 Ala Glu
Leu Leu Lys Leu Ile Glu Ile Gly Val Gln Thr Gly Ser 1325
1330 1335 Thr Ala Gln Ile Leu Gln Pro
Asp Ser Gly Thr Thr Leu Ser Ser 1340 1345
1350 Pro Pro Val 1355 671298PRTHomo sapiens
67Met Gln Arg Gly Ala Ala Leu Cys Leu Arg Leu Trp Leu Cys Leu Gly 1
5 10 15 Leu Leu Asp Gly
Leu Val Ser Gly Tyr Ser Met Thr Pro Pro Thr Leu 20
25 30 Asn Ile Thr Glu Glu Ser His Val Ile
Asp Thr Gly Asp Ser Leu Ser 35 40
45 Ile Ser Cys Arg Gly Gln His Pro Leu Glu Trp Ala Trp Pro
Gly Ala 50 55 60
Gln Glu Ala Pro Ala Thr Gly Asp Lys Asp Ser Glu Asp Thr Gly Val 65
70 75 80 Val Arg Asp Cys Glu
Gly Thr Asp Ala Arg Pro Tyr Cys Lys Val Leu 85
90 95 Leu Leu His Glu Val His Ala Asn Asp Thr
Gly Ser Tyr Val Cys Tyr 100 105
110 Tyr Lys Tyr Ile Lys Ala Arg Ile Glu Gly Thr Thr Ala Ala Ser
Ser 115 120 125 Tyr
Val Phe Val Arg Asp Phe Glu Gln Pro Phe Ile Asn Lys Pro Asp 130
135 140 Thr Leu Leu Val Asn Arg
Lys Asp Ala Met Trp Val Pro Cys Leu Val 145 150
155 160 Ser Ile Pro Gly Leu Asn Val Thr Leu Arg Ser
Gln Ser Ser Val Leu 165 170
175 Trp Pro Asp Gly Gln Glu Val Val Trp Asp Asp Arg Arg Gly Met Leu
180 185 190 Val Ser
Thr Pro Leu Leu His Asp Ala Leu Tyr Leu Gln Cys Glu Thr 195
200 205 Thr Trp Gly Asp Gln Asp Phe
Leu Ser Asn Pro Phe Leu Val His Ile 210 215
220 Thr Gly Asn Glu Leu Tyr Asp Ile Gln Leu Leu Pro
Arg Lys Ser Leu 225 230 235
240 Glu Leu Leu Val Gly Glu Lys Leu Val Leu Asn Cys Thr Val Trp Ala
245 250 255 Glu Phe Asn
Ser Gly Val Thr Phe Asp Trp Asp Tyr Pro Gly Lys Gln 260
265 270 Ala Glu Arg Gly Lys Trp Val Pro
Glu Arg Arg Ser Gln Gln Thr His 275 280
285 Thr Glu Leu Ser Ser Ile Leu Thr Ile His Asn Val Ser
Gln His Asp 290 295 300
Leu Gly Ser Tyr Val Cys Lys Ala Asn Asn Gly Ile Gln Arg Phe Arg 305
310 315 320 Glu Ser Thr Glu
Val Ile Val His Glu Asn Pro Phe Ile Ser Val Glu 325
330 335 Trp Leu Lys Gly Pro Ile Leu Glu Ala
Thr Ala Gly Asp Glu Leu Val 340 345
350 Lys Leu Pro Val Lys Leu Ala Ala Tyr Pro Pro Pro Glu Phe
Gln Trp 355 360 365
Tyr Lys Asp Gly Lys Ala Leu Ser Gly Arg His Ser Pro His Ala Leu 370
375 380 Val Leu Lys Glu Val
Thr Glu Ala Ser Thr Gly Thr Tyr Thr Leu Ala 385 390
395 400 Leu Trp Asn Ser Ala Ala Gly Leu Arg Arg
Asn Ile Ser Leu Glu Leu 405 410
415 Val Val Asn Val Pro Pro Gln Ile His Glu Lys Glu Ala Ser Ser
Pro 420 425 430 Ser
Ile Tyr Ser Arg His Ser Arg Gln Ala Leu Thr Cys Thr Ala Tyr 435
440 445 Gly Val Pro Leu Pro Leu
Ser Ile Gln Trp His Trp Arg Pro Trp Thr 450 455
460 Pro Cys Lys Met Phe Ala Gln Arg Ser Leu Arg
Arg Arg Gln Gln Gln 465 470 475
480 Asp Leu Met Pro Gln Cys Arg Asp Trp Arg Ala Val Thr Thr Gln Asp
485 490 495 Ala Val
Asn Pro Ile Glu Ser Leu Asp Thr Trp Thr Glu Phe Val Glu 500
505 510 Gly Lys Asn Lys Thr Val Ser
Lys Leu Val Ile Gln Asn Ala Asn Val 515 520
525 Ser Ala Met Tyr Lys Cys Val Val Ser Asn Lys Val
Gly Gln Asp Glu 530 535 540
Arg Leu Ile Tyr Phe Tyr Val Thr Thr Ile Pro Asp Gly Phe Thr Ile 545
550 555 560 Glu Ser Lys
Pro Ser Glu Glu Leu Leu Glu Gly Gln Pro Val Leu Leu 565
570 575 Ser Cys Gln Ala Asp Ser Tyr Lys
Tyr Glu His Leu Arg Trp Tyr Arg 580 585
590 Leu Asn Leu Ser Thr Leu His Asp Ala His Gly Asn Pro
Leu Leu Leu 595 600 605
Asp Cys Lys Asn Val His Leu Phe Ala Thr Pro Leu Ala Ala Ser Leu 610
615 620 Glu Glu Val Ala
Pro Gly Ala Arg His Ala Thr Leu Ser Leu Ser Ile 625 630
635 640 Pro Arg Val Ala Pro Glu His Glu Gly
His Tyr Val Cys Glu Val Gln 645 650
655 Asp Arg Arg Ser His Asp Lys His Cys His Lys Lys Tyr Leu
Ser Val 660 665 670
Gln Ala Leu Glu Ala Pro Arg Leu Thr Gln Asn Leu Thr Asp Leu Leu
675 680 685 Val Asn Val Ser
Asp Ser Leu Glu Met Gln Cys Leu Val Ala Gly Ala 690
695 700 His Ala Pro Ser Ile Val Trp Tyr
Lys Asp Glu Arg Leu Leu Glu Glu 705 710
715 720 Lys Ser Gly Val Asp Leu Ala Asp Ser Asn Gln Lys
Leu Ser Ile Gln 725 730
735 Arg Val Arg Glu Glu Asp Ala Gly Arg Tyr Leu Cys Ser Val Cys Asn
740 745 750 Ala Lys Gly
Cys Val Asn Ser Ser Ala Ser Val Ala Val Glu Gly Ser 755
760 765 Glu Asp Lys Gly Ser Met Glu Ile
Val Ile Leu Val Gly Thr Gly Val 770 775
780 Ile Ala Val Phe Phe Trp Val Leu Leu Leu Leu Ile Phe
Cys Asn Met 785 790 795
800 Arg Arg Pro Ala His Ala Asp Ile Lys Thr Gly Tyr Leu Ser Ile Ile
805 810 815 Met Asp Pro Gly
Glu Val Pro Leu Glu Glu Gln Cys Glu Tyr Leu Ser 820
825 830 Tyr Asp Ala Ser Gln Trp Glu Phe Pro
Arg Glu Arg Leu His Leu Gly 835 840
845 Arg Val Leu Gly Tyr Gly Ala Phe Gly Lys Val Val Glu Ala
Ser Ala 850 855 860
Phe Gly Ile His Lys Gly Ser Ser Cys Asp Thr Val Ala Val Lys Met 865
870 875 880 Leu Lys Glu Gly Ala
Thr Ala Ser Glu His Arg Ala Leu Met Ser Glu 885
890 895 Leu Lys Ile Leu Ile His Ile Gly Asn His
Leu Asn Val Val Asn Leu 900 905
910 Leu Gly Ala Cys Thr Lys Pro Gln Gly Pro Leu Met Val Ile Val
Glu 915 920 925 Phe
Cys Lys Tyr Gly Asn Leu Ser Asn Phe Leu Arg Ala Lys Arg Asp 930
935 940 Ala Phe Ser Pro Cys Ala
Glu Lys Ser Pro Glu Gln Arg Gly Arg Phe 945 950
955 960 Arg Ala Met Val Glu Leu Ala Arg Leu Asp Arg
Arg Arg Pro Gly Ser 965 970
975 Ser Asp Arg Val Leu Phe Ala Arg Phe Ser Lys Thr Glu Gly Gly Ala
980 985 990 Arg Arg
Ala Ser Pro Asp Gln Glu Ala Glu Asp Leu Trp Leu Ser Pro 995
1000 1005 Leu Thr Met Glu Asp
Leu Val Cys Tyr Ser Phe Gln Val Ala Arg 1010 1015
1020 Gly Met Glu Phe Leu Ala Ser Arg Lys Cys
Ile His Arg Asp Leu 1025 1030 1035
Ala Ala Arg Asn Ile Leu Leu Ser Glu Ser Asp Val Val Lys Ile
1040 1045 1050 Cys Asp
Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asp Pro Asp Tyr 1055
1060 1065 Val Arg Lys Gly Ser Ala Arg
Leu Pro Leu Lys Trp Met Ala Pro 1070 1075
1080 Glu Ser Ile Phe Asp Lys Val Tyr Thr Thr Gln Ser
Asp Val Trp 1085 1090 1095
Ser Phe Gly Val Leu Leu Trp Glu Ile Phe Ser Leu Gly Ala Ser 1100
1105 1110 Pro Tyr Pro Gly Val
Gln Ile Asn Glu Glu Phe Cys Gln Arg Leu 1115 1120
1125 Arg Asp Gly Thr Arg Met Arg Ala Pro Glu
Leu Ala Thr Pro Ala 1130 1135 1140
Ile Arg Arg Ile Met Leu Asn Cys Trp Ser Gly Asp Pro Lys Ala
1145 1150 1155 Arg Pro
Ala Phe Ser Glu Leu Val Glu Ile Leu Gly Asp Leu Leu 1160
1165 1170 Gln Gly Arg Gly Leu Gln Glu
Glu Glu Glu Val Cys Met Ala Pro 1175 1180
1185 Arg Ser Ser Gln Ser Ser Glu Glu Gly Ser Phe Ser
Gln Val Ser 1190 1195 1200
Thr Met Ala Leu His Ile Ala Gln Ala Asp Ala Glu Asp Ser Pro 1205
1210 1215 Pro Ser Leu Gln Arg
His Ser Leu Ala Ala Arg Tyr Tyr Asn Trp 1220 1225
1230 Val Ser Phe Pro Gly Cys Leu Ala Arg Gly
Ala Glu Thr Arg Gly 1235 1240 1245
Ser Ser Arg Met Lys Thr Phe Glu Glu Phe Pro Met Thr Pro Thr
1250 1255 1260 Thr Tyr
Lys Gly Ser Val Asp Asn Gln Thr Asp Ser Gly Met Val 1265
1270 1275 Leu Ala Ser Glu Glu Phe Glu
Gln Ile Glu Ser Arg His Arg Gln 1280 1285
1290 Glu Ser Gly Phe Arg 1295
68923PRTHomo sapiens 68Met Glu Arg Gly Leu Pro Leu Leu Cys Ala Val Leu
Ala Leu Val Leu 1 5 10
15 Ala Pro Ala Gly Ala Phe Arg Asn Asp Lys Cys Gly Asp Thr Ile Lys
20 25 30 Ile Glu Ser
Pro Gly Tyr Leu Thr Ser Pro Gly Tyr Pro His Ser Tyr 35
40 45 His Pro Ser Glu Lys Cys Glu Trp
Leu Ile Gln Ala Pro Asp Pro Tyr 50 55
60 Gln Arg Ile Met Ile Asn Phe Asn Pro His Phe Asp Leu
Glu Asp Arg 65 70 75
80 Asp Cys Lys Tyr Asp Tyr Val Glu Val Phe Asp Gly Glu Asn Glu Asn
85 90 95 Gly His Phe Arg
Gly Lys Phe Cys Gly Lys Ile Ala Pro Pro Pro Val 100
105 110 Val Ser Ser Gly Pro Phe Leu Phe Ile
Lys Phe Val Ser Asp Tyr Glu 115 120
125 Thr His Gly Ala Gly Phe Ser Ile Arg Tyr Glu Ile Phe Lys
Arg Gly 130 135 140
Pro Glu Cys Ser Gln Asn Tyr Thr Thr Pro Ser Gly Val Ile Lys Ser 145
150 155 160 Pro Gly Phe Pro Glu
Lys Tyr Pro Asn Ser Leu Glu Cys Thr Tyr Ile 165
170 175 Val Phe Ala Pro Lys Met Ser Glu Ile Ile
Leu Glu Phe Glu Ser Phe 180 185
190 Asp Leu Glu Pro Asp Ser Asn Pro Pro Gly Gly Met Phe Cys Arg
Tyr 195 200 205 Asp
Arg Leu Glu Ile Trp Asp Gly Phe Pro Asp Val Gly Pro His Ile 210
215 220 Gly Arg Tyr Cys Gly Gln
Lys Thr Pro Gly Arg Ile Arg Ser Ser Ser 225 230
235 240 Gly Ile Leu Ser Met Val Phe Tyr Thr Asp Ser
Ala Ile Ala Lys Glu 245 250
255 Gly Phe Ser Ala Asn Tyr Ser Val Leu Gln Ser Ser Val Ser Glu Asp
260 265 270 Phe Lys
Cys Met Glu Ala Leu Gly Met Glu Ser Gly Glu Ile His Ser 275
280 285 Asp Gln Ile Thr Ala Ser Ser
Gln Tyr Ser Thr Asn Trp Ser Ala Glu 290 295
300 Arg Ser Arg Leu Asn Tyr Pro Glu Asn Gly Trp Thr
Pro Gly Glu Asp 305 310 315
320 Ser Tyr Arg Glu Trp Ile Gln Val Asp Leu Gly Leu Leu Arg Phe Val
325 330 335 Thr Ala Val
Gly Thr Gln Gly Ala Ile Ser Lys Glu Thr Lys Lys Lys 340
345 350 Tyr Tyr Val Lys Thr Tyr Lys Ile
Asp Val Ser Ser Asn Gly Glu Asp 355 360
365 Trp Ile Thr Ile Lys Glu Gly Asn Lys Pro Val Leu Phe
Gln Gly Asn 370 375 380
Thr Asn Pro Thr Asp Val Val Val Ala Val Phe Pro Lys Pro Leu Ile 385
390 395 400 Thr Arg Phe Val
Arg Ile Lys Pro Ala Thr Trp Glu Thr Gly Ile Ser 405
410 415 Met Arg Phe Glu Val Tyr Gly Cys Lys
Ile Thr Asp Tyr Pro Cys Ser 420 425
430 Gly Met Leu Gly Met Val Ser Gly Leu Ile Ser Asp Ser Gln
Ile Thr 435 440 445
Ser Ser Asn Gln Gly Asp Arg Asn Trp Met Pro Glu Asn Ile Arg Leu 450
455 460 Val Thr Ser Arg Ser
Gly Trp Ala Leu Pro Pro Ala Pro His Ser Tyr 465 470
475 480 Ile Asn Glu Trp Leu Gln Ile Asp Leu Gly
Glu Glu Lys Ile Val Arg 485 490
495 Gly Ile Ile Ile Gln Gly Gly Lys His Arg Glu Asn Lys Val Phe
Met 500 505 510 Arg
Lys Phe Lys Ile Gly Tyr Ser Asn Asn Gly Ser Asp Trp Lys Met 515
520 525 Ile Met Asp Asp Ser Lys
Arg Lys Ala Lys Ser Phe Glu Gly Asn Asn 530 535
540 Asn Tyr Asp Thr Pro Glu Leu Arg Thr Phe Pro
Ala Leu Ser Thr Arg 545 550 555
560 Phe Ile Arg Ile Tyr Pro Glu Arg Ala Thr His Gly Gly Leu Gly Leu
565 570 575 Arg Met
Glu Leu Leu Gly Cys Glu Val Glu Ala Pro Thr Ala Gly Pro 580
585 590 Thr Thr Pro Asn Gly Asn Leu
Val Asp Glu Cys Asp Asp Asp Gln Ala 595 600
605 Asn Cys His Ser Gly Thr Gly Asp Asp Phe Gln Leu
Thr Gly Gly Thr 610 615 620
Thr Val Leu Ala Thr Glu Lys Pro Thr Val Ile Asp Ser Thr Ile Gln 625
630 635 640 Ser Glu Phe
Pro Thr Tyr Gly Phe Asn Cys Glu Phe Gly Trp Gly Ser 645
650 655 His Lys Thr Phe Cys His Trp Glu
His Asp Asn His Val Gln Leu Lys 660 665
670 Trp Ser Val Leu Thr Ser Lys Thr Gly Pro Ile Gln Asp
His Thr Gly 675 680 685
Asp Gly Asn Phe Ile Tyr Ser Gln Ala Asp Glu Asn Gln Lys Gly Lys 690
695 700 Val Ala Arg Leu
Val Ser Pro Val Val Tyr Ser Gln Asn Ser Ala His 705 710
715 720 Cys Met Thr Phe Trp Tyr His Met Ser
Gly Ser His Val Gly Thr Leu 725 730
735 Arg Val Lys Leu Arg Tyr Gln Lys Pro Glu Glu Tyr Asp Gln
Leu Val 740 745 750
Trp Met Ala Ile Gly His Gln Gly Asp His Trp Lys Glu Gly Arg Val
755 760 765 Leu Leu His Lys
Ser Leu Lys Leu Tyr Gln Val Ile Phe Glu Gly Glu 770
775 780 Ile Gly Lys Gly Asn Leu Gly Gly
Ile Ala Val Asp Asp Ile Ser Ile 785 790
795 800 Asn Asn His Ile Ser Gln Glu Asp Cys Ala Lys Pro
Ala Asp Leu Asp 805 810
815 Lys Lys Asn Pro Glu Ile Lys Ile Asp Glu Thr Gly Ser Thr Pro Gly
820 825 830 Tyr Glu Gly
Glu Gly Glu Gly Asp Lys Asn Ile Ser Arg Lys Pro Gly 835
840 845 Asn Val Leu Lys Thr Leu Glu Pro
Ile Leu Ile Thr Ile Ile Ala Met 850 855
860 Ser Ala Leu Gly Val Leu Leu Gly Ala Val Cys Gly Val
Val Leu Tyr 865 870 875
880 Cys Ala Cys Trp His Asn Gly Met Ser Glu Arg Asn Leu Ser Ala Leu
885 890 895 Glu Asn Tyr Asn
Phe Glu Leu Val Asp Gly Val Lys Leu Lys Lys Asp 900
905 910 Lys Leu Asn Thr Gln Ser Thr Tyr Ser
Glu Ala 915 920 69931PRTHomo sapiens
69Met Asp Met Phe Pro Leu Thr Trp Val Phe Leu Ala Leu Tyr Phe Ser 1
5 10 15 Arg His Gln Val
Arg Gly Gln Pro Asp Pro Pro Cys Gly Gly Arg Leu 20
25 30 Asn Ser Lys Asp Ala Gly Tyr Ile Thr
Ser Pro Gly Tyr Pro Gln Asp 35 40
45 Tyr Pro Ser His Gln Asn Cys Glu Trp Ile Val Tyr Ala Pro
Glu Pro 50 55 60
Asn Gln Lys Ile Val Leu Asn Phe Asn Pro His Phe Glu Ile Glu Lys 65
70 75 80 His Asp Cys Lys Tyr
Asp Phe Ile Glu Ile Arg Asp Gly Asp Ser Glu 85
90 95 Ser Ala Asp Leu Leu Gly Lys His Cys Gly
Asn Ile Ala Pro Pro Thr 100 105
110 Ile Ile Ser Ser Gly Ser Met Leu Tyr Ile Lys Phe Thr Ser Asp
Tyr 115 120 125 Ala
Arg Gln Gly Ala Gly Phe Ser Leu Arg Tyr Glu Ile Phe Lys Thr 130
135 140 Gly Ser Glu Asp Cys Ser
Lys Asn Phe Thr Ser Pro Asn Gly Thr Ile 145 150
155 160 Glu Ser Pro Gly Phe Pro Glu Lys Tyr Pro His
Asn Leu Asp Cys Thr 165 170
175 Phe Thr Ile Leu Ala Lys Pro Lys Met Glu Ile Ile Leu Gln Phe Leu
180 185 190 Ile Phe
Asp Leu Glu His Asp Pro Leu Gln Val Gly Glu Gly Asp Cys 195
200 205 Lys Tyr Asp Trp Leu Asp Ile
Trp Asp Gly Ile Pro His Val Gly Pro 210 215
220 Leu Ile Gly Lys Tyr Cys Gly Thr Lys Thr Pro Ser
Glu Leu Arg Ser 225 230 235
240 Ser Thr Gly Ile Leu Ser Leu Thr Phe His Thr Asp Met Ala Val Ala
245 250 255 Lys Asp Gly
Phe Ser Ala Arg Tyr Tyr Leu Val His Gln Glu Pro Leu 260
265 270 Glu Asn Phe Gln Cys Asn Val Pro
Leu Gly Met Glu Ser Gly Arg Ile 275 280
285 Ala Asn Glu Gln Ile Ser Ala Ser Ser Thr Tyr Ser Asp
Gly Arg Trp 290 295 300
Thr Pro Gln Gln Ser Arg Leu His Gly Asp Asp Asn Gly Trp Thr Pro 305
310 315 320 Asn Leu Asp Ser
Asn Lys Glu Tyr Leu Gln Val Asp Leu Arg Phe Leu 325
330 335 Thr Met Leu Thr Ala Ile Ala Thr Gln
Gly Ala Ile Ser Arg Glu Thr 340 345
350 Gln Asn Gly Tyr Tyr Val Lys Ser Tyr Lys Leu Glu Val Ser
Thr Asn 355 360 365
Gly Glu Asp Trp Met Val Tyr Arg His Gly Lys Asn His Lys Val Phe 370
375 380 Gln Ala Asn Asn Asp
Ala Thr Glu Val Val Leu Asn Lys Leu His Ala 385 390
395 400 Pro Leu Leu Thr Arg Phe Val Arg Ile Arg
Pro Gln Thr Trp His Ser 405 410
415 Gly Ile Ala Leu Arg Leu Glu Leu Phe Gly Cys Arg Val Thr Asp
Ala 420 425 430 Pro
Cys Ser Asn Met Leu Gly Met Leu Ser Gly Leu Ile Ala Asp Ser 435
440 445 Gln Ile Ser Ala Ser Ser
Thr Gln Glu Tyr Leu Trp Ser Pro Ser Ala 450 455
460 Ala Arg Leu Val Ser Ser Arg Ser Gly Trp Phe
Pro Arg Ile Pro Gln 465 470 475
480 Ala Gln Pro Gly Glu Glu Trp Leu Gln Val Asp Leu Gly Thr Pro Lys
485 490 495 Thr Val
Lys Gly Val Ile Ile Gln Gly Ala Arg Gly Gly Asp Ser Ile 500
505 510 Thr Ala Val Glu Ala Arg Ala
Phe Val Arg Lys Phe Lys Val Ser Tyr 515 520
525 Ser Leu Asn Gly Lys Asp Trp Glu Tyr Ile Gln Asp
Pro Arg Thr Gln 530 535 540
Gln Pro Lys Leu Phe Glu Gly Asn Met His Tyr Asp Thr Pro Asp Ile 545
550 555 560 Arg Arg Phe
Asp Pro Ile Pro Ala Gln Tyr Val Arg Val Tyr Pro Glu 565
570 575 Arg Trp Ser Pro Ala Gly Ile Gly
Met Arg Leu Glu Val Leu Gly Cys 580 585
590 Asp Trp Thr Asp Ser Lys Pro Thr Val Glu Thr Leu Gly
Pro Thr Val 595 600 605
Lys Ser Glu Glu Thr Thr Thr Pro Tyr Pro Thr Glu Glu Glu Ala Thr 610
615 620 Glu Cys Gly Glu
Asn Cys Ser Phe Glu Asp Asp Lys Asp Leu Gln Leu 625 630
635 640 Pro Ser Gly Phe Asn Cys Asn Phe Asp
Phe Leu Glu Glu Pro Cys Gly 645 650
655 Trp Met Tyr Asp His Ala Lys Trp Leu Arg Thr Thr Trp Ala
Ser Ser 660 665 670
Ser Ser Pro Asn Asp Arg Thr Phe Pro Asp Asp Arg Asn Phe Leu Arg
675 680 685 Leu Gln Ser Asp
Ser Gln Arg Glu Gly Gln Tyr Ala Arg Leu Ile Ser 690
695 700 Pro Pro Val His Leu Pro Arg Ser
Pro Val Cys Met Glu Phe Gln Tyr 705 710
715 720 Gln Ala Thr Gly Gly Arg Gly Val Ala Leu Gln Val
Val Arg Glu Ala 725 730
735 Ser Gln Glu Ser Lys Leu Leu Trp Val Ile Arg Glu Asp Gln Gly Gly
740 745 750 Glu Trp Lys
His Gly Arg Ile Ile Leu Pro Ser Tyr Asp Met Glu Tyr 755
760 765 Gln Ile Val Phe Glu Gly Val Ile
Gly Lys Gly Arg Ser Gly Glu Ile 770 775
780 Ala Ile Asp Asp Ile Arg Ile Ser Thr Asp Val Pro Leu
Glu Asn Cys 785 790 795
800 Met Glu Pro Ile Ser Ala Phe Ala Gly Glu Asn Phe Lys Val Asp Ile
805 810 815 Pro Glu Ile His
Glu Arg Glu Gly Tyr Glu Asp Glu Ile Asp Asp Glu 820
825 830 Tyr Glu Val Asp Trp Ser Asn Ser Ser
Ser Ala Thr Ser Gly Ser Gly 835 840
845 Ala Pro Ser Thr Asp Lys Glu Lys Ser Trp Leu Tyr Thr Leu
Asp Pro 850 855 860
Ile Leu Ile Thr Ile Ile Ala Met Ser Ser Leu Gly Val Leu Leu Gly 865
870 875 880 Ala Thr Cys Ala Gly
Leu Leu Leu Tyr Cys Thr Cys Ser Tyr Ser Gly 885
890 895 Leu Ser Ser Arg Ser Cys Thr Thr Leu Glu
Asn Tyr Asn Phe Glu Leu 900 905
910 Tyr Asp Gly Leu Lys His Lys Val Lys Met Asn His Gln Lys Cys
Cys 915 920 925 Ser
Glu Ala 930 706PRTHomo sapiens 70Ser Leu Thr Arg Lys Asp 1
5 716PRTHomo sapiens 71Cys Asp Lys Pro Arg Arg 1
5 725PRTHomo sapiens 72Ala Asn Ile Thr Val 1 5
739PRTHomo sapiens 73Ala Asn Ile Thr Val Asn Ile Thr Val 1
5
User Contributions:
Comment about this patent or add new information about this topic:
People who visited this patent also read: | |
Patent application number | Title |
---|---|
20150319572 | Systems and Methods of Location and Tracking |
20150319571 | NETWORK INDEPENDENT LOCATION SERVICES |
20150319570 | Geofence with Kalman Filter |
20150319569 | MOBILE DEVICES AND RELATED METHODS FOR CONFIGURING A REMOTE DEVICE |
20150319568 | APPARATUS AND METHOD FOR GENERATING, DISPLAYING AND IMPLEMENTING A GEO-FENCE USING LOCATION DETERMINATION OF MOBILE DEVICES WITHIN A LOCATION-BASED GROUP |